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Abstract 
Oral delivery of proteins and peptides, particularly insulin, has been a major focus of 
research in recent times. While the earliest attempts to develop an oral insulin dates back to 
1920s. Technology advances over the past few years have made it possible for several 
research groups to refocus on this area again. Research in this area has been primarily 
formulation centric with the exception of a few attempts to build in the desired properties 
at the molecular level itself.  
Biocon, a leading biotechnology company has embarked upon developing oral insulin 
using a combination approach of modification at the molecular level and formulation 
development. Modification at the molecular level is achieved by conjugation of 
recombinant human insulin and a short chain alkyl-polyethylene glycol. The modified 
molecule is then converted into a tablet dosage form using standard unit processes. The 
modification provides resistance towards enzymatic degradation in gut. However, to ensure 
absorption of the molecule, the conjugated molecule is formulated with a permeation 
enhancer, the sodium salt of capric acid. Capric acid is a short chain fatty acid that is 
present in palm oil in large quantities and is known to increase gut permeability in a 
reversible manner. 
The current thesis is focused on evaluation of various aspects of this oral insulin product. 
The first part focuses on evaluating the effects of formulation process on the structure and 
biological activity of pegylated insulin. The process of manufacturing involves high shear 
processes such as blending and compression of this blend. During blending the molecule 
experiences shear force due to friction against excipient particles. The tablet compression 
is a more complex process where the blend experiences friction while flowing through the 
hopper and on the rotating turret. Also, during compression of the table heat is released 
19 
 
locally at the point of contact in each of the tablet. Since proteins are fragile molecules it 
was important to understand the effects of these process stresses and strains on the 
structural stability of the molecule as well as effect on biological activity. 
The other two chapters of this thesis explore the in-vitro and in-vivo metabolism of the 
pegylated insulin analogue and also focus on determining the fate of the oligomer in a rat 
model. The pharmacokinetic profile mimics an ultra-rapid acting insulin profile, with peak 
maxima between 15 to 30 min from the time of administration, and the circulating levels of 
pegylated insulin coming back to baseline within 120 min. Since insulin therapy is a 
chronic potential life-long therapy, determining the fate of oligomer is important. The 
metabolism of pegylated insulin using a HepG2 cell line, which is a human hepatocyte cell 
line, was investigated and metabolites were identified over a period of 10 days using mass 
spectrometry. Subsequently, Pegylated insulin metabolism was studied in Wistar rats to 
trace the metabolites in Urine and faeces.  
Pegylated Insulin is a first generation oral insulin and so in the last chapter the thought 
process and preliminary in-silico towards future potential development of improved oral 
insulin derivatives has been described. If oral insulin has to be truly successful and benefit 
patients in the long run, considerably more research is required. Making an orally 
bioavailable Insulin analogue also establishes technology that can be applied to developing 
orally bioavailable forms of other protein and peptide drugs. 
  
20 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
 
Introduction and Literature Review 
 
 
 
 
 
 
 
21 
 
1.1 Introduction 
Diabetes is broadly categorized into type 1 and type 2. Type 1 diabetes is caused by loss of 
an ability to produce insulin due to the destruction of beta cells. Type 2 diabetes is a result 
of increased insulin resistance followed by loss of beta cell mass over a period of time. 
Type 2 diabetes is a progressive disorder. All type 1 diabetes patients require exogenous 
insulin throughout their lives to control hyperglycemia, while type 2 diabetes can be 
managed with oral anti diabetic agents (OAD) initially, depending on the stage of disease 
(Figure 1.1).  Eventually, many type 2 diabetes patients require insulin treatment, which is 
shown to reverse insulin resistance (Scarlett et al. 1982). Early insulinization has been 
shown to have beneficial effects on preservation of residual beta cell function (Alvarsson 
et al. 2003). Even a transient insulin therapy has been shown to have beneficial effects in 
newly diagnosed patients with type 2 diabetes (Ryan et al. 2004, Ilkova et al. 1997). 
Irrespective of the aetiology of the diabetes, insulin remains the final treatment option.  
 
Figure 1.1: Diabetes treatment continuum and the duration of disease for type 2 diabetes 
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In type 2 diabetic patients the earliest defect observed is beta cell death, with the loss of 
first phase response (Weyer et al. 1999, Butler et al. 2003). The loss of first phase response 
results in inadequate suppression of endogenous glucose production resulting in 
postprandial hyperglycemia (Luzi et al. 1989). At the time of diagnosis of diabetes, it is 
believed that the beta cell mass is already reduced by 50% (Figure 1.2) (Lebovitz 1999).  
 
Figure 1.2: Beta cell function and progression of type 2 diabetes (adapted from Lebovitz 
1999) 
Several years of research has not yielded any effective treatment for type 1 diabetes and 
insulin remains the only treatment for these patients. However, current insulin therapy is 
not physiological and has its own issues. Recently some new potential therapies are being 
developed for type 1 diabetes. Pramlintide, an analogue of amylin, enhances insulin action 
(Fineman et al. 2002) while others such as SGLT2 inhibitors increase the elimination of 
glucose via renal filtration and are not dependent on insulin action (Idris et al. 2009). 
Alternatively, alpha-glucosidase inhibitors prevent breakdown of starch to glucose 
(Chiasson et al. 1994) and thereby reduce glucose spikes. Some of these newer medicines 
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have the potential to be used in both Type 1 and Type 2 diabetes due to their non-specific 
insulin independent action. However, their long term safety and effectiveness is still being 
evaluated, which would be known over the next few years. 
Over the years several drugs have been developed for the treatment of type 2 diabetes. The 
mechanisms of some of these drugs, biguanides, phenformin and metformin, are not fully 
understood even now. Although phenformin is no longer used in clinical practice due to 
increased death caused by lactic acid acidosis (Conlay et al. 1976), metformin is still 
considered a drug of choice as a first line therapy for type 2 diabetes (Bailey et al. 1996). 
Once metformin starts failing to control glycemic excursions, there are several other drugs 
like sulfonylureas, glitazones, DPP IV inhibitors, and SGLT2s inhibitors that can be used 
in conjunction with metformin. Sulfonylureas, insulin secretogogues, result in 
hypoglycemic events, and coax the pancreas to secrete more insulin, thereby causing 
increased rates of beta cell death (Matthews et al. 1998), and so these drugs have fallen out 
of favour. Clinical conclusions for these established drugs have been arrived at from meta-
analysis of data available across multiple clinical trials and post marketing survey analysis 
and lack controlled experimental evidence. In developing countries such as India, 
sulfonylureas are still widely used as a second line of therapy after metformin therapy 
failure. Similarly, glitazones have been implicated in increased cardiovascular risk after 
long term treatment (Nissen et al. 2007). 
Recently, there has been a spate of drugs which work on inhibition of DPP-IV enzyme, 
indirectly increasing circulating concentration of GLP-1 (Holst et al. 2005), which in turn 
helps in controlling glycemia. GLP-1 is a very promising therapy in the management of 
diabetes. The advantages of GLP-1 are that it increases insulin sensitivity, causes weight 
loss and has been shown to reduce insulin requirement over time. There is some animal 
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data which also indicates that GLP-1 may have a role in increasing beta cell mass. On the 
other hand, there has been a growing concern that GLP-1 treatments could be somehow 
connected to higher incidence of pancreatitis, as there are some sporadic reports of 
pancreatitis as well as thyroid cancer, although confirmatory evidence is still required. 
Exenatide, a naturally occurring GLP-1 analogue is used for the treatment of diabetes. It 
works by increasing insulin secretion in response to increased glucose levels in blood and 
also reduces gastric motility, thereby reducing glycemic excursions (Cervero et al. 2008). 
Exenatide also increases satiety, resulting in weight loss in patients with type 2 diabetes 
(Kolterman et al. 2003, Dupre et al. 2004). Another synthetic GLP-1 analogue Liraglutide, 
was recently approved for the treatment of type 2 diabetes (Vilsboll et al. 2007). Despite so 
many different drugs being available for the treatment of type 2 diabetes, with time many 
patients stop responding to any of these therapies and finally have to resort to using insulin. 
Despite close to eight decades of work on Insulin and diabetes, both remain incompletely 
understood. While there is considerable research which shows that diabetes affects the 
entire metabolism and eventually impact multiple different organs, the aetiology or the 
trigger to the disease is not very well established. We still do not know why insulin 
resistance increases in the first place in Type 2 diabetics. There are genetic and 
environmental factors that are known to increase the risk but there is no clear evidence of 
one event or series of events which conclusively leads to diabetes. There are other 
categories of latent onset diabetes in the young and in adults that have been identified over 
the last 2 decades or so. This occurs in a small percentage of the population having insulin 
deficiency similar to Type 1 diabetes, although it develops more slowly and can be 
misdiagnosed and mistreated as Type 2 diabetes (Groop et al. 1986). 
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For all forms of diabetes the treatments have been very glucose centric and symptomatic. 
The emergence of GLP-1 treatment has made the research community think beyond 
glucose and insulin and also emphasized that diabetes involves several other gut hormones 
in addition to insulin. Considerable focus has been given to understanding the biology of 
gut hormones, which affect gastric motility, gastric emptying satiety and play a role in 
glucose absorption and utilization by the body.  
Besides these therapies, there have been attempts to regenerate beta cell mass and efforts 
are being taken to study beta cell biology, which may lead to the development of 
regenerative therapies. GLP-1s have been shown to increase beta cell mass in rodents but 
there is no evidence of increase in beta cell mass in humans (Wang et al. 1997). There are 
several proteins that have been reported to increase beta cell mass by either differentiation 
of ductal cells to beta cells or by increasing beta cell proliferations. One such protein which 
has been studied, Islet Neogenesis associated Protein (INGAP), belongs to the regulatory 
III protein family. It was shown to differentiate ductal cells into beta cells which produce 
insulin. In an experimental setting Rosenberg et al. wrapped a cellophane around the head 
of the pancreas in Syrian golden hamsters. After 5 days, ductal epithelia hyperplasia was 
observed, by 2 weeks lining of duct were formed by Pseudostratified epithelial cells with 
prominent goblet cells and new islet cells were observed (Rosenberg et al. 1983). The fact 
that the hyperplasia and new islet cells were observed without any external stimuli, led to 
the identification of INGAP protein (Rafaeloff et al. 1997). 
A recent publication in Pancreas confirmed positive effects of chronological appearance of 
INGAP on beta cell mass, pdx-1 containing cells and insulin secretion in foetuses and 
neonatal wistar rats (Madrid et al. 2013). Researchers have tested a 15-mer peptide derived 
from INGAP protein in the clinic (Rosenberg et al. 2004). The molecule being tested in the 
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clinic is less potent than the native INGAP protein hence it would be interesting to see the 
clinical outcome. There are other peptides like betatrophin (22kDa) and osteocalcin that 
have been shown to have an impact on beta cell mass, however, the mechanism and role of 
these peptides is not yet fully understood. While regenerative therapies are some time 
away, there is enough evidence to show that they are likely to be a reality one day, given 
adequate research focus. Such a therapy may make insulin therapy redundant. However, 
until then there is likely to be no alternative to Insulin therapy especially in Type 2 
diabetes. 
Natural secretion of Insulin is glucose dependent whereas current therapies are not which 
puts the patient at a higher risk of hypoglycemia. There have been few attempts to develop 
glucose dependent insulin formulation. Hydrogels with concanavalin A have been shown 
to release insulin in glucose dependent manner by sensing glucose levels (Obaidat et 
1996).  
1.2 Glucose metabolism: 
In normal healthy individuals, glucose once ingested is absorbed rapidly. There are 
receptors in the gut which trigger gastric hormone secretion and insulin. The gastric 
hormones help in slowing down the gut mobility, slowing down the absorption, while 
insulin helps in glucose removal from the circulation and uptake into various tissues. Liver 
is the primary organ where a large portion of ingested glucose is disposed off either by 
breakdown through glycolysis or storage into glycogen. In addition to glucose uptake, 
endogenous glucose production shuts down with glucose and insulin signalling, thereby 
reducing the total amount of glucose that is needed to be disposed of.  
In diabetes patients, the glucose metabolism is significantly impaired when absorbed 
glucose is incompletely taken up by the liver, spilling out large quantities of glucose to be 
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taken care of by other peripheral tissues. In addition, gluconeogenesis in liver is 
incompletely suppressed, resulting in larger amount of circulating glucose. Earlier the 
belief was that gluconeogenesis is a major function of liver and incomplete suppression of 
gluconeogenesis contributes to hyperglycemia in diabetes. However, recently a better 
understanding of this process has evolved. It is now well established that inefficient 
glucose uptake by the liver contributes to hyperglycemia and is greater than the 
contribution of gluconeogenesis. A treatment improving glucose uptake by liver is likely to 
benefit patients more than the current injectable insulin therapy. 
1.3 Development in Insulin treatment 
Over eight decades of research has resulted in improved quality of the Insulin available and 
also in understanding the best insulin treatment regimen. In the first few decades after 
insulin discovery, animal derived insulin was being used, which had a limitation of supply 
as well as quality. The focus then was to solve these two problems. During 1960s and 70s 
the arrival of recombinant therapy enabled us to move from animal derived insulin to 
recombinant insulin as well as achieving higher purity of Insulin. In the past three decades 
or so, the focus has moved towards making insulin therapy more physiological or the 
development of alternate routes of delivery. Several new Insulin analogues have been 
developed in an effort to minimize variability, improve patient convenience/compliance 
and mimic insulin’s natural secretory pattern. 
The natural insulin secretory pattern involves a rapid sharp burst of Insulin followed by a 
sustained release of insulin. The short burst of insulin, also called first phase response of 
insulin, is believed to play a critical role in switching the liver from anabolic state to 
catabolic state. The switch may be important since during anabolic states the liver produces 
glucose via gluconeogenesis and glycogen breakdown. When external glucose from food 
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starts getting absorbed, the switch helps in reducing the amount of glucose that needs to be 
disposed of.  
During the progression of Type 2 diabetes especially, it is reported that in the pre-diabetic 
stage, the first phase insulin response starts diminishing, which is compensated by 
increased secretion of Insulin during second phase. Over time, with an increase in insulin 
resistance, the pancreatic cells get exhausted and produce less and less insulin due to 
progressive beta cell death. By the time a person is detected as diabetic, the beta cell mass 
is already down to about 50% of its original mass (Lebovitz 1999). A true replacement for 
Insulin therapy not only needs to restore the first phase, but also the second phase of 
insulin release in a physiologic manner. That is, insulin should primarily act on liver, 
which is the target organ. Ideally it should also mimic the glucose dependent secretory 
pattern of natural insulin. 
In a normal individual, Insulin is secreted by beta cells of the pancreas in to the portal vein 
and is then carried to the liver first, where a large portion of insulin is extracted by the 
liver. The effect of variable insulin clearance on post prandial glucose was studied by 
Caumo et al. 2007. Caumo et al. in this study describe a mathematical model to predict the 
effect of variable hepatic clearance. The finding suggested that a small reduction to the 
tune of 20% reduction in hepatic extraction of insulin increased the plasma insulin 
concentration dramatically. Edgerton et al. 2006 showed a clear dominant effect of portal 
insulin on liver. The importance of first phase release of insulin has been extensively 
discussed in the literature (Mitrakou et al. 1992). Luzi and Defronzo 1989, in their 
hyperglycemic clamp study, where in phasic insulin release was artificially mimicked, 
concluded that the loss of first phase response may play a role in better glucose control. 
Pfifer et al. 1981, in a short review published in American Journal of medicine, captured 
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the difference between normal subjects. The study showed that while first phase response 
was lacking in non-insulin dependent diabetes, second phase response was more or less 
preserved. In the case of insulin dependent diabetes subjects, however, clearly both the 
phases were missing. The first phase insulin response has been suspected to play a role in 
signalling the liver to change from a catabolic state to an anabolic state. Insulin helps 
transfer glucose from the blood stream to adipocytes through translocation of glucose 
transporter 4 (Pessin et al. 1999) and gets stored as glycogen. It also increases body fat 
storage and increases protein synthesis (Zhang et al. 1999, Pilkis et al. 1974). On the other 
hand, it is possible that the first phase insulin response is an artefact of experimental 
settings where a sudden large bolus dose of sugar is administered, resulting in a sudden 
burst of insulin being released in response, which is unlike a meal situation. The research 
done by Caumo et al. 2004 concludes that while the first phase response against a meal 
might not exist in real life, the pulsatile release of insulin in portal vein serves the purpose. 
Physiological insulin is secreted by the Pancreas under influence of glucose signal in the 
portal vein, which is then carried to the liver via the portal vein. In the liver, a significant 
amount of insulin is extracted by the liver and only a fraction of secreted insulin reached 
the peripheral circulation. The injectable insulins do not mimic this physiological gradient. 
In fact, the portal peripheral axis is reversed in the case of injectables with higher 
peripheral levels of insulin. This reversal in the physiological axis leads to weight gain, 
higher incidences of hypoglycemic events and other long term complications (Carlson et 
al. 1993). Weight gain is due to the fact that the higher exposure to insulin in the periphery 
results in storage of glucose in the muscle tissue instead of liver. This weight gain is 
associated with increases in peripheral insulin resistance, leading to high insulin dose 
requirements, increasing weight gain further, essentially resulting in long term 
complications, which may be attributed to the higher insulin exposure. It would be ideal to 
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develop an insulin therapy which does not cause weight gain and slows down progression 
of insulin resistance if not improving it. 
1.4 Insulin Analogues: 
Lispro, aspart and glulisine are faster acting analogues with rapid onset of action, as 
compared to soluble insulin formulation (Braak et al. 1996, Mudaliar et al. 1999, Becker et 
al. 2005). The rapid onset of action means patients now can take their insulin closer to the 
start of the meal and get a better control on the post prandial excursions. Also there has 
been a considerable reduction in hypoglycemic events as the late effect of insulin is 
minimized due to a shorter tail of the Insulin pharmacokinetic profile. The attempt to 
develop fast acting analogues is to provide a replacement of first phase insulin release, 
which is critical for reducing the post prandial glucose spike.  
Insulin absorbed from the gut is the only insulin which may maintain physiologic portal 
peripheral axis. The rationale and potential advantages of oral insulin have been captured 
in few review articles (Hoffman et al. 1997, Arbit 2004). An effective, rapid acting oral 
insulin is likely to benefit not only from the physiology point of view but is likely to 
relieve patients by reducing the number of insulin injections that need to be administered 
on a chronic basis. 
Insulin therapy for control of diabetes is suggested to generally involve a two step 
approach. Firstly the fasting glucose levels need to be brought down, and then the residual 
post-prandial glycemic excursions need to be controlled. Fasting plasma glucose indicates 
worsening insulin resistance and leads to a rapid increase in glycation of proteins and is 
linked to microvascular and macro vascular complications in the late stages of diabetes, 
while post-prandial glucose excursions have been shown to correlate strongly with 
cardiovascular risks.  
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From the patient point of view, multiple injections in a day is a major factor for poor 
compliance, and also increases the risk of hypoglycemia. Replacing these injections with 
alternate delivery could prove to be more beneficial than a traditional approach of 
development of long acting formulation. There are several potential advantages of alternate 
delivery. Since current therapy is an injectable therapy, by the time insulin therapy is 
initiated very little residual beta cell activity is remaining. It is hypothesized, that if insulin 
therapy is initiated early during disease progression, there may be a possibility of 
preserving beta cell mass, thereby slowing down disease progression. Alternate routes of 
delivery would potentially enable early initiation of insulin therapy. 
1.5 Alternate routes of insulin delivery 
1.5.1 Inhalable Insulin 
Several alternate routes have been reported in the literature and a few have reached clinical 
development or market. Exubera was the first alternate insulin product to get approval for 
marketing authorisation and this was in the US in 2006. It was developed as an alternative 
to injectable rapid acting insulin, based on technology developed by Nektar Pharma. 
During the review, however, regulators in the UK and EU did not find Exubera to be any 
better than injectable insulin, reducing its utility only to that of enabling an alternative to 
injections. The product was withdrawn from the market in late 2009 due to poor sales and 
safety risks. The failure of this product in the market can also be attributed to high cost and 
difficulty in handling the device.  
Recently, another inhalable product Afrezza was approved for marketing. The product is a 
rapid acting meal time dry powder inhalation insulin product. The second generation 
device is sleek, making it convenient for handling and usage. Afrezza was approved 
primarily on the basis of 2 clinical trials. The first trial was conducted to show superiority 
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over placebo in type 2 diabetes patients. The drug managed to show non-inferiority over 
Insulin aspart injection. The margin of non-inferiority was 0.4% in HbA1c change for the 
difference in the treatment efficacy. However, the study proved that over a background 
therapy of basal insulin Afrezza was non-inferior to Insulin aspart, but the treatment was 
statistically worse compared to Injectable insulin. This could be due to the fact that 
Afrezza in a way is an ultra-rapid acting insulin and controls glucose excursion over a 
period of 2 to 3 hours while Insulin aspart injection has a longer pharmacokinetic profile 
resulting in a post-prandial coverage for up to 4 to 5 hours (Rave et al. 2009). In addition, 
the Afrezza group needed to increase the dose of basal insulin to maintain a good glucose 
control. It is likely that if the basal insulin had not been adjusted, the difference between 
the two treatment groups would have been larger and not in favour of Afrezza. Considering 
these results, it would be interesting to see how Afrezza works in real life settings once 
larger patient pools are exposed. 
1.5.2 Insulin transdermal patches 
Transdermal drug delivery is an interesting option as a non-invasive delivery system. 
Several hydrophobic, low dose molecules are available in the form of transdermal patches. 
Scopolamine patches were the first ones to get approved by FDA followed by Nicotine 
patches (Paudel et al. 2010). Subsequently several patches containing analgesics, 
contraceptives and local anesthetic drug patches have been approved with increasing 
frequency. Transdermal delivery offers several advantages over oral or injectable delivery. 
It helps bypass the first pass metabolism in liver following oral delivery. Also, it is painless 
and easy to apply and prevents generation of unwanted medical waste (Praustnitz and 
Langer 2008). 
33 
 
Despite these advantages, the challenge of low skin permeability needs to be overcome, 
which has driven advancement of the patch technology. Lately, to improve the drug 
delivery efficiency, patches have been combined with microneedles (Zhu et al. 2013), 
sometimes made from dissolvable polymer. This has also been combined with a pump 
through which more sustained delivery has been achieved (Zisser et al. 2006).  
Several attempts have been made to develop insulin transdermal patches. A group of 
Japanese researchers reported delivery of insulin using CaCO3 nanoparticles suspended in 
petroleum jelly. The jelly was applied on the skin of ddY mice and samples were collected 
to study the pharmacokinetics.  
ddY mice strain was introduced between 1910 and 1920s from Germany and established as 
a strain for hyperdyslipidemia at the, the National Institute of Infectious Diseases, Yoken. 
The ddY strain was derived from a mouse colony at the Institute of Infectious Diseases of 
Tokyo University (Denken) presently known as the Institute of Medical Sciences of Tokyo 
University. The strain name ddY stands for Deutschland, Denken, and Yoken (Yamakazi 
et al. 2012). 
From figure 1.3 one can clearly see the difference in the profile of nanoparticle delivered 
insulin versus subcutaneous insulin monomer. While the overall bioavailability reported 
was between 2 and 3%, the nanoparticle delivery was found to be more sustained as 
against a rapid bolus profile for subcutaneous injection. 
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Figure 1.3: The closed black circle (○) represent insulin levels in serum from nanoparticle 
application. The open circle (●) represents subcutaneous administration of monomeric 
insulin. The error bars represent standard deviation (adapted from Higaki M et al., Diabetes 
Technology and therapeutics). 
The nanoparticle Insulin reduced blood glucose levels in a dose dependent manner as seen 
from the figure 1.4 below. 
 
Figure 1.4: Time course profiles of blood glucose in ddY mice. Blood glucose levels with 
transdermal nano insulin [200 (        ), 100 (          ), 50 (          ), and 0 (         ) μg] and 
subcutaneous monomer insulin (3 μg (         ) were measured. The results are shown as 
mean ± SD. (adapted from Higaki M et al., Diabetes Technology and therapeutics, 2006) 
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The decrease in blood glucose was dose dependent for insulin delivered transdermally 
using nanoparticles. The difference in the blood glucose at 4 hour and 6 hours was 
statistically significant compared to subcutaneous insulin. The pharmacodynamics profile 
of nanoparticles matched closely with the pharmacokinetic profile (Higaki et al. 2006). 
Similarly King et al. demonstrated absorption of insulin using a biphasic lipid system 
(King et al. 2002) delivered using a patch in a Sprague-Dawley rat model. The 
pharmacokinetic bioavailability of insulin was reported to be between 20 to 30% and the 
glucodynamic effect was reported to be around 39%. Subsequently, ultrasound along with 
sodium lauryl sulphate has been reported to have synergistic effect on mannitol absorption 
(Mitragotri et al. 2000). Similarly, a microneedle patch combined with Iontophoresis was 
reported as a delivery system for Insulin (Chen et al. 2009). In this system, the preparation 
of insulin solution in PBS encapsulated in Nano-vesicles prepared from soy lecithin and 
polyethylene glycol was shown to have a considerable impact on the rate of insulin uptake. 
Various charges on nano-vesicles were imparted by incorporating 0.4% cetyltrimethyl 
ammonium bromide (CTAB), 0.4% sodium dodecyl sulfate (SDS) and 0.03% SDS into the 
nanovesicles.  Almost all the preparations tried in this system showed considerable 
reduction in blood glucose levels in male Sprague-Dawley rats. 
In another study, the development of transdermal patches with dissolving microneedles has 
been described. The microneedles were made up of peptidoglycan chondroitin sulphate, 
which is naturally present in the skin and could be safe for long term use. The study proved 
the feasibility of transdermal delivery of insulin (Ito et al. 2012, Morawski et al. 2009). 
Overall, the transdermal delivery system offers a lot of promise in terms of non-invasive 
delivery of macromolecules. The challenges specifically for insulin that need to be 
overcome are an ability to mimic either a short acting profile, which would replace a first 
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phase insulin response, or a basal profile, which would provide cover for the basal insulin 
requirement.  
1.5.3 Oral Insulin 
1.5.3.1 Potential benefits of oral insulin 
The earliest attempts reported towards the development of oral insulin date back to 1936 
where Lasch et al. tried to inject insulin directly in the intestinal loop. Later, Draggs et al. 
in 1937 and Young et al. in 1939 used a formulation containing hexyl resorcinol to deliver 
insulin orally and showed reduction in blood glucose levels in dogs and later in healthy 
volunteers. Early research started off targeting improvements in patient acceptance since 
the injections were not readily acceptable by patients. Until a couple of decades ago, oral 
insulin was looked upon as an alternative delivery system from the patient’s point of view. 
However, several recent publications suggested that there is more to oral insulin than just 
patient convenience. From 1980 onwards, several research groups have tried to 
differentiate intraportal effects of insulin from peripheral insulin.  
Stevenson et al. 1982 conducted a study using a dog model, wherein they tried to 
differentiate metabolic effects of intraportal insulin from peripheral insulin. The group 
monitored the effect on glycerol, 3-hydroxy butyrate, alanine and lactate. With peripheral 
insulin they noted a considerable rise in insulin levels in periphery. Correspondingly, there 
was a drop in glucose levels. It was found that peripheral insulin reduced glycerol and 3-
hydroxybutyrate levels at all infusion rates but did not impact levels of alanine and lactate 
significantly. The portal delivery of insulin on the other hand resulted in very little rise in 
peripheral insulin levels and showed a drop in glucose, but the magnitude of this drop was 
less than that from peripheral insulin. However, there was a large drop in the levels of all 
four metabolic precursors at all infusion rates. The experiment clearly demonstrated that 
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portal insulin clearly affected gluconeogenic as well as protein synthesis precursors, and 
had a wider metabolic impact as compared to peripheral insulin. 
Later Shishko et al. 1992 compared the effects of continuous peripheral infusion with 
intraportal insulin infusion for four months in insulin dependent diabetes patients and 
monitored the effects on glucose, HbA1c and metabolic precursors. They found that insulin 
requirement for intraportal infusion was lower compared to peripheral infusion, despite the 
difference, the fasting plasma glucose levels in intraportal group were near normal, 
whereas the group which received peripheral infusion had very high and abnormal fasting 
plasma glucose. By the end of four months, in the group which received intraportal insulin, 
HbA1c had dropped from a mean of 13.8% to 5.5%, whereas in the peripheral insulin 
infusion group, HbA1c had dropped from 14.8% to 10.0%, clearly indicating superior 
effect of intraportal insulin delivery. It was also noted that intraportal insulin caused a 
significantly larger decrease in the gluconeogenic and protein synthesis precursors 
compared to peripheral infusion.  
Later the same group published that the intraportal infusion caused a greater decrease in 
growth hormone levels and IGFBP-1 protein levels, compared to continuous peripheral 
infusion, as well as conventional insulin therapy. Corresponding to the lowering of IGFBP-
1, there was an increase in IGF-1 levels. Only intraportal insulin infusion restored the IGF-
1 levels to normal levels, indicating that the route of administration of insulin played a 
major role in IGF-1 (Shishko et al. 1994).  
Intraportal insulin achieves better glycemic control through suppression of endogenous 
glucose production and improved glucose uptake (Sindelar et al. 1998). Besides the 
positive effects on metabolic precursors, glycemic control and insulin resistance, portal 
insulin also has been reported to have a smaller fall in energy expenditure compared to 
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injectable insulin and has better respiratory quotient (Freyse et al. 2006). Overall, portal 
delivery of insulin seems to have considerable physiological benefits, however, due to lack 
of effective delivery technologies these potential benefits have not been realised. Upon oral 
delivery, insulin once absorbed from the gut is expected to move into the portal vein and 
will get carried to the liver first, thus mimicking natural physiological secretion of insulin. 
Hence oral insulin has drawn considerable interest lately. 
1.5.3.2 Challenges in development of oral Insulin: 
While there are potential benefits of oral insulin, for a successful oral delivery of insulin, a 
variety of challenges must be overcome. First and foremost is what happens to insulin 
upon oral delivery? Insulin being a protein is degraded extensively by the stomach 
enzymes like pepsin, trypsin and chymotrypsin in different parts of the gut. Besides the 
digestive enzymes, there are brush border enzymes which hydrolyze proteins. These 
enzymes have been well characterized and are shown in Figure 1.5. 
 
Figure 1.5: Important brush border membrane peptidases and their substrate requirements 
(Image taken from Langguth et al. 1997).  
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If anything survives the luminal enzymes, it gets filtered by the mucin layer, which 
essentially acts as a gel permeation layer and prevents large molecules from getting closer 
to the intestinal walls. Beyond this, the next challenge is to cross the tight junctions, where 
the non-specific proteases and insulin degrading enzymes are lurking to digest any 
remaining insulin. As the name suggests, tight junctions are the junctions which control the 
transport of ion, water and other molecules. Tight junctions were first identified under 
electron microscopy by Farquhar and Palade, 1963. It was only in late 1980’s and early 
90’s when the proteins associated with tight junctions were identified (Citi et al. 1988, 
Gumbiner et al. 1991, Furuse et al. 1993). It was the same group of researchers who later 
established the interaction of Occludin proteins and Zonula Occludin-1(Furuse et al. 1994). 
In addition to that, the domains responsible for the association were identified by protein 
sequencing. This interaction has considerable importance for improving the absorption of 
macromolecules as will be evident in the later part of this chapter. All these barriers result 
in poor bioavailability. To overcome these challenges, considerable effort has been put into 
the development of formulations that will result in oral bioavailability of insulin, but with 
little success. 
1.5.3.3 Approaches for Oral Insulin Delivery 
Several methods have been explored and reported towards attempts to deliver insulin 
orally. Out of many approaches a few have focused on addressing the degradation in gut 
and the transportation barrier in the gastrointestinal tract (GIT). The enzymatic degradation 
has been commonly addressed using inhibitors (Langguth et al. 1997, Shah et al. 2004, 
Bernkop-Schnurch 1998), pro-drug strategies (Sood et al. 2001, Steffansen et al. 2004, Han 
et al. 2000), and encapsulation (Damage et al. 2007, Delie et al. 2005, Leobandung et al. 
2002). Uptake through the gastrointestinal membranes is typically addressed by use of 
carriers (Thwaites et al. 2007, Pang et al. 2003, Foster et al. 2005, Ronnestad et al. 2007), 
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enhancing receptor-mediated transport (Liu et al. 2003, Tsuji et al. 1996, Shah et al. 1996), 
and the use of specific or non-specific permeation enhancers (Salama et al. 2006, Anderson 
et al. 1995, Salamat-Miller et al. 2005). Each of these approaches have had limited success 
and the proof of concept has been shown in animal models; but none of them have really 
moved into clinical development. The different approaches are discussed in more detail 
below. 
1.5.3.4 Enzyme Inhibitors 
The extent of absorption is likely to be a function of the residual concentration of intact 
protein available for absorption post enzymatic degradation. If protein can be made to 
survive longer, one can expect an improvement in the overall bioavailability. Hence to 
reduce the loss of protein, enzyme inhibitors have been tried. Multiple factors need to be 
considered for choosing the right inhibitor, for example, site of absorption. In the stomach, 
pepsin is present, in the duodenum and intestines trypsin and chymotrypsin are the main 
enzymes. In the lumen, brush-border and intracellular environments, non-specific or 
enzymes with broad specificity are present, which makes it challenging to find a single 
enzyme inhibitor. While making a choice of inhibitor, one needs to ensure that the 
inhibitory activity is reversible to prevent any potential safety concern that may arise due 
to long term usage of proteolytic inhibitors. Several enzyme inhibitors have been identified 
and reported in literature. Interesting approaches have been used to co-administer the 
inhibitors with the protein of interest. There are some reports of covalent binding the 
inhibitors with the protein of interest (Marschutz et al. 2000, Bernkop-Schurch et al. 1998, 
Bernkop-Schurch et al. 1998), which essentially is building up dual functionality in one 
molecule. 
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The enzymes of the Gastrointestinal tract are well studied, so a systematic assessment of 
the digestion of each protein therapeutic can be performed in vitro and in vivo (Bernkop-
Schnurch 1998). Identification of the individual enzymatic boundary for any protein helps 
identify or develop specific enzyme inhibitors which are expected to just block the action 
of the specific enzyme. These enzyme inhibitors include but are not limited to 
pepsinostreptin, aprotinin, chymastatin, elastatinal, EDTA, chitosan-EDTA, soybean or 
essential pancreatic trypsin inhibitor, amastatin, puromycin, bestatin, phosphinic corrosive 
dipeptide analogues, and enterostatin (Sood et al. 2001, Bernkop-Schnurch 1998, 
Larionova et al. 1999, Hussain et al. 2004). Often enzyme inhibitors are concomitantly 
administered with the protein of interest. Plate et. al. 2002, in their study, developed a 
delivery system which included immobilized pancreatic and soybean trypsin inhibitor 
demonstrating low degradation of insulin in the presence of trypsin, α-chymotrypsin, and 
elastase. Similarly, citric acid and aminopeptidase inhibitors have been shown to prevent 
degradation of model peptide when released along with the drug (Langguth et al. 1997). In 
a similar study aprotinin was used as the enzyme inhibitor (Larionova et al. 1999). 
Despite many attempts using various technologies, an oral insulin continues to be a distant 
reality. It may require a problem solving at multiple levels before oral insulin becomes a 
real option in the treatment of diabetes. For the past several decades, oral insulin 
development has been attempted across various groups. Various approaches have evolved 
and can be categorized as follows: Encapsulation, use of permeation enhancers and 
modification of Insulin.  
1.5.3.5 Encapsulation 
Encapsulation with chitosan, polylactide-co-glycolide co-polymer, cyanoacrylates, beta-
cyclodextrin and liposomes are some technologies that have been reported extensively 
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(Co´zar-Bernal et al. 2011, Sullivan et al. 2004, Chao et al. 1994). However, these 
approaches solve only part of the problem. Encapsulation in micro- or nano-particles 
prevents enzymatic degradation, however, the absorption of particles is dependent on 
pinocytosis process or uptake via peyer’s patches, which could be slow and variable 
(Zhang et al. 2009). In addition, variability of the release of the payload, and the timing of 
such a release, have not been very well understood. Most of these studies are done in 
animals, primarily rodents, where under overnight fasting the data looks impressive. 
However, more studies are required to understand the usefulness of these systems in a real 
life setting. 
1.5.3.6 Use of permeation enhancers 
Proteins are generally absorbed by the active transport system, receptor mediated transport, 
or a paracellular pathway. Smaller peptides like octreotide, desmopressin, and thyrotropin 
releasing hormone are believed to be absorbed via paracellular transport (Pauletti et al. 
1996). Large proteins cannot get absorbed through the tight junctions of epithelial cells. 
However, efficiency of paracellular transport can be increased in the intestine through the 
use of permeation or absorption enhancing materials to allow increased absorption of 
larger protein like insulin.  
Often paracellular absorption enhancers are used in addition to enzyme inhibitors. Studies 
by Takeyama et al. 1991 and Komada et al. 1985 exhibited that nafamostat when used as 
an absorption enhancer inhibits enzymatic degradation of insulin. In the studies performed 
by Radwan et al. 2001, different permeation enhancers were tried and their effect on 
degradation with chymotrypsin was evaluated. The published data showed that glycerrhizic 
acid and deoxycholic acid were the most effective in preventing insulin degradation by 
chymotrypsin.  
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Several other chemicals have been tried as permeation enhancers, including short chain 
fatty acids, their salts and esters, zolnula occludens toxin (ZOT), bile salts, beta-cycldextrin 
and its derivatives. ZOT in particular was found to have a profound effect on Insulin 
uptake. ZOT is derived from a toxin produced by Vibrio cholera that is known to 
reversibly change or modulate the tight junction permeability in intestine (Fassano et al. 
1991). It is an octapeptide derived from the binding site of a large 399 amino acid native 
protein (Boudry et al. 1992). It increases permeability reversibly of the tight junction via 
PKCα mediated polymerisation of actin fibres in a dose dependent manner. While there are 
several publications which show promising results from the use of ZOT, it being a toxin 
means that concerns exist about its safety (Fassano et al. 1997). However, it is still a very 
promising permeation enhancer showing the desired safety profile and good effectiveness 
as a permeation enhancer. 
Another interesting permeation enhancer is the sodium salt of capric acid. Lindmar et al. in 
their studies compared caproate (C6), caprylate (C8), caprate (C10) and laurate (C12) short 
chain fatty acids for the transport of mannitol across CaCo2 cell line in a dose dependent 
manner and found that concentrations above critical micellar concentrations were the ones 
which were effective (Lindmark et al. 1995). In an intresting experiment by Tomita et al. it 
was concluded that caprate improves colonic absorption more than the jejunal absorption 
of cefmetazole (Tomita et al. 1992). It is shown to be effective in increasing permeability 
of a variety of molecules (Maher et al. 2009) in a concentration range of 10 to 13 mM. It is 
shown to cause reversible permeation enhancement without causing damage to the 
epithelial layer. Sodium caprate has been shown to enhance uptake of several molecules. 
Kim et al. showed that in Caco-2 cells it can enhance transport of insulin by as much as 70 
fold (Kim et al. 2003). 
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There have been some publications on the use of bile salts as permeation enhancers. Bile 
salts are secreted by the gall bladder to facilitate emulsification of fat and transport of fat 
across intestinal walls (Hofmann 1963). Several other permeation enhancers have been 
reported in the literature. Most of them have been shown to be effective in animal models 
but very few have been tried in humans, and those that were tried showed limited success. 
Considerable research is required to identify efficient and safe permeation enhancers that 
will take the field of oral delivery of peptides forward. 
1.6 Protein modification 
1.6.1 Pegylation  
Pegylation as a protein/peptide modification is a technique of choice to improve the 
physicochemical properties of these drugs. Pegylation has been studied for several decades 
now with a considerable understanding of its toxicity in vivo across several rodent and 
non-rodent species. PEG of various different molecular sizes are used to either improve 
pharmaceutical properties like increasing solubility, or improving stability at room 
temperature. Several examples of modified proteins for sustained systemic exposure or for 
targeted delivery to the disease sites have been reported. Although several years of 
research has gone in the study on pegylation, the choice of PEG is still largely trial and 
error with limited ability to forecast the pharmacokinetic behaviour. The rate of absorption 
and extent of absorption of modified or pegylated proteins are believed to be governed by 
physiological factors, physicochemical properties and the interaction of the two in-vivo. 
Pegylation primarily results in increase in molecular size, which results in reduced renal 
clearance. This slower rate of clearance combined with ampiphilicity of the PEG results in 
peripheral distribution and possibly passive diffusion into several tissues. On the one hand, 
the large polymer size helps in prolonging the residence time in the body, while on the 
other hand, it might also result in tissue accumulation. There is some evidence of tissue 
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accumulation correlating with the molecular size of PEG. Lower molecular weight PEGs 
are readily cleared by the kidneys while for PEGs of molecular weights greater than 50 
kDa the clearance was primarily hepatic (Yamaoka et al. 1994). Do the changes in the 
physicochemical properties of protein result in different clearance pathway? A very good 
example is a study published by Chen et al. 2000. In this study the authors reported that 
pegylated interleukin-2 showed 130 times lower partitioning into the lymph node from the 
peripheral compartment and also had a significantly reduced rate of clearance. 
1.6.2 PEGs for reducing Immunogenicity 
In another study adenosine deaminase (ADA) was modified with polyethylene glycol using 
cyanuric chloride chemistry. The modified adenosine deaminase (PEG-ADA) showed 
lesser immunogenicity in mice following multiple dosing via intravenous administration. 
PEG-ADA showed lesser reactivity to the antibodies raised against native ADA, 
suggesting a change in the binding epitope. Pegylation also resulted in increased 
circulating half-life of PEG-ADA. The reduced immunogenicity and longer circulating 
half-life made PEG-ADA suitable for the treatment of ADA deficiency (Davis et al. 1981).  
On the other hand there are reports suggesting reduced pharmacokinetic exposure of 
pegylated liposomes. Ishida et al. have published multiple research articles clearly showing 
enhanced clearance of liposomes after repeated injections. The response across species is 
similar except for difference in time of preconditioning (Ishida et al. 2003, Ma et al. 2012). 
The same group reported the role of the spleen in enhancing the rate of clearance (Ishida et 
al. 2006). Koide et al. reported a connection between particle size of liposomes and the 
accelerated clearance of pegylated liposomes from circulation. The particles above 50 nm 
appeared to elicit an immune reaction resulting in faster clearance (Koide et al. 2008).  
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1.6.3 Pegylated insulins 
Considerable work has been undertaken to improve various aspects of insulin therapy. 
Several approaches have been reported in the literature pertaining to insulin conjugation. 
The focus has been towards either making faster acting insulin, for example lispro, aspart 
and glulisine, or towards insulin analogues having longer duration of action, for example 
glargine and detemir. Along the lines of detemir, there have been several other attempts of 
modifying insulin by conjugating insulin with fatty acids, PEGs or mono or 
polysaccharides, sialic acid etc. (Gregory et al. 2005). 
Work presented by Uchio et al. demonstrated that diglycosylated Insulin at B1 and Lys 
B29 position exhibit lower propensity for fibrillation while retaining biological activity. 
Conjugation at Gly A1 appears to result in decreased potency. On the other hand 
modification with PEG resulted in longer half-life and reduced immunogenicity as 
compared to glycosylated Insulins (Caliceti et al. 2003, Uchio et al. 1999). 
1.6.4 Pegylation for increasing half-life 
There are reports of pegylated insulin with increased half-life (Hinds et al. 2002). Hinds et 
al. studied the effect of site specific attachment of 750 Da and 2000 Da polyethylene glycol 
moiety. They tried conjugation at B1 and B29 sites and found that largely the secondary 
and tertiary structures remained unaffected. They reported a change in aggregation 
propensity with pegylation, pegylated insulin having lower propensity. B1 conjugated 
insulin showed significantly higher stability upon shaking. In addition, they also reported 
considerably lower antibody formation when injected in mice compared to unconjugated 
insulin.  The conjugated insulins also showed a relatively high bioavailability when 
injected in dogs. The half-life increased depending on the size of PEG. Larger PEG 
showed longer half-life. Similar increased half-life due to pegylation has also been 
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reported for other proteins. Walsh et al. (2003) reported increase in half life and reduced 
antibody reactivity for a 27 kDa endoprotease lysostaphin by attaching it to a PEG. The use 
of branched PEG for conjugation increased the half-life to 24 h as compared to less than 
the 1 h for unconjugated lysostaphin. However, no information could be found in literature 
regarding metabolism and clearance of pegylated lysostaphin. Glucagon was pegylated 
with PEG 5000 for achieving longer circulating half-life. Structural analysis showed 
monopegylated glucagon to have better physical and chemical stability during purification 
and freeze drying (Stigsnaes et al. 2007). No information was found in the literature 
regarding the metabolism and clearance of pegylated glucagon. 
Granulocyte colony stimulating factor (GCSF) and interferon are other two proteins which 
have been pegylated to increase circulating half-life of the molecule. The pegylated GCSF 
is marketed as Neulasta while Interferon alpha 2b is marketed as Interon and interferon 
alpha 2a is marketed as Pegasys. There are several reports stating the changes in the 
physicochemical properties as well as improved pharmacokinetic properties of proteins 
upon pegylation (Pasut et al. 2009, Bansal et al. 2011). Modi et al. reported that Peg 
interferon alpha 2a was primarily cleared by liver (Modi et al. 2000). There is very little 
information available on metabolism and clearance of pegylated proteins, although 
individually PEGs and proteins have been studied for many years.  
Currently, the modification of PEG is done empirically and it is difficult to predict the 
changes in the biopharmaceutical properties. Similarly, it is difficult to predict the 
metabolism and clearance pathway for pegylated proteins.  
1.7 Metabolism and elimination of PEG 
Abuchowski et al., 1977 reported modification of bovine serum albumin by covalently 
linking it to polyethylene glycol methyl ethers of 1900 and 5000 Da. The pegylated bovine 
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serum albumin did not elicit any immunogenic response in rabbits on intramuscular or 
intravenous administration. Pegylated bovine serum albumin was double labelled with 125I 
and 14C for the study. Both the labels were recovered completely in urine after 30 days, 
indicating complete clearance from the body. Additionally, researchers also reported 
significantly different solubility, sedimentation, electrophoretic and chromatographic 
behaviour of modified bovine serum albumin (Abuchowski et al. 1977). 
There are no definitive metabolism studies conducted on the PEG molecule. However, 
Webster et al. (2000) have published an extensive review of the available information in 
the literature on PEG metabolism. The metabolism of PEG appears to occur through the 
oxidation of the hydroxyl group of the PEG giving rise to dicarboxylic acid. For example, 
PEG metabolites like diacid and hydroxy acid were recovered in plasma and urine of burn 
patients, rabbits and in the biliary secretions of cats (Harold et al. 1989, Friman et al. 1993, 
Friman et al. 1990). Since PEG oxidation requires free alcohol groups, a similar 
degradation is not expected when the alcohols are blocked by methyl groups via ether 
linkages. PEG is reportedly metabolized via sulfation in the excised liver from guinea pig 
and in in vitro liver preparations of rat/guinea pig, by Roy et al., 1987, 1988. It can be 
concluded that ethylene glycol monomer is not recovered as a metabolite of PEG400 in 
humans (Schaffer et al. 1950). 
1.8 PEG toxicity 
PEG is metabolized by alcohol dehydrogenase in a phase 1 metabolism reaction in 
mammalian systems (Harold et al. 1989). P450s were suspected to play a role in PEG 
oxidation (Veronese and Pasut 2005).  The literature evidence shows that PEG metabolites, 
generated by a series of first and second phase metabolism reactions, show very little 
serious toxic effect in animals. However, overdosing of PEG is reported to give rise to 
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carboxylic metabolites and has been correlated with increases in calcium concentration in 
serum (Bruns et al. 1982). The rise in serum calcium and reduction in ionized calcium was 
attributed to calcium chelation due to dicarboxylate metabolites of absorbed polyethylene 
glycol. 
Upon chronic oral administration of PEG1500 at a dose of 0.06 g/kg/ day and PEG4000 at 
0.02 g/kg/day, for a period of 2 years, no serious adverse effects were seen in a rat model. 
When PEG1500 and 4000 were mixed with food at 4% concentration and given to rats, no 
adverse effects were observed. No effects were seen with PEG400 at 2% concentration in 
food, with higher doses not showing any specific effects on the liver. These data indicate 
that chronic administration of PEG in rats did not result in any serious toxicity issue. In a 
year long chronic toxicology study with PEG 400 to PEG 4000 in dogs no adverse effects 
were seen (Smyth et al. 1955).  
In a study conducted in monkeys, lesions on kidney were observed post oral administration 
of PEG200 at a dose of 2.2 to 4.4 g/kg. The lesions were associated with renal deposition 
of oxalate crystals but no clear association with adverse effects was reported (Prentice et 
al. 1978). PEG400 also has been reported to show adverse events in Monkeys upon 
intravenous administration. The side effects involved loss of appetite, a greasy texture of 
their lower extremities, swelling on the genitals and legs, and deteriorating infusion sites 
(Lockard et al. 1979). PEGs are neither associated with any teratogenicity or reproductive 
toxicity, nor do they cause mutagenesis or cancer (Fruijtier-Polloth 2005). 
Yamaoka et al. 1994 conducted a very systematic clearance study of PEG. They 
established a clear relationship of molecular weight of PEG with the rate of clearance from 
the body as well as distribution.  
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Figure 1.6: Effect of molecular weight on distribution of PEG and relationship of PEG 
molecular weight and its circulating half-life. (Reproduced from the publication of 
Yamaoka et al., 1994) 
The study covers the molecular weight range from 6 KDa to 170 KDa. The data presented 
clearly showed distribution of PEG to extravascular tissues as the PEG molecular weight 
decreased. Beyond molecular weights of 50 KDa, the PEG uptake by liver increased again, 
and the mechanism reported is pinocytosis. Does this mean that choosing the appropriate 
size of PEG for modification of a protein could be used for liver targeted delivery? And if 
it is indeed true, then it is all the more surprising that a liver targeted pegylated Insulin has 
not been reported yet. 
1.9 Absorption, Distribution, Metabolism and Elimination (ADME) 
Absorption, Distribution, Metabolism and Elimination (ADME) studies are conducted 
during development to assess metabolic/degradation pathway, rate of distribution, rate and 
route of elimination of the drug compounds, and to identify any potential toxic metabolites 
ahead of in-vivo testing. Typically, ADME studies are carried out by radiolabelling the 
molecule which enables the tracking of molecules even after transformation within the 
body. Several in-vitro systems have been developed to study the metabolites and have been 
reviewed by Plant 2004. No formal ADME studies are generally carried out for proteins as 
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the proteins are expected to get processed by proteases and the amino acid subsequently 
recycled. 
1.9.1 Insulin degradation: 
Insulin degradation has been extensively studied and reported in the literature. There are 
several reports on the mechanism of insulin metabolism in various in vitro and in vivo 
systems. Insulin degradation activity was reported in isolated liver cells by Varandani et 
al., 1976. The data presented in the publication tracked the sequential degradation of 
insulin, where two chains of insulins are separated first by glutathione insulin 
transhydrogenase followed by proteolytic digestion. It was also shown that the A-chain 
accumulated when the samples were treated with EDTA. At higher concentration of insulin 
EDTA was not effective in inhibiting the proteolysis. Duckworth et al. (1997) reported two 
separate pathways of insulin degradation, one pathway which could be inhibited by insulin 
degrading enzyme inhibitors and another pathway that could be blocked with inhibitors of 
cellular processing. It is generally recognized that the rate of insulin degradation is 
governed by the rate of binding of insulin to its receptor. The insulin bound to its receptor 
is metabolized by proteases associated with cell surface and the internalized insulin and 
insulin fragments are metabolized by lysosomes. 
Monoiodinated and tritiated Insulin were studied for metabolism by rat hepatocytes. Upon 
incubation at 15°C and lower, hepatocyte bound insulin showed no degradation for a 
period of 2 h. While at 37°C, fragments with higher mobility in gel electrophoresis as 
compared to Insulin were detected. The fragments showed binding to anti-insulin 
antibodies, indicating that the binding epitope was unaltered. On the other hand, affinity 
towards the insulin receptor was greatly compromised. The fragments were identified to be 
Insulin cleaved at Arginine B22. Accumulation of Insulin upon incubation with lysozyme 
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in the presence of Chloroquine, an inhibitor of lysozyme, confirmed that one of the 
pathways involved in Insulin degradation involves lysozyme. The group reported the 
presence of two separate degradation pathways for Insulin (Misbin et al. 1983).  
Yu et al. 1996 proved that the proteins tyrosine phosphatase inhibitors, Peroxovanadate 
and vanadate, inhibit insulin degrading enzymes in isolated rat liver endosomes. While 
studying the impact of peroxovanadium on receptor phosphorylation, Bevan et al. further 
confirmed modest inhibition of insulin degradation in rat liver using intra portal injection 
of vanadate. Insulin degradation within isolated rat liver endosomes was inhibited by 1,10-
phenanthroline. In the presence of excess Cobalt the degradation got reactivated, 
confirming that the degradation of insulin involves metalloproteases. Based on kinetics 
data and subsequent recovery of intermediates with intact A-chain, it was further 
concluded that endosomal degradation occurs simultaneous to degradation of B-chain with 
the disulphide bond still intact. The two chains are later separated by disulphide bond 
cleavage. Simultaneous appearance of various intermediates led to the conclusion that 
degradation of Insulin does not happen through sequential reactions, but through more 
complex parallel processes (Bevan et al. 2000, Seabright et al. 1996). Despite these studies 
there is considerable ambiguity in the sequence of degradation of insulin. 
Insulin processing has been fairly well studied. A significant proportion of secreted insulin 
is processed in liver during the first pass. The first step in the degradation involves 
separation of chain A and chain B. This reaction is reported to be mediated by an enzyme 
called glutathione insulin transhydrogenase. Subsequently each of the polypeptide chain 
undergoes proteolytic cleavage.  
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A conjugated insulin analogue Levemir® has been developed and marketed by Novo 
Nordisk. In their NDA submission package the comparison of metabolic pathway of 
Insulin Detemir (Des B30 analogue with myristic acid modification at lysine B29) and 
insulin in the presence of liver and kidney cytosol was presented to the FDA. The results 
indicated that Detemir and insulin degraded in a similar manner in the liver or kidney 
cytosol in in-vitro experiment and the first step in degradation was separation of two chains 
by cleavage of disulphide bonds (Medical review, US FDA document number 21-536).  
1.10 Pegylated Insulin: A novel Insulin analogue: 
Oral delivery of peptides and proteins is an attractive alternative to parenteral delivery and 
has remained as a formidable challenge despite several research groups attempting to 
improve the bioavailability of proteins upon oral delivery. Technologies to improve the 
translocation of proteins across membranes are needed to achieve high oral bioavailability 
of protein or peptides. The following approaches have been explored for achieving high 
bioavailability: modification or conjugation of proteins to improve solubility, improved 
resistance to digestive enzymes, increased transport across membrane, or novel 
formulation technologies which will increase survival of the molecule, as well as transport 
of the molecule through gut wall (Sakuma et al. 2001). So far the individual approaches 
have not yielded any approved new drug products. It is very likely that a hybrid approach 
of modification combined with a formulation technology may give better success. 
1.10.1 Modification of Insulin: 
Pegylated insulin, a novel insulin analogue, is being developed by Biocon Limited. 
Bangalore (India), for the treatment of diabetes.  It has identical polypeptide sequence to 
that of native insulin, and has a modification with alkyl peg at ε-amino group lys-B29 
(figure 1.7). Pegylated insulin is unique in that no new molecules with small molecular 
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weight PEG modification have made it to the clinical development stage. Preparation and 
purification process of pegylated insulin is disclosed by Dave et al. (2008). The human 
recombinant insulin conjugated using NHS ester of an oligomer via site specific reaction 
conditions. The oligomer was then purified using a series of preparative HPLCs to reach 
desired purity. 
 
Figure 1.7: Structure of pegylated insulin 
The pegylated insulin purified as described above is then converted in to a tablet dosage 
form. The tableting process involves unit processes which can result in high shear during 
blending and high compression forces during the tablet punching. As part of our research 
for this thesis, we have tried to determine the impact of these high shear unit processes on 
the structure of pegylated insulin. Insulin having three disulphide bridges is a fairly stable 
protein. However, the tableting process exposes the molecule to high pressure at the time 
of compression in a dry powder form. All the literature that is available today is around 
understanding the effect of hydrostatic pressure in the liquid state. Little or no information 
is available regarding the effect of high pressure on protein crystals in a dry state.  
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1.10.2 Effect of pegylation and tableting on structural integrity of the molecule 
Upon oral delivery of pegylated insulin, the peak plasma levels are reached in about 20 
min and the molecule is cleared from circulation in about 60 to 80 min. This rapid 
pharmacokinetic profile helps in reducing the post prandial glycemia up to about 2 h. The 
rapid onset and peaking makes the molecule a fast acting insulin in development (Iyer et al. 
2010, Khedkar et al. 2010).  
1.11 Aim of research 
In the work presented in this thesis, we have made an attempt to understand in vitro and in 
vivo metabolism for pegylated insulin, so as to understand the fate of oligomer. Once the 
pegylated insulin is absorbed, it is important to understand if the PEG moiety remains 
attached to the polypeptide chain or is likely to get cleaved off. In the case where it 
remains linked to the amino acid, there is a possibility that some fraction of the conjugated 
amino acid would get incorporated into protein synthesis and lead to accumulation, as this 
is expected to be a chronic therapy. The accumulation if found, could raise safety concerns 
which would need to be studied further. In addition, we were also interested in 
understanding if the pegylation alters or interferes with the degradation pathway of insulin. 
To our knowledge, no publications could be found that investigate the impact of pegylation 
on the insulin or any other pegylated protein degradation pathway. We also made attempts 
to identify the metabolites of pegylated insulin in the hepatoblastoma cell line using mass 
spectrometry. Besides studying degradation using a cell line we have also attempted to 
study in-vivo degradation in a rat model. The objective here was to understand how the 
pegylated insulin is likely to get processed and to understand the fate of the oligomer in a 
rat model. 
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Our hypothesis was that pegylated insulin is likely to be processed similarly to native 
Insulin in both in-vitro and in-vivo systems and that pegylation does not influence the 
processing of Polypeptide. Based on the literature survey on PEG metabolism and 
clearance, the alkyl PEG used in conjugation of Insulin is likely to get cleared from the 
system without any adverse effect on the body. The experimentation involved testing of 
this hypothesis in rat hepatocyte cell line and the in-vivo studies were carried out in a 
normal wistar rat model and the route of elimination of these metabolites was identified. 
 
The aim of our research was to understand the impact of formulation on structural changes 
of pegylated insulin toward oral insulin development.  
In addition, we also studied the metabolism of pegylated insulin in an in-vitro setting and 
identify the metabolites.  
We also aimed to study metabolism in an in-vivo setting, and traced the route of 
elimination for these metabolites. 
Lastly, we studied the enzymatic degradation of pegylated insulin, as well as degradation 
in blood, in an attempt to devise a strategy for future development. 
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Chapter 2 
 
 
Effect of tableting on the structure of 
pegylated insulin 
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2.1 Background and Introduction 
For a commercially viable product, development of a dosage form is critical. Formulation 
development of pegylated insulin is a key component of developing a bioavailable delivery 
form. Even though pegylation improves the in vivo survival of insulin, due to its large size 
a permeation enhancer is needed to take it across membranes. Since Insulin therapy is a 
chronic therapy, safety of the permeation enhancer is an important concern. Several 
permeation enhancers are reported in the literature, out of which salts of short chain fatty 
acids are considered safest. Amongst the short chain fatty acids, lauric acid and capric acid 
were found to be better than other fatty acids. Based on PK/PD studies carried out in a 
pancreatomized dog model at Vanderbilt University, capric acid was chosen as the 
permeation enhancer as use of capric acid showed higher systemic exposure to insulin.  
Capric acid is a liquid in its acid form, hence a sodium salt was used in the formulation. 
Sodium caprate is an unconventional excipient and there is practically no experience of 
using it as a pharmaceutical excipient. Sodium caprate is a waxy, fibrous material (figure 
2.3) and is difficult to handle during the manufacturing process. Much of the challenge 
faced during process development was due to sodium caprate. Sodium caprate can cause 
local irritation of nasal mucosal layers if inhaled, which makes handling it difficult. 
Additionally, the powder has poor and inconsistent flow properties, compression index and 
low bulk density, which makes it difficult to compress tablets of required hardness. 
Hardness of the tablet is important for physical stability during manufacturing and 
transportation. In addition, the bulk density of sodium caprate varied considerably. During 
development, the bulk density was found to vary from 0.04 g/cm3 to 0.27 g/cm3. This 
variation causes significant variation in capacity utilization and also affects mixing 
homogeneity, which poses content uniformity challenges. To overcome inconsistency in 
the flow properties, the powder was converted to granules by using a wet granulation 
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technique with isopropyl alcohol as the granulating agent, which helped fusing the fibres 
together resulting in considerable change in surface properties of the caprate particles. The 
granulated sodium caprate had higher bulk density (~ 0.3 g/cm3 vs 0.04 g/cm3) and better 
flow properties and compressibility index than the initial powder. Increase in the density 
had an impact on the batch size and capacity utilization of high shear granulator. Improved 
flow property resulted in better flow through the hopper, less segregation on the turret and 
more consistent filling of tablet die, thereby improving consistency on tablet weight. Better 
compressibility index enabled compression of tablets with high hardness, which gave the 
tablet better physical stability without affecting dissolution or other parameters. 
Mannitol was selected as a diluent. Mannitol being a non-reducing sugar was chosen over 
lactose, starch or maltodextrin. The concern with lactose, starch and maltodextrin are that 
they contain glucose, which is a reducing sugar. Proteins are known to undergo the 
maillard reaction with reducing sugars. This concern was eliminated by the choice of 
Mannitol. The other components of formulations are disintegrating agent, glidant and 
lubricant.  
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A flowchart on the manufacturing process of pegylated insulin tablets is presented 
below; 
 
Dispensing and Sieving 
Spray dried mannitol, 
crosspovidone and fumed silica 
Pegylated insulin and Magnesium 
stearate were dispensed and passed 
through a sieve. 
 Granulation of Sodium caprate 
Sodium caprate is granulated using 
alcohol as the granulating agent. The 
granules are dried and sized as per 
requirement using Quadro Co mill. 
  
  
 Checked for residual IPA content  
 Checked for moisture content 
 
 
Blending 
 
Pegylated insulin Drug substance is blended with other excipients using geometric 
mixing for 30 min using an octagonal blender. 
 
 
Lubrication 
The blend is lubricated with Magnesium stearate prior to compression for 3 min. 
                                                                             Tested for Moisture Content, Bulk 
                                                                             density (tapped & untapped),  
                                                                             Compressibility index, Hausner ratio 
                                                                             Repose angle and Blend Uniformity. 
 
Tablet Compression 
 
In-process testing (Weight, Hardness, Thickness, Friability and Disintegration),   
Complete Analysis of Tablets 
2.1.1 Solid solid mixing: 
The tablet manufacturing process involves mixing of all the excipients in the solid state. 
For any solid-solid mixing to happen homogeneously, the physical compatibility of all the 
material is important. There are no mathematical models currently available which can 
predict multi component solid-solid mixing accurately. Hence it is a good practice to 
ensure that the size and shape of all the components are closely matched as much as 
possible to prevent segregation of individual components from the mixture. Typically, 
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smaller particles tend to segregate from the larger particles in the hopper due to the 
vibrations of the machine, leading to variation in content uniformity or weight variation. In 
addition, segregation is also possible in the turret due to the continuous motion. The 
difference in density, and differential amounts of each material, adds to the complexity of 
solid-solid mix and are leading causes of segregation of material (Ottino et al. 2000). The 
surface morphology of the various excipients was studied under scanning electron 
microscope to get an idea of size and shape of the particles.  
2.1.2 Proteins under pressure 
Behaviour of proteins has been a subject of intrigue for several years. For example, life in 
the ocean can exist at very high pressure and studies in this area have led to some 
understanding of protein requirements at high pressure. Several publications subsequently 
have shown that high pressure prevents fibrillation. Dzwolak et al. 2003, reported that 
when bovine insulin is subjected to pressure it prevents aggregation. Later Jansen et al. 
2004 reported that under pressure insulin tended to grow fibrils elongating in one direction 
and formed circular loops of fibrils which was contradictory to the previous reports. In 
some cases, preformed aggregates dissociate back to non-aggregated state (Gorowits et al. 
1998) and in some cases pressure leads to formation of aggregates (Ferro-Gonzales et al. 
2000).  
Since, there are no tablet dosage forms for therapeutic proteins available in the market, 
hence virtually no studies have been reported towards understanding the behaviour of 
proteins in solid dosage forms, nor is the impact of the manufacturing process well 
understood. The compression of pegylated insulin tablets involves a pressure of 25 kg/cm2 
to ensure that the tablets have sufficient hardness, so that they can survive the packaging 
process and later do not lose integrity during shipping. In addition, an increase in 
62 
 
temperature during tablet compression is a well-documented phenomenon. Pressure is one 
of the factors known to affect the secondary and tertiary structure of proteins and has been 
well studied. At pressures below 200 MPa, the structural changes are typically reversible, 
however, at higher pressure (pressures above 200 MPa) the compaction brings the 
molecules close enough to result in changes that are irreversible in nature. When the 
molecules are close to each other and pressure is applied, one of the major changes that 
was expected was aggregation of pegylated insulin.  
The functionality of a protein is closely associated with its structure, which is sensitive to 
high temperature and pressure (Meersman et al. 2006). Application of pressure to proteins 
may lead to reversible or irreversible denaturation (Mozhaev et al. 1996). Hummer et al. 
1998 reported that protein destabilization under pressure results from insertion of water 
into the molecule, which leads to disturbance in hydrophobic bonds within the molecular 
structure, leading to destabilization. Hence dry proteins do not undergo denaturation due to 
temperature or pressure (Goossens et al. 1996). 
Pressure induced changes in the three dimensional structure, dynamics and function of 
proteins has been reviewed extensively in the literature (Mozhaev et al. 1996). A pressure 
greater than 200 MPa or 2 kBar has been shown to cause irreversible denaturation of 
biological membranes and proteins (Jonas et al. 1994). Studies suggest that pressure 
induced denatured proteins have a high percentage of residual structure conserved and the 
changes are of a reversible nature (Li et al. 1976). Research by another group suggested 
that the pressure induced changes are irreversible in nature (Wong et al. 1988). The 
difference between these two conclusions could have been due to the concentration of the 
protein. At lower concentrations the changes were found to be reversible while at 10 fold 
higher concentration, the same protein exhibited irreversible pressure induced changes. 
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Thus once the pressure influence is removed there is a high probability that a protein 
regains its native structure if denaturation is not complete. Most of the literature is focused 
on studying pressure effects in the liquid state, primarily because traditionally proteins are 
used in solution form. Attempts to understand the pressure effects on protein in a solid 
state are important for the potential future development of solid dosage forms of proteins. 
Existing literature was not directly applicable to our investigation due to the difference in 
the state of the samples. 
While the data from animal experiments (not published) and human experiments (Khedkar 
et al. 2010) showed that pegylated insulin gets absorbed intact, bioavailability of it is still 
low. There is considerable scope for improvement in bioavailability. As mentioned earlier, 
proteolytic degradation could play a big role in bioavailability. It is also important to 
understand if there are any structural changes to the molecule during the process of tablet 
manufacturing. The potential structural changes were studied primarily using circular 
dichroism in the experimentation study described in this thesis chapter. Pullen et al., 1976 
have studied biological properties of chemically modified insulins (modification at A1) 
and they concluded that the modification at A1 leads to change in conformation and loss of 
biological activity.molecular conformation is critical for activity. Hence studying the 
impact of the tableting process on structure is important. 
The ensemble of therapeutic proteins has expanded exponentially in recent years due to 
rapid biotechnological advances (Dimitrov 2012). Although the common route of 
administration of therapeutic proteins has been through injections, a lot of research and 
development is being done towards achieving oral delivery of such proteins (Singh et al. 
2008). Pegylated orally bioavailable Insulin is one such anti diabetic therapeutic protein 
that is expected to be amenable to oral delivery (Khedkar et al. 2010) in the form of tablets. 
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The unit processes involved in tablet manufacturing involves high shear and high 
compression forces, which may affect structural stability of proteins. The heat release 
during the tablet compression has been well documented (Wurster et al. 1986, Zavaliangos 
et al. 2008).  
 
Figure 2.1: Infrared temperature map of the tablets. Below the tablet, image of the lower 
die is visible. (Image reproduced from Zavaliangos et al. 2008) 
From figure 2.1 it can be seen that the temperature at the top surface and the sides, which 
comes in contact with upper punch and the walls of the die, had higher temperature 
compared to the edges and the lower surface. The magnitude of the temperature rise was 
reported to be approximately 8 to 12 ̊C. If a similar magnitude of temperature rise occurred 
during tablet compression for pegylated insulin, it could potentially be enough to affect 
protein structure and function. 
The tableting process involves mixing of pegylated insulin API with the excipients sodium 
caprate, mannitol, polyvinyl pyrrolidone, colloidal silica, and magnesium stearate, which 
is referred to as ‘blend.’ The tablet is formed by compression (under pressure of 25 
kg/cm2) of the pegylated insulin blend, and this is referred to as ‘tablet’ throughout this 
chapter. In this study, it was assumed that any structural attribute that is present in the solid 
state of the blend and the tablet will be carried over into the solution state and would 
thereby influence the solution results obtained. It was also assumed that the results 
obtained were likely to represent irreversible changes, as during transition of the tablet to a 
solution any reversible changes would be lost. 
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With the above background, as part of this work, the pressure induced effects on pegylated 
insulin were studied using CD spectroscopy, mass spectrometry, and size exclusion 
chromatography (SEC). 
2.1.3 Selection of pH for the experiment 
The physicochemical attributes with respect to structure of pegylated insulin in blend and 
tablet in physiological solution conditions (pH 7.4) were studied to decipher the effect of 
the tableting procedure on pegylated insulin’s structural integrity. Besides the 
physiological condition, the studies were also performed in alkaline solution conditions 
(pH 9.6). It is known that at pH>9 the oligomer formation tendency of the Insulin 
molecule increases (Brange 1994) owing to differential disulphide interactions, arising 
probably due to changes in the side chain packing of Insulin at high pH. Considering that 
pegylated insulin is analogous to Insulin, any change in the side-chain packing should be 
reflected, more so under high pH condition, hence the selection of this pH condition.  
One of the ways to study the effect of pressure on the protein structure is through 
unfolding studies by temperature and chemical melting. Unfolding by temperature melt 
enables determination of the melting temperature and the enthalpy change associated with 
melting, thus giving both quantitative and qualitative insight into the stability of and 
structural attributes of the molecule (Benjwal et al. 2006). Chemical denaturation using 
Urea or Guanidine hydrochloride helps to determine the free energy change associated 
with unfolding, as well as aids in understanding the protein unfolding process, since 
depending on the denaturant concentration used, one can trap and study, besides the 
unfolded and native states, the partially folded intermediate states and low energy excited 
states (Pace 1986). Thus using both thermal and chemical denaturation studies one can 
experimentally access the widely accepted ‘funnel view’ model of protein folding, which 
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is also known as the ‘energy landscape model’ (Plotkins et al. 1997). With this additional 
background, we also studied the thermal denaturation of pegylated insulin present in tablet 
and blend monitored at 222 nm by CD spectroscopy. It is expected that this study will 
form the basis to analyze the conformational stability of pegylated insulin in tablet and 
thereby provide insights into its circulatory time in the body. 
2.2 Materials and Methods 
2.2.1 Pegylated insulin blend and tablet preparation and dissolution in solvents for 
solution studies 
The pegylated insulin was prepared as described previously by Partha et al. 2012. Blend 
was prepared by the addition of all the excipients in a geometric ratio of 1:1.6. The tablets, 
containing 5 mg of pegylated insulin, were prepared by direct compression of pegylated 
insulin API blended with sodium caprate, mannitol, polyvinyl pyrrolidone, colloidal silica, 
magnesium stearate as excipients. 
For preparation of the stock solutions used in this study, 337 mg of blend containing 5 mg 
of pegylated insulin and one 5 mg tablet were dissolved in 15 mL of buffers to give a final 
concentration of 50 μM of pegylated insulin. The basic solution was prepared by 
dissolving one tablet in 20 mM Tris- HCl buffer (pH=9.6). Similarly for the preparation of 
neutral solution, dissolution was done in 7 mM Phosphate buffer (pH=7.4). Working 
stocks were appropriately prepared for each experiment. 
2.2.2 Scanning electron microscopy: 
SEM scans of all the excipients were done using a JSM 6701 F field emission scanning 
electron microscope manufactured by JEOL Company limited, Japan. The samples were 
fixed on a stub of metal with carbon paste adhesive, coated with 40Ǧ60nm gold and then 
scanned under the microscope. 
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2.2.3 CD spectroscopy 
Samples were prepared in both 20 mM Tris- HCl buffer (pH=9.6) and 7 mM Phosphate 
buffer (pH=7.4) to give final concentration of 50 μM of pegylated insulin, for which Far-
UV (260-200 nm) scans were acquired using a JASCO J-815 CD Spectrometer was 
obtained using 1 mm cuvette, with data pitch as 0.1nm, Data Integration Time (D.I.T) of 1 
second and scanning speed of 200 nm/min. 
2.2.4 Thermal denaturation and melting curve data fitting 
Thermal denaturation was studied using CD technique by temperature melting 
experiments. The temperature melting was carried out from 15°C to 95°C with the help of 
the Peltier Temperature Controller (PTC-423S/15) with ramp rate and the temperature 
interval optimised at 3°C/min and 2°C, respectively. The data were fitted into the equation, 
ݕ௢௕௦ ൌ
ቈሺ௬೙ା௠೙்ሻାሺ௬ೠା௠ೠ்ሻ௘ቀ
οಹೠೃ೅ శ
οೄೠೃ ቁ቉
ቈଵା௘ቀ
οಹೠೃ೅ శ
οೄೠೃ ቁ቉
 ………...……….. (Dignam et al. 2001) 
Where, 
yobs= Observed ellipticity, yn = y intercept of native baseline, mn = slope of native baseline, 
yu = y intercept of unfolded baseline, mu = slope of unfolded baseline, T = absolute 
temperature (°K), R = Gas constant (1.98 cal/mol °), ΔHu = Enthalpy change of unfolding, 
ΔSu = Entropy change of unfolding, using Microsoft Solver which is a very powerful 
routine based on the Marquardt–Levenberg algorithm and is used for the nonlinear least-
squares curve-fitting. The structural content were calculated using data fitting into Chen’s 
equation. 
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2.2.5 LC-ESI-MS data acquisition and analysis: 
The LC-ESI-MS analysis was carried out using ESI HCT Ultra PTM discovery system 
(Bruker Daltonics, Germany) using 10 mM Ammonium acetate buffer (pH=7.4 and 
pH=9.6) and 100% Acetonitrile (ACN) as mobile phases and ACE® C-18, 250 mm x 4.6 
mm, 5 μm particle size, as column. The column was initially equilibrated with 25% 
acetonitrile and the percentage of acetonitrile increased gradually to 40 in 15 min, during 
which the compound eluted at around 12 min. This was further followed by a wash step of 
5 min with 60% acetonitrile and column re-equilibration. Mass Spectrometric analysis was 
carried out for the before and after melt samples in the respective buffers and data acquired 
in positive ionization mode with nebulizer gas pressure of 65 psi, dry gas flow of 11.0 L 
min-1, drying temperature of 365°C and a target mass of 1400 m/z. 15 μL of sample was 
injected with a flow rate of 1.0 mL/min.   
2.2.6 Size Exclusion Chromatography: 
The buffers employed were 7 mM phosphate (pH 7.4), 20 mM Tris (pH 9.6) and an 
Arginine buffer (L-Arginine (1 g/L)/acetic acid/acetonitrile 65/15/20 v/v/v). Size exclusion 
column manufactured by Waters (Insulin HMWP SEC Column, 125Å, 10 μm, 7.8 mm X 
300 mm, 5K - 150K, [WAT201549]), was employed for an isocratic method of 30 min 
duration having a flow rate of 0.5 ml/min with the injection volume of 100 μl sample (1 
mg dissolved in 1ml of the respective buffer). 1mg/ml lysozyme served as a marker. 
2.2.7 Hydrogen Deuterium exchange: 
The pegylated insulin was reconstituted in 5 mM phosphate buffer for structural studies 
through D2O exchange. The hydrogen atoms in pegylated insulin were replaced with 
deuterium by maintaining a ratio of 1:15 (hydrogen: deuterium) for 10 min. The 
experiment is purely temperature dependent and hence the temperature was maintained at 
69 
 
21°C. The exchange was stopped by the addition of ice cold 25 mM citric acid. In order to 
maintain low levels of back exchange, the samples were spotted immediately using alpha-
cyano-4-hydroxy-cinnamic acid, on a chilled Matrix assisted laser desorption ionisation 
(MALDI) target plate and the spectrum was acquired within a time frame of 3-5 min.  
2.3 Results and Discussion 
As part of an exercise to understand the nature, size and shape of the particles, all the 
components of the formulation were studied under scanning electron microscope. The 
SEM pictures below reveal the detailed information on the particles for each of the 
excipient. 
The particles were observed under different magnification wherein the magnification was 
chosen based on the particle size distribution found during the initial scan. For SEM to 
work, the samples need to be dry and should not be deliquescent. Pegylated insulin being a 
freeze dried material has tendency to absorb moisture when exposed to atmosphere but was 
not found to be deliquescent in nature which allowed us to scan it under SEM. None of the 
other excipients posed any challenge in handling during sample preparation for SEM. 
A B  
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C  
Figure 2.2: SEM image of crystals of pegylated insulin. First image of the particles (top 
left, Panel A) was acquired at 1000X magnification, the top right image (panel B) was 
acquired was under 10000X magnification and the image at the bottom left (panel C) was 
acquired under 25000X. All the images were acquired from nearby fields. 
From the SEM images (figure 2.2) of pegylated insulin, it appears that the crystals are 
fractured and contains a wide size distribution. The particles range from 100 nm to 20 
micron size. Smaller particles appear to be present in clusters and the larger particles have 
non-homogeneous shape and size. Some crystals are cuboidal with well-defined edges 
where as several particles appear to be fractured. The impact of this wide distribution in 
particles size and shape is not clear but it was conceivable that it could be playing a role 
during blending. 
 A   B  
Figure 2.3: Above SEM scans show that sodium caprate before granulation is fibrous in 
nature (panel A). The diameter of the fibre is around 60 nm to 300 nm (panel B).  
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 A     B   
Figure 2.4: SEM scan of sodium caprate granules (panel A), after granulation the fibres 
appear to be fused with one another (panel B).  
The SEM scans, figure 2.3, of sodium caprate before granulation shows that the caprate in 
its native state is fibrous with fibres ranging from 60 nm to 300 nm in thickness. Caprate is 
also waxy in nature and develops static charge easily. These properties of sodium caprate 
make it a very challenging excipient to work with during tableting. Figure 2.4 left image 
(panel A) shows SEM scans of sodium caprate acquired after granulation of sodium 
caprate. The image on the left shows sodium caprate granules which look completely 
different from the sodium caprate before granulation. The granulation was done using 
isopropyl alcohol as a solvent at very low volume. The amount of solvent used was just 
enough to wet the sodium caprate. Granulation results in the fibres fusing together and 
forming slightly more compact particles. The use of isopropyl alcohol perhaps results in 
dissolution of the surface of caprate (figure 2.4, right image, panel B), which helps during 
the granulation stage. Granulation of caprate improves the flow properties of the caprate 
significantly and also helps during handling. 
SEM scans of all the other excipients were taken (not shown here), which clearly showed 
that particle size and shape of each of the excipient varied considerably, which could 
potentially create issues during mixing as well as could result in segregation during off 
loading the blend, or in the hopper of the tableting machine, or on the turret during 
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compression. Hence the blending was done in a geometric fashion to attain a homogenous 
blend. 
2.3.1 Pegylation does not alter structure of insulin. 
The CD spectra in these experiments were recorded from 200 nm to 260 nm. There was 
considerable noise observed when we attempted to record the spectra below 200 nm. Due 
to this, there was a limitation in getting a definitive estimate of random coil and to some 
extent alpha helical content. The minima for random coil typically appears at 204 nm and 
one of the minima for helix is expected at 207 nm. During the melting experiments it was 
observed that the RMS values obtained from curve fitting using Chen’s equation (Chen et 
al 1974), increased beyond 20% consistently at higher temperature, hence the calculations 
of structural contents were less reliable. But from the graphs, it was possible to understand 
the changes in the structure.  
The first set of experiments was performed to compare recombinant human insulin and 
pegylated human insulin. When the purified lyophilized crystals of either product were 
dissolved in 0.1N hydrochloric acid (figure 2.5 and figure 2.6) at room temperature, the 
CD profile showed clear minima at 208 nm and 222 nm, indicating well-formed structure 
with helical content. Beta sheet content was also seen, with a CD minima around 214 nm. 
During the melting experiment, upon heating to 95 ̊C, the structure was stable up to 
temperatures of around 50 ̊C, after which there was a visible sign of unfolding. The helical 
content decreased from 36% to about 16% with increase in temperature in both the 
products. 
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Figure 2.5 CD spectra overlay at various different temperatures for pegylated insulin 
dissolved in HCl at pH 2.0 
 
Figure 2.6: CD spectra overlay at various different temperatures for Insulin dissolved in 
HCl at pH 2.0 
 
At pH 7.4 in phosphate buffer, upon melting (figure 2.7 and figure 2.8), the minima shifted 
towards 204 nm and we also saw a lowering of elipticity at 200 nm, indicating unfolding of 
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the structure.  The unfolding resulted in increases in coil content for both the products. The 
extent of retention of residual structure appeared to be higher for pegylated insulin. 
 
Figure 2.7: CD spectra overlay at various different temperatures for pegylated insulin 
dissolved in Phosphate buffer at pH 7.4 
 
 
Figure 2.8: CD spectra overlay at various different temperatures for insulin dissolved in 
Phosphate buffer at pH 7.4 
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In tris buffer at pH 9.6 (figure 2.9 and figure 2.10), there was no change in the minima 
from 208 nm. However, the minima at 208 nm became more pronounced. There was no or 
minimal change in the minima with rise in temperature but the magnitude was less 
pronounced at higher temperature. The profile appeared to be different from what was seen 
at pH 7.4 in phosphate buffer, although the CD data doesn’t enable determination of the 
exact structural differences.  
 
 
Figure 2.9 CD spectra overlay at various different temperatures for pegylated insulin 
dissolved in Tris buffer at pH 9.0 
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Figure 2.10 CD spectra overlay at various different temperatures for insulin dissolved in 
Tris buffer at pH 9.0 
The helical content of the pegylated insulin molecule in the blend and tablet was found to 
be similar (~30%) by Far-UV Circular Dichrosim (CD) spectra showing that the 
compaction pressure did not affect the global secondary structure of pegylated insulin. 
This was substantiated by similar electro-spray-ionization (ESI) spectra, Hydrogen-
Deuterium (HD) exchange values, and profiles for blend and tablet which are discussed 
later in the chapter.  
2.3.2 Formulation excipients may have a protective effect on pegylated insulin 
For facilitating tablet dosage for manufacturing, the active drug was mixed with excipients 
prior to compression. These excipients play a key role in ensuring that the tablets are 
aesthetic, and release the drug at the site of absorption in the desired manner. To ensure 
that all the tablets behave consistently, homogenous mixing is critical. At large scale, 
mixing is done using blenders; such as an octagonal blender, ribbon blender, cone or 
double cone blender. Blending is typically achieved with a tumbling motion inside the 
blenders. Due to this tumbling motion, the large bulk of particles move inside the blender 
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resulting in friction between the particles. The particle surface properties, density and 
particles size all play an important role. The blend of pegylated insulin and its excipients 
was dissolved in HCl buffer at pH 2.0, and separately in phophate buffer 7.4, and the blend 
was subjected to CD, mass spectrometric analysis and hydrogen-deuterium exchange. 
A hydrostatic pressure greater than 300 MPa is known to irreversibly damage the structure 
of proteins in solution state, whereas lower pressure results in reversible changes in 
proteins (Heremans K 1993). No literature is available regarding the effect of pressure on 
completely powdered forms of proteins. When pressure is applied onto pegylated insulin 
during tableting process, irreversible changes to the pegylated insulin structure were 
anticipated. However, the tableting pressure was not detrimental to the pegylated insulin 
structure.. The overall global structural attributes were intact even after high pressure 
applied during tablet manufacturing process and the local effects were small.  
 
 
Figure 2.11: CD spectra overlay at various different temperatures for pegylated insulin 
blended with all the formulation excipients, dissolved in HCl at pH 2.0 
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Figure 2.12 CD spectra overlay at various different temperatures for pegylated insulin 
blended with all the formulation excipients, dissolved in Phosphate buffer at pH 7.4 
 
Figure 2.11 shows CD spectra from melting experiment performed with pegylated insulin 
blended with excipient dissolved in HCl. The excipients fumed silica, magnesium stearate 
and crosspovidone were insoluble in water and were removed by centrifugation. The 
supernatant was used for the melting experiment. The spectra of blend and the spectra of 
purified pegylated insulin were similar and showed similar temperature profiles. When the 
Tm values were compared, an increase of approximately 9 °K was observed for the blend 
over Tm value of the drug itself. 
When pegylated insulin was dissolved in phosphate buffer at pH 7.4, a slight increase of 
about 5 °Kelvin in the Tm value was observed, compared to that for a solution in HCl. This 
increase was expected, as at pH 2.0 human insulin is known to be in a monomeric state 
whereas at neutral pH, it is known to be present in a hexameric state. When the pegylated 
insulin blend was dissolved in phosphate buffer (figure 2.12) and CD spectrum was 
compared with purified pegylated insulin solution in phosphate buffer. It was noted that the 
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degree of unfolding was less in presence of excipients. Only at temperature above 85 °C 
was a slightly higher amount of random coil observed in the blend, as seen from a slight 
shift in the minima from around 208 nm to 204 nm. 
An explanation of the intriguing fact that the protein pegylated insulin was not affected by 
a 25 kg/cm2 (2.45 MPa) pressure may lie in the shielding that the excipients provide to the 
protein molecules. To explore this aspect we compared the size exclusion chromatograms 
of pegylated insulin API and blend (Fig. 2.13A). It was appealing to see that the blend 
exhibited a higher oligomeric state when compared with that of insulin, giving direct 
evidence that the excipients play a role in the oligomerization of pegylated insulin. A 
closer look at excipients shows that two of them, namely polyvinyl pyrrolidone and 
colloidal silica, can act as pressure absorbers. The colloidal silica may be visualized as 
cushioning pegylated insulin from high pressure and polyvinyl pyrrolidone might be 
triggering higher oligomer formation for pegylated insulin, considering its ability to bind 
rather strongly with polar moieties.  
To obtain insight into the type of oligomerization (covalent or non-covalent), we acquired 
the SEC data for the samples in buffers of different pH. Thus size exclusion 
chromatography for blend and tablet solutions prepared in basic buffer was performed 
using neutral buffer and vice versa. In the chromatograms (Figs. 2.13B & C) 
corresponding to these acquisitions it is interesting to observe that the oligomers present in 
the neutral buffer are highly stable (Fig. 2.13B) and hence are most likely covalent in 
nature. However, the same is not true for the basic conditions, since the higher molecular 
size oligomers break into lower molecular size oligomers (Fig. 2.13C) when the SEC data 
is acquired in neutral solution for the blend and tablet dissolved in basic solution.  This 
may be attributed to pegylated insulin accessing a different conformation in basic buffer. 
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This is corroborated by the thermal unfolding data for the blend and tablet at basic pH 
(Fig. 2.13D), which shows a Tm shift of 10 °C when compared with the Tm in neutral 
condition (Table 1). 
Sample Solvent Average ∆Hu (cal/mol) 
Average ∆Su 
(cal.mol-1K-1) 
Tm  
(°Kelvin) 
Pegylated 
insulin Blend 
7mM 
Phosphate 
buffer 
5769.65 17.54 328.57 
Pegylated 
insulin Tablet 
7mM 
Phosphate 
buffer 
8266.395 24.42 338.41 
Pegylated 
insulin API 0.01N HCl 11213.04 34.69 323.65 
Pegylated 
insulin Blend 
20 mM Tris –
HCl buffer 7154.8 21.47 337.58 
Pegylated 
insulin Tablet 
20 mM Tris –
HCl buffer 9498.79 27.244 348.96 
Table 2.1 Average ΔH, ΔS and Tm values for three repeats of thermal denaturing 
acquisitions in neutral (7mM Phosphate buffer; pH 7.4) and basic (20 mM Tris –HCl 
buffer; pH 9.6) buffers 
The enthalpy and melting temperature values obtained from fitting the CD melting curve 
at 222 nm, showed that the compaction pressure did influence the three dimensional 
structure of pegylated insulin. The higher melting temperature obtained for the tablet 
seemed to indicate that the application of compaction pressure led to formation of a 
stabilized pegylated insulin molecule. This was corroborated by the differences observed 
in the SEC chromatograms after melt. However these structural changes must be subtle 
and local since any global change should have reflected in the CD spectra and SEC 
chromatograms. 
The assumption that tablet formation stabilizes the pegylated insulin structure, however, 
held true since the tablet shows an increase of 10°K when compared with the blend. 
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From Figure 2.13A, it can be observed that the pegylated insulin in blend elutes earlier 
than the pegylated insulin API, indicating higher state of association in the blend. 
However, the chromatograms of blend and tablets overlap completely (fig 2.13B), 
suggesting the association state of pegylated insulin in blend and tablet does not show any 
difference. The increased Tm at basic pH may be attributed to non-covalent oligomer 
formation that is not very different from that formed in neutral pH and hence does not lead 
to a substantial change in retention time in the SEC (figs. 2.13A and B). These non-
covalent oligomers may be thought of as arising due to a different conformation of 
pegylated insulin that is driven by electrostatic forces. Due to this it appears stable in terms 
of Tm but is vulnerable to pH changes and shows higher association state inferred from 
earlier retention time, when the pH is changed from basic to neutral (Fig. 2.13C).  
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Figure 2.13: Overlay of Size Exclusion Chromatogram of (A) Pegylated insulin Blend (---) 
and Pegylated insulin API (-) prepared in basic buffer run in basic buffer, (B) Pegylated 
insulin Blend ( - ) and Pegylated insulin Tablet (---) prepared in basic buffer run in neutral 
buffer, (C) Pegylated insulin Blend (-.-) and Pegylated insulin Tablet (…) prepared in 
neutral buffer and run in basic buffer. The curves in (D) represent the overlay of the 
normalised fraction folded values of Pegylated insulin Tablet (solid line) and Pegylated 
insulin Blend (broken line) at 222 nm in basic pH obtained from the melting curve. 
83 
 
2.3.3 Tablet formation stabilizes pegylated insulin structure:  
As described previously, pegylated insulin tablet formation involves the application of 
about 2.45 MPa pressure (25 kg/cm2) on the blend. Hence it may be expected that 
pegylated insulin present in the tablet will be irreversibly denatured. Surprisingly however, 
a Far UV CD spectrum, which can be regarded as a selective probe for changes in the 
secondary structure of proteins (Greenfield 2006), showed no difference between purified 
drug, blend and tablets with helical content of more than 30% in the tablet. The melting 
temperature (Tm) of a protein is indicative of its overall stability in a particular solution 
condition (Mergny et al. 2003). Furthermore, the enthalpy change (ΔH) associated with 
thermal unfolding provides insight into the thermodynamic stability of the protein (Ross et 
al. 1981). Differential scanning calorimetry (DSC) and CD spectroscopy are the two 
techniques that are used to monitor and decipher the corresponding thermodynamic 
parameters for thermal unfolding of proteins. CD based analysis of the temperature 
dependent unfolding gives a direct insight into the secondary structure melts. Thus, 
observing the changes in the CD signal at 222 nm as a function of temperature helps in 
elucidating the behaviour of the helices present in a protein when exposed to temperature 
ramps. This not only aids in knowing if the thermal unfolding is multi-step or not, but also 
gives quantitative outputs like Tm and ΔH.  
CD based Thermal unfolding data on blend and tablet in neutral pH was acquired at 222 
nm and was fitted to equation 1. The average Tm and ΔH values obtained from three 
repetitions of this experiment are summarized in Table 2.1. The single sigmoidal curves 
for blend and tablet show a single step unfolding of pegylated insulin in both blend and 
tablet, again indicating that the tableting pressure did not dramatically alter the structure of 
pegylated insulin. However, a shift in the Tm value by 10 °C indicates that the pegylated 
insulin structure has been stabilized after tablet formation. This stabilization may be 
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attributed to the increased van-der-waals and/or electrostatic interactions amongst the 
pegylated insulin molecules that come close to each other due to the pressure. One may 
argue that once the tablet is dissolved such interactions must also disappear, but the fact 
that an increased Tm is seen for the tablet indicates that these interactions are stable but 
perhaps localized within the structural folds and hence are not picked up by the 
experiments described in the previous sections, probably due to the plasticity of the 
molecule that does not let the local interactions affect the overall globular fold of 
pegylated insulin. The Far-UV CD scan before and after temperature melt further 
corroborates this stabilization, since the spectra for blend after melt seems to show almost 
complete loss of structure for pegylated insulin, but this is not so for the tablet. The tablet 
seems to retain most of the secondary structural characteristics even after the melt as seen 
from the overlay of normalized fraction folded (2.13D). 
 
2.3.4 CD spectra of melting experiments on pegylated insulin tablets 
The tablets of pegylated insulin are compressed directly after the blending step. During 
tableting the blend or mixture with excipients pass through the hopper onto the turret. 
During the compression, there is release of heat, as noted earlier. Temperature mapping 
shows that local temperatures at the surface and the sides can rise as high as 10 to 15 °C, 
which is a large change for protein molecules. The effects of changes in temperature are 
well documented to be of more severe and irreversible in nature as compared to effect of 
pressure. These changes were studied and results have been captured in the figures below. 
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Figure 2.14: CD spectra overlay at various different temperatures for pegylated insulin 
tablet dissolved in HCl at pH 2.0 
 
Figure 2.15: CD spectra overlay at various different temperatures for pegylated insulin 
tablet dissolved in Phosphate buffer at pH 7.4. 
Figure 2.14 is the CD spectra of tablets dissolved in HCl. The data showed that at lower 
temperatures the structure of insulin is largely intact but with an increase in beta sheet 
content, which may be due to the existence of higher oligomeric states. At higher 
temperature, the unfolding was more pronounced compared to purified crystals and tablet 
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blend. When the tablets were dissolved at neutral pH the data again showed more beta 
sheet and turn at lower temperature, as seen from the shift in the minima to around 215 nm. 
As the temperature increased there was a significant loss of structure with an increase in 
random coil content. 
Size Exclusion Chromatography is a time tested technique to deduce the amount of 
oligomers present in a protein solution (Gabrielson et al. 2007). One can also infer the 
tendency of oligomerization of a protein in different solution conditions based on the size 
exclusion chromatograms, where the higher oligomers elute before the lower oligomers 
and the monomer. Brange et.al. 1994 showed that Insulin at high pH has an increased 
tendency for oligomerization, probably due to disulphide scrambling. Insulins show a 
tendency for oligomer formation and the hexameric state is known to be the most stable 
oligomer that is physiologically active (Dunn MF 2005). Since pegylated insulin is an 
Insulin analogue, one may expect similar behaviour for pegylated insulin in SEC to that of 
Insulin.  
The Size Exclusion Chromatograms in figures 2.16A and 2.16 B do not show any 
differences between the association states pegylated insulin in the blend and the tablet in 
neutral or basic pH conditions, which contradicts the finding from CD data. This could be 
due to reversible nature of oligomeric state or the oligomeric state could be insoluble and 
hence could not be detected in the chromatography. 
2.3.5 Globular fold of pegylated insulin is not affected by the tableting compression: 
Charge state distribution in ESI spectrum and HD exchange are elegant techniques to 
probe the folding and dynamics of proteins (Nettleton et al. 2000, Katta et al. 1993). Any 
change in the globular fold of a protein due to unfolding or conformational change will 
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result in changes in the charge states in ESI mass spectrum when compared with charge 
states observed for the completely folded native conformation of the protein. 
 
Figure 2.16 Overlay of Size Exclusion Chromatogram of (A) Pegylated insulin Blend (-) 
and Pegylated insulin Tablet (---) sample prepared in basic buffer run in basic buffer. (B) 
Pegylated insulin Blend (-) and Pegylated insulin Tablet (---) sample prepared in neutral 
buffer run in neutral buffer. 
 
When the blend samples and the tablets were dissolved in Tris buffer, pH 9.6 and were 
chromatographed at basic pH, the profiles were perfectly overlapping for blend and tablet. 
There was no visible peak of aggregate observed. In size exclusion chromatography, higher 
molecular weight peaks elute earlier and lower molecular weight peaks appear later. The 
monomer peak of pegylated insulin eluted at around 12 min. No peak was seen before the 
main peak. After the main peak a small peak was seen at the base on the main peak around 
12.5 min which was a smaller molecular weight species. It could be due to some of the 
excipients or small quantities of separated A-chain and B-chain, due to high pH where 
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disulphide scrambling is known to occur. The peak at 15 min is probably due to the buffer 
itself, as it was also seen in blank injections (not shown here). 
 
 
Figure 2.17 ESI-MS spectrum of Pegylated insulin (A) Blend, (B) Tablet and (C) 
Deconvoluted mass. The left panel corresponds to acquisitions in neutral pH while the 
right panel corresponds to acquisitions in basic buffer conditions. 
Positive ion ESI mass spectrum of pegylated insulin tablet and blend acquired in 
physiological solution pH of 7.4 shows a similar profile with respect to the charge state 
distribution, with a relatively intense 4+ peak (Fig. 2.17). This similarity is also seen for the 
ESI-MS spectra acquired in solution with basic pH of 9.6 for tablet and blend.  These 
similarities suggest that the overall globular fold of pegylated insulin is not altered due to 
the pressure applied for tablet formation. The ESI spectrum acquired in the basic solution 
shows a relative increase in the 5+ charge state when compared to the spectrum acquired at 
pH 7.4. This change may be attributed to opening up of the three dimensional structure, 
resulting in exposure of more protonating sites through the structure leading to populating 
higher charge states. Another reason for this change may come from the buffer effect of the 
charge state distributions. This stems from the fact that the ammonium acetate buffer 
results in increased ionization in a molecule due to its higher ion-pairing effect. Whatever 
the reason, it is reasonable to conclude form this data that the overall structural attributes of 
pegylated insulin is similar in both blend and tablet. Furthermore, the ESI spectrum also 
serves the purpose for identifying pegylated insulin, from the deconvoluted mass (Fig. 2.17 
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C) that matches with the theoretical average mass of pegylated insulin (6025.6 Da). 
Complete characterization of this molecule has been described previously (Partha et. al. 
2012). The deconvoluted mass (M+H+) was 6026.3, which corresponded to the mass of 
intact pegylated insulin. The charge envelop consisted of 3+, 4+ and 5+ charge states. 
 
Figure 2.18 MALDI-TOF spectra of Hydrogen - Deuterium exchanged Pegylated insulin 
blend (A) and Tablet (B). The exchange times are mentioned in the individual panels. In all 
cases the deuteration results in addition of about 40 Daltons. 
In the hydrogen-deuterium exchange experiment (fig 2.18), when the samples were 
subjected to MALDI-MS at different time points, the blend samples showed an increase in 
mass by 38 Da over mass of intact pegylated insulin within 2 min and the mass increase 
stabilized across all the samples up to 30 min. For tablet samples, the 2 min samples 
showed an increase of 34 Da, which increased further to 6066.5 Da at 5 min, a 38 daltons 
90 
 
increase. The 30 min sample showed a slightly lower mass. No additional masses were 
observed in the samples. 
These observation corroborate results of ESI/MS experiment. If a protein is partially 
unfolded there exists a high probability that a higher number of exchangeable protons, 
especially the backbone and side chain amides, will be exposed to the solvent and hence 
such a moiety will take up higher number of deuterons. Using this argument one can say 
that the pegylated insulin does not show any degree of unfolding in the tablet since the 
extent of deuteration is similar in blend and tablet.  
2.4 Conclusion 
At higher temperatures the insulin protein structure partially unfolded. At higher pH the 
amount of helix was about 10 to 12% lower than at acidic or neutral pH. There was no 
difference found in the structures of pegylated insulin and non-pegylated insulin, indicating 
that pegylation did not affect the structure of recombinant human insulin. 
When the crystals were dissolved in Phosphate buffer or Tris buffer, upon melting 
pegylated insulin retained its structure better than recombinant human insulin did at higher 
temperatures. Pegylated insulin continued to show higher helical content even at higher 
temperature, although unfolding of the structure was clearly observed. Recombinant 
human insulin unfolded more readily with temperature than pegylated insulin. At pH 9.6 
there were visible differences in the behaviour of the two proteins. Pegylated insulin 
retained a higher helical content even at higher temperature, whereas human insulin 
showed significantly larger amounts of beta sheet structure. Overall this shows that 
conjugation with small alkyl PEG improves the structural stability of human insulin.  
91 
 
In the next set of experiments, purified crystals of pegylated insulin were compared with 
excipient blend before and after compression of the tablet. Based on retention of the 
structure and observed increase in the Tm value, it was concluded that the excipient had a 
protective effect on pegylated insulin and also the blending process did not have any 
destabilization effect in acidic pH. 
However, overall behaviour of the pegylated insulin was not altered in the presence of 
excipients. In HCl solution or phosphate buffer solution there was a protective effect of the 
excipients on the structural stability of pegylated insulin.  
The CD spectra of pegylated insulin tablets (figure 2.14) dissolved in HCl buffer at pH 2 
showed that the structure of pegylated insulin at lower temperature was largely unaffected, 
with helical minima observed at 208 nm and 222 nm. However, from the melting profile, at 
67 C̊ and 87 ̊C it appeared that there was some aggregation, with a distinct increase in beta 
sheet and turn content, and corresponding decreases in both alpha helical content and 
random coil. When the tablet was dissolved in Phosphate buffer (figure 2.15) at pH 7.4, 
again it was evident that there was a difference in the melting behaviour of pegylated 
insulin. At higher temperature there was more beta sheet and random coil, with less helical 
structure. The spectra in phosphate buffer was noticeably different from that in HCl buffer. 
At high temperature, a minima was observed at around 215 nm, which indicated increased 
beta sheet content. Near 200 nm elipticity shifted downwards compared to that at lower 
temperature, indicating there was more random coil present. The reason for the different 
CD behaviour was further explored using size exclusion chromatography with phosphate 
buffer, where higher molecular aggregates would be seen as separate peaks in SEC 
chromatogram. However, no peaks were observed for high molecular weight species 
(figure 2.16). The changes observed by CD may have been of a temporary nature and 
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weren’t due to any irreversible aggregation. Hence, when the samples were solubilized in 
HCl buffer where the solubility is very high, any temporary changes that occurred due to 
compression were reversed and the structure in the monomeric state matched closely 
between pegylated insulin from tablet with that from purified crystals dissolved in HCl. 
However, basic pH is known to be detrimental to the insulin structure due to disulphide 
scrambling (Yang et al. 1993) and so for that reason a significant structural change is 
observed at basic pH. The behaviour of pegylated insulin was found to be significantly 
different from that of insulin during melting experiments.  
The high Tm values seen in Tris buffer of pH 9.6 could be due to a possible high 
oligomeric state. This may be due to a combination effect of compression related changes, 
followed by exposure to not so favourable pH conditions and exposure to high 
temperature. 
When the samples were analysed using electrospray ionisation mass spectrometer (figure 
2.17), no changes in the charge envelope were seen, further confirming that there was no 
real structural change at neutral or basic pH. The results from basic pH were surprising, as 
we had speculated that the higher Tm values and the changes seen for the CD data could be 
due to a higher oligomerization state, perhaps as a result of disulphide scrambling. Higher 
oligomerization states would change the charge envelop, as the larger molecules are likely 
to hold more charges. In this case, since neither the charge state was different nor the 
charge envelop, it can be concluded there were structural changes, but they were not due to 
aggregation or a higher association state, but could be simply due to the opening of the 
structure, and were of temporary nature. If oligomerization did take place it was reversible 
in nature. 
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The hydrogen deuterium exchange experiment (figure 2.18) also showed that the time 
taken to incorporate deuterium was probably slightly longer with the tablets than with the 
blend, but within about 20 min the final equilibrium state of the two samples was the same. 
Lastly, when the tablets were extracted in phosphate buffer at pH 7.4 and tested for glucose 
uptake in an in vitro assay, the activity of the pegylated insulin extracted from the tablet 
was identical to that of the purified pegylated insulin crystals. 
From the results in this chapter it can be concluded that the effect of tableting has minimal 
or no impact on the structure and function of pegylated insulin. Any changes that were 
observed were only detected at higher temperature in the CD experiments and were 
probably reversible in nature. Pegylated insulin was found to be more stable than human 
recombinant insulin. However, it is not clear if the differences were significant. The 
pressure effects were also reversible in nature, which is consistent with the literature 
available on pressure effects on protein structure. Melting experiments show that the effect 
of temperature is pronounced, and in combination with higher pH may be detrimental to 
the protein stability and function. Pegylation has the potential to provide some protection 
against temperature and pH. Insulin is an interesting molecule where there are three 
disulphide linkages within a small peptide, making it comparatively more resistant to 
structural changes. However, the research described in this chapter indicates that there is 
potential to develop conventional oral dosage forms of proteins without the process of 
manufacturing the dosage form being detrimental to the structure-function of proteins, 
particularly for insulin. As more and more proteins are developed for oral delivery, a more 
complete understanding of the effects of tableting and formulation technologies will be 
required for successful oral delivery. 
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3. 1 Introduction 
The development of pharmaceuticals and biopharmaceuticals in recent years has seen an 
increased use of polymer conjugated drugs that lead to higher efficacy (Jevesevar et al. 
2010). Pegylated insulin (Iyer et al. 2010), a novel insulin analogue, is one such conjugate 
drug that is being developed for the treatment of diabetes.  It has a polypeptide sequence 
which is identical to that of native insulin, and has a modification with an alkyl peg at ε-
amino group lys-B29. The modification allows absorption of Insulin from the GUT with 
peak maxima seen between 10-30 min, with the levels rapidly coming to baseline within 
2h (Khedkar et al. 2010). Pegylated insulin is unique in that no other molecules with a 
small molecular weight PEG modification have so far made it to clinical development.  
3.1.1 Metabolism of Polyethylene glycols 
Pegylation, as a protein/peptide modification, is a technique of choice to improve 
physicochemical properties, and has been studied for several decades, with considerable 
understanding of its safety (Webster et al. 2007). However despite several years of 
research on pegylation, the ability to forecast the balance of pharmacokinetics and 
pharmacodynamics behaviour of a pegylated protein/peptide is still limited (Fishburn 
2008). The rate and extent of absorption of modified or pegylated proteins are governed by 
physiological factors, physicochemical properties and the interaction of the two in-vivo. 
Pegylation primarily results in increased molecular size and thereby reduce renal clearance. 
This slower rate of clearance combined with ampiphilicity of PEG results in peripheral 
distribution, and possibly passive diffusion in to several tissues, leading to PEG-mass 
related tissue accumulation as observed by Yamaoka et al.. It is interesting to note that 
lower molecular weight PEGs are readily cleared by the kidney’s, while for PEGs of 
molecular weights greater than 50 KDa, the clearance is primarily hepatic (Yamaoka et al. 
1994). The size and solubility perhaps play a role in the processing of PEGs. 
96 
 
Although literature on definitive metabolism studies of Pegylated molecules are 
unavailable, it appears that the metabolism of PEG happens through oxidation of the 
hydroxyl group giving rise to di-carboxylic acid. For example, PEG metabolites di-acid 
and hydroxyl-acid were recovered in plasma and urine of burn patients, rabbits and in the 
biliary secretions of cats (Harold et al. 1989, Friman et al. 1993, Friman et al. 1990). Roy 
et al. reported that PEG metabolized via sulphate ion in the excised liver from guinea pig 
and in an in-vitro liver preparations of rat/guinea pig (Roy et al. 1987, Roy et al. 1988). 
The literature evidence shows that PEG metabolites, generated by a series of first and 
second phase metabolism reactions, do not lead to serious toxic effects in animals (Harold 
et al. 1989, Roy et al. 1987). However, overdosing of PEG is reported to give rise to 
carboxylic metabolites and has been correlated with increased calcium concentration in 
serum (Bruns et al. 1982). Nevertheless, no serious adverse effects were seen upon chronic 
oral administration of PEG in rats over a period of 2 years. Similarly, in a year-long 
chronic toxicology studies with PEG 400 to PEG 4000 in dogs, no adverse effects were 
seen (Smyth et al. 1955). In this context it is important to understand how the processing of 
pegylated protein occurs by the cells, to identify the major metabolites associated with the 
use of pegylated proteins as biopharmaceutics as well as to understand the fate of the PEG 
moiety. With this background we present here the identification of the major metabolites 
associated with the protein pegylated insulin in an in-vitro system.  
3.1.2 Insulin processing 
Processing of insulin has been extensively studied both in-vitro and in-vivo (Krupp et al. 
1982, Varandani et al. 1976). In a study of Insulin metabolism by rat adipocytes, it was 
shown that Insulin was prone to fragmentation at Arginine B22 (Misbin et al. 1983). In the 
same study, it was also reported that the protein tyrosine phosphatase, Per-oxo-vanadate 
and vanadate, inhibit insulin degrading enzymes in the isolated rat liver endosomes. Bevan 
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et al. 2000 showed that the endosomal degradation of Insulin occurred simultaneous to 
degradation of B-chain with disulphide bonds still intact. The two chains were later 
separated by cleavage of both the inter-chain disulphide bonds. Though these studies seem 
to indicate that the Insulin metabolism occurs via specific pathways, simultaneous 
appearance of various intermediates in a few studies (Seabright et al. 1996) led to the 
conclusion that degradation of Insulin does not happen through sequential reactions, but 
must be happening through more complex reactions or through the simultaneous action of 
multiple enzymes. 
Nonetheless, these studies showed that cultured cells with specific functionalities can form 
a significant in-vitro system to study Insulin metabolism. The major target tissues for 
Insulin are fat, muscle and liver. Hence HepG2, a liver cell line derived from a human 
hepatoblastoma and expressing a wide variety of liver-specific metabolic functions (Javitt 
et al. 1990, Bouma et al. 1989, Thrift et al. 1986), serves as an acceptable system for in-
vitro metabolite studies of Insulin. HepG2 maintains both the gross liver cell morphology 
and liver cell function as determined by the synthesis and secretion of several liver specific 
proteins including albumin, alpha-feto protein, transferrin (Knowles et al. 1980).  
3.1.3 Choice of cell line: 
Since HepG2 cells express high-affinity insulin receptors meeting all the expected criteria 
for classic insulin receptors, we chose them for the study of pegylated insulin metabolism. 
We report here studies of the metabolism of a pegylated insulin analogue using HepG2 
cells. Our studies demonstrate that pegylated insulin metabolism occurs via B-chain 
degradation. Although typical ADME studies, as well as all the earlier reports on insulin 
degradation, were carried out using labelled compounds, in the case of pegylated insulin 
the conjugated alkyl PEG molecule acted as an intrinsic label for these studies. Therefore, 
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an LC/MS/MS method was used for tracking the chronological appearance of metabolites 
formed during HepG2 mediated pegylated insulin metabolism.  
3.2 Materials and Methods 
3.2.1 Chemicals and reagents:  
Lysine.HCl was purchased from S.D fine chemicals (Mumbai, India, N-Hydroxy 
Succinamide activated Oligomer was prepared in-house, HPLC grade Acetonitrile was 
purchased from JT Baker (Center Valley, PA, US). All other chemicals were analytical-
reagent grade and were used without further purification. The water used for mobile phase 
preparation was purified with a Milli Q system (Millipore, Billerica, MA USA).  
3.2.2 Preparation of standards 
 Lysine-ε-Oligomer was synthesized by conjugating Lysine and Activated NHS-Ester of 
oligomer at pH 8.5 in borate buffer. Three products were observed. Lysine-N-oligomer and 
lysine-ε-oligomer were found to have different fragmentation; Lysine-ε-Oligomer (mass 
and fragmentation matches with metabolite observed in the HepG2 cell supernatants). For 
further analysis the Lysine-ε-Oligomer was purified to greater than 90% purity using 
RPHPLC followed by lyophilisation. 
Free oligomer was obtained by hydrolysis of NHS ester of Oligomer at pH 8.5 in borate 
buffer. The free oligomer was purified using RPHPLC and Lyophilized. Samples were 
analyzed with LCMS/MS for comparison of intact mass and fragments in MSMS mode.  
3.2.3 Experimental Procedure  
Human Hepatoblastoma cells (HepG2)  were obtained from ATCC and were grown in T25 
flasks at 3x105 cells /ml in RPMI 1640 media with 10% FBS, 1mM HEPES and 1% 
sodium pyruvate. Flasks were incubated at 37°C incubator which was maintained 
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constantly at 5% CO2. At the time of plating 25 μg/ml of pegylated insulin was added to 
the various time point assigned flasks. Samples were collected at 16, 40, 48, 64, 72, 96, 
168, 192, 207, 216, 232 and 240 h. All the samples were stored at -20°C until the time of 
analysis. Media alone, cells alone and Media with pegylated insulin were kept as controls 
to avoid any confusion.  
Confirmation of role of glutathione insulin transhydrogenase:  
Experimental procedure described above was used. Five sets were prepared. To set 1, 25 
μg/mL of pegylated insulin was added while plating.  To set 2, only 0.5 mg/mL of 
bacitracin was added, to set 3, 1 mg/mL of bacitracin was added, to set 4, 25 μg/mL 
pegylated insulin along with 0.5 mg/mL of bacitracin were added, and to set 5, 25 μg/mL 
pegylated insulin with 1 mg/mL of bacitracin were added. Samples were harvested every 
24 h up to 168 h. Chromatographic separation was achieved using a Vydac C18 column 
(250 mm x 4.6 mm ID, 5 μm particle size) at a column temperature of 40°C, with the flow 
rate kept at 1 mL/min, and UV detection at 215 nm. The analysis was carried out using 
gradient conditions (Mobile phase A: 90% Acetonitrile 0.1% TFA; Mobile phase B: water 
with 0.1% TFA) 
In this experiment, since the cell supernatant did not undergo any specific sample 
preparation, hence an internal standard was not required. Additionally, considering the 
objective of the experiment of identifying the metabolites, a highly quantitative method 
was not developed. 
3.2.4 MS Instrument parameters 
MS was performed using an ESI-Ion Trap HCT Ultra PTM Discovery system (Bruker 
Daltonics, Bremen, Germany) as well as LTQ orbitrap XL (Thermo fisher, San Jose, CA, 
USA) with Nexera LC (Schimadzu, Kyoto, Japan) as a front end. The analysis was carried 
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out using electrospray ionization in positive mode. The scan range was from 50 m/z to 
2200 m/z. Capillary exit voltage was kept at 181 mV, skimmer voltage 40 mV, trap drive 
104.6%, accumulation time 100 ms. For orbitrap, ESI parameters were maintained as given 
here: capillary temperature 340 °C, sheet gas flow 5 L/h and sweep gas flow 2 L/h. 
3.3 Results and discussion  
Pegylated insulin analogue was seen as multiply charged species when injected in ESI-MS 
figure 3.3. The m/z of 1507 had four charges and the deconvoluted mass was seen as 6025 
Da, which matched with the theoretical mass of pegylated insulin. The standard lysine-ε-
oligomer peak showed a value of 365.2. In addition to the protonated mass, a sodium 
adduct of mass 387 was also seen. The fragmentation pattern of 365.2 m/z shows loss of 
water molecule (347 m/z), a combined loss of NH2 and CO (302 m/z), an additional loss of 
CH2 resulting in 288 m/z, a loss of 44 m/z gave 244. This loss of 44 m/z could be arising 
out of a loss of O-CH2CH2. Further loss of O-CH2CH2 gave 200 m/z. A mass of 154.8 m/z 
appears to have a mass error of 1.1 Da and could be due to additional loss of O-CH2CH2 
from the 200 m/z fragment. A mass of 181.9 m/z could not be assigned to any particular 
fragment. It appears to be arising out of a water loss from the 200 m/z fragment. A loss of 
O-CH2CH2 from 181.9m/z gave 137.8.m/z. Since the MS/MS was performed in an ion 
trap, fragment below 30% cut off of 365 m/z could not be seen.  
Figure 3.1 shows overlay of total ion chromatograms (TIC) obtained from 240 h sample of 
pegylated insulin incubated with HepG2 cells overlaid along with the control of only 
HepG2 cells incubated for 240 h. From this overlay, clearly an additional peak at 8.3 min 
which is circled could be seen above the control profiles. The mass of this peak was found 
to be 365 m/z and the fragmentation of 365 m/z matches with that of MS/MS of lysine-ε-
oligomer. All the other peaks were essentially the cell components. 
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The samples being highly complex, besides the lysine-ε-oligomer, no other metabolite 
could be identified from TIC, hence extracted ion chromatogram (EIC) was used for 
further analysis. Peak 2 depicted in figure 3.2 corresponds to lysine-ε-oligomer at RT ~8.0, 
Peak 2 in EIC clearly showed presence of some residual pegylated insulin, peak 3 was 
identified as deamidated pegylated insulin and peak 4 was identified as reduced B-chain.  
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Figure 3.1: TIC of pegylated insulin incubated with HepG2 Cells at 240 h (blue line) overlaid with supernatant of HepG2 Cells grown as 
control. The samples from control were drawn at different timepoints from (16-240 h) and overlaid with the test sample. Only the test sample 
(blue line) showed presence of a unique peak at approximately 8.0 min. 
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Figure 3.2: EIC chromatogram showing lysine-ε-oligomer, Chain-B of pegylated insulin, pegylated insulin in HepG2 Cells. The levels of 
lysine-ε-oligomer were found to be increasing with time of incubation. 
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Figure 3.3: Mass Spectra for observed Metabolites after start of incubation (A) Full-Scan 
Mass spectrum of the peak eluting at 41.3mins pegylated insulin, (B) Full-Scan Mass 
spectrum of the peak eluting at 42.2mins. Chain-B of pegylated insulin, (C) Full-Scan 
Mass spectrum of the peak eluting at 8.8 mins (D) MS/MS Mass spectrum of the peak 
eluting at 8.8 mins. 
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Figure 3.3 represents the experiment, where pegylated insulin was incubated with HepG2 
cells in presence of bacitracin. The data shows that the mass spectra of different peaks seen 
in the samples. Panel A shows a mass profile of intact pegylated insulin. Along with that a 
mass of 1359.8 was seen in all the samples. The mass appeared to have a charge state of 3 
and was found to be present only in the sample set containing bacitracin. Panel B shows 
m/z which corresponded with deconvoluted mass of B-chain of pegylated insulin (3646 
Da). The mass of B-chain of human insulin is 3429. Pegylation increases the mass of B-
chain by 217 Da which works out to a total mass of 3646 Da. Panel C shows mass of 
lysine-ε-oligomer which corresponds to 365 Da and panel D shows MS/MS fragmentation 
of 365 Da.  
 
 
Figure 3.4: Fragments of lysine-ε-oligomer observed after performing MS/MS. 
 
Figure 3.4 shows potential structures that were assigned to the fragments. However, some 
of the masses could not be assigned to any structure, which indicates that during the 
MS/MS experiment, it is likely that the lysine-ε-oligomer undergoes some sort of 
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rearrangement and the unassigned fragments could be the result of this rearrangement. The 
fragments appeared similar to the ones which have been reported for polyethylene glycol 
fragments post low energy collision induced dissociation (Chen et al. 2002) where PEG 
ethers showed repeating loss of 44 Da. 
 
Figure 3.5: A. TIC chromatogram showing Lysine-ε-Oligomer and B29 Oligomer in 
pegylated insulin HepG2 Cells. B. EIC chromatogram showing the Lysine-ε-Oligomer and 
lysineB29-Oligomer in pegylated insulin HepG2 Cells. 
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Figure 3.6: Panel A. Mass Spectra showing Lysine-ε-Oligomer m/z 365 and B29 Oligomer 
in pegylated insulin HepG2 Cells m/z 365. In addition 387.1 which is a sodium adduct is 
seen as well. Panel B. MS/MS Spectra showing the fragmentation of Lysine-ε-Oligomer 
(top figure) and B29 Oligomer in pegylated insulin HepG2 Cells (bottom figure). 
 
Further confirmation that the peak showing molecular mass of 365 m/z indeed 
corresponded to lysine-ε-oligomer, the TIC was overlaid with the TIC obtained after 
injecting standard lysine-ε-oligomer (figure 3.5). Both peaks overlaid perfectly and showed 
identical mass and fragmentation pattern (figure 3.6). 
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Figure 3.7: Extracted Ion Chromatogram extracted for free oligomer for all the timepoints. 
 
 
Figure 3.8: EIC chromatogram showing Oligomer standard and free Oligomer in pegylated 
insulin in HepG2 Cells 
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In addition to lysine-ε-oligomer, another small peak was identified from the total ion 
chromatogram. The molecular mass was found to be 237 m/z (figure 3.7), which was 
similar to the molecular mass obtained after injecting a standard of free oligomer in acid 
form. The peaks seen in extracted ion chromatograms from both the sample overlaid well 
(figure 3.8) and the molecular mass for both peaks was identical (Figure 3.9).  
The Insulin-receptor complex is known to degrade via a pathway that includes 
simultaneous occurrence of chain separation and B-chain degradation. It appears that the 
degradation pathway of modified insulin follows a similar pattern to that reported for 
insulin, where the two polypeptide chains were separated first and subsequently broken 
down into smaller peptides.  
B 
A  
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3.3.1 Pegylated Insulin degradation occurs via chain separation  
From figure 3.10, it can be seen that when a control sample using pegylated insulin 
incubated with media alone showed no decline in TIC intensity for intact pegylated insulin, 
although a small increase in deamidated pegylated insulin was observed over time in the 
control set. The MS and MS/MS data obtained clearly showed the presence of various 
peaks, which could be traced back to pegylated insulin. In a sample where pegylated 
insulin was incubated with HepG2 cells, a steady loss of intensity was seen with a 
corresponding increase in the intensity of the separated B-chain. Pegylated insulin as well 
as the B-chain intensity dropped sharply after 96 hrs of incubation, which corresponds to 
the time of cells reaching 100% confluence. Post 72 hrs, a peak at 365 m/z in the MS 
spectrum increased steadily until 168 hrs. No free A-chain was seen during the duration of 
the experiment, which could be due to rapid degradation of the A-chain. Free insulin B-
chain was observed from the beginning of incubation, indicating that the first major step in 
degradation is probably separation of the two chains by reduction of disulphide linkage.  
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3.3.2 B-chain degradation is a prominent feature of the metabolism of Pegylated 
Insulin  
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Figure 3.10: Panel A shows time course of pegylated insulin and its metabolites by Hep G2 
cells in absence of Bacitracin. Control refers to pegylated insulin in the media incubated 
without any cells, no metabolites were seen. Panel B shows time course of metabolite 
formation in presence of bacitracin. 4075 Da (1359.3+3) metabolite is observed in presence 
of bacitracin due to suppression of glutathione insulin transhydrogenase. 
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Soon after the observation of separated B-chain, a consistent increase in lysine-ε-oligomer 
was seen from around 40 hrs until the end of the experiment. The increase in signal of lys-
ε-oligomer correlated with reduction in B-chain signal, indicating that perhaps proteolytic 
cleavage of the B-chain gives rise to lys-ε-oligomer in a step subsequent to disulphide 
reduction. As mentioned in the previous section, from 168 hrs onwards a small but steadily 
increasing signal was seen for free oligomer, indicating further hydrolysis of ε-amide bond 
to give rise to free oligomer (figure 3.10, upper panel). No further metabolites of oligomer 
were found in the supernatant.  
3.3.3 The chain separation is mediated by Glutathione Transhydrogenase  
Tomizawa isolated Glutathione insulin transhydrogenase from human liver and showed 
that the enzyme was responsible for degradation of insulin (Tomizawa et al. 1965) and 
later Varandani et al. 1972 characterized the role of glutathione insulin transhydrogenase 
extensively and also reported that bacitracin inhibits glutathione insulin transhydrogenase 
activity and prevents separation of two chains (Duckworth 1981) Recently, a mechanism 
of how bacitracin inhibits Protein disulphide isomerase, an enzyme having functional 
similarity to glutathione insulin transhydrogenase, has been reported (Dickerhof et al. 
2011). The insulin degradation is thought to be important in the signal transduction process 
of insulin inside the cell as well as helps in keeping check on the effect of insulin on 
various cellular processes (Caro et al. 1980). 
To confirm the role of glutathione transhydrogenase or a similar enzyme in the observed 
degradation, bacitracin, reportedly a non-specific inhibitor of glutathione 
transhydrogenase, was added to the media along with pegylated insulin in the next 
experiment (Roth et al. 1981). Upon analysis, samples containing bacitracin did not show 
any presence of B-chain, instead they showed a new metabolite wherein partially clipped 
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A-chain and B-chain were still bound together via the disulphide linkage. The molecular 
mass of this new metabolite was deconvoluted to 4075 da. 
 
Figure 3.11: Structures of all major metabolites observed. Metabolite A and B were 
observed in absence of bacitracin along with B-chain. While the 4075 Da fragment was 
observed in presence of bacitracin. 
It is likely that the separation of the two chains could be mediated by the glutathione 
insulin transhydrogenase, which was indirectly confirmed by bacitracin induced inhibition 
of reduction of disulphides (figure 3.10, lower panel). All the metabolites of pegylated 
insulin, identified under these experimental conditions with and without bacitracin, are 
listed in Table 3.1 and their structures are given in Figure 3.11. Most of the metabolites 
that have been identified as fragments of the B-chain are around the B29 lysine. The 
presence of oligomer on B-29 lysine perhaps makes it easier to identify the fragments 
around that site.  
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Table 3.1: List of metabolites 
Metabolites Pegylated insulin 
with Hep G2 cells 
Pegylated insulin 
and 0.5 mg/ml of 
bacitracin with Hep 
G2 cells 
Pegylated insulin 
and 1 mg/ml of 
bacitracin with Hep 
G2 cells 
A-chain X X X 
B-chain √ X X 
Free-oligomer √ √ √ 
K(oligo) √ √ √ 
K(oligo)T √ √ √ 
PK(oligo)T √ √ √ 
TPK(oligo)T X √ √ 
4075 da fragment X √ √ 
 
3.3.4 Metabolite characterization and identification in the Supernatant  
The major metabolite observed with m/z 365 was found to match in retention times with an 
in-house standard Lysine-ε-Oligomer solution (tR = 8.3 mins), with further confirmation 
obtained by matching the fragmentation pattern of 365 m/z with the standard. Similarly, 
other metabolites were identified using MS and MS/MS patterns. This metabolite, as 
mentioned previously, was stabilized for 168 hours of incubation after which there was a 
slight decline in its intensity. This loss appeared to correspond to subsequent rise in a peak 
of 259 m/z, which was later confirmed as free oligomer by comparing the retention times 
and fragmentation with an Oligomer standard. 
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3.4 Conclusion 
Abundant literature is available on the topic of insulin degradation with several research 
groups having investigated insulin degradation. Many cleavage sites for insulin in the A-
chain and B-chain have been identified and reported in the literature. The B-chain has been 
proven to undergo extensive proteolytic degradation. Whereas only couple of cleavage 
sites have been identified in the A-chain, namely A13-A14 and A14-A15 (Duckworth et al. 
1987). It is possible that the A-chain undergoes cleavage at other sites, which have not 
been identified yet or reported. For insulin, several cleavage sites have been reported in the 
B-chain between B7 to B19 residues and between B22 to B26 residues.  
There are reportedly two pathways for insulin degradation. Insulin in bound form to its 
receptor and the free circulating form of insulin are processed differently. Insulin–receptor 
complex internalizes into endosomes and undergoes proteolytic cleavage of the B-chain 
and separation of the chains from each other (Carpentier et al. 1979, Gliemann et al. 1978). 
It was speculated that both these processes occur simultaneously. With the current 
experiment, we have proven indirectly that the two processes could be simultaneous and 
not sequential. It was observed that the proteolytic cleavage happens from N- and C- 
terminal of both the chains (figure 3.11). In the presence of bacitracin, no cleavage was 
observed between A7 to A20 and B7 to B19, which could be due to the sites becoming 
inaccessible to proteases due to intact disulphide bonds. 
When pegylated insulin was incubated with HepG2 cells, a significant amount of B-chain 
was seen in the supernatant in the initial stages, indicating that reduction of the disulphide 
bond plays a big role in degradation of insulin. On the other hand, when pegylated insulin 
was incubated with HepG2 cells in the presence of bacitracin, the separation of two chains 
was inhibited. 4075 m/z could be a metabolite with the A-chain cleaved between A5-A6 
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and A20-A21, all the disulphides still intact, B-chain cleaved between B1-B2 and another 
cleavage between B22-B23. A chain cleavage positions have not been previously reported 
for insulin. This could be because no metabolite identification studies have been reported 
in the presence of bacitracin. While we could not find any reports for these cleavage sites, 
we do not anticipate it to be different from insulin, since the A-chain is unmodified in our 
analogue. It is interesting to note that both these cleavage sites were found between 
charged amino acids and cysteine, however, the data is not sufficient to form a hypothesis 
on the specificity of the protease involved. We have captured the cleavage sites reported 
for Insulin as well as cleavage sites identified for Pegylated insulin in figure 3.12 below. 
 
Figure 3.12: Proteolytic degradation sites in the insulin molecule (top) and degradation 
sites in Pegylated insulin (bottom). K is modified lysine with alkyl PEG. 
 
Most of the previously reported work on Insulin processing involves 125I labelling, 
chromatographic separation and Edman degradation for identification of cleavage 
products. As far as we can deduce, this is the first report where insulin metabolites have 
been identified using LC/MS without using a radiolabelling. The presence of oligomer 
served as a tag and allowed us to identify metabolites which had the oligomer tag still 
attached. This also indicates that small alkyl-PEG in conjunction with LC/MS could prove 
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to be useful in identifying potential metabolites of proteins without the use of 
radiolabelling. In case of traditional methods of radio-labelling, the scintigraphy makes it 
easier to identify metabolites but there is a possibility of labelling falling off the molecule 
and the presence of radioactivity in certain tissue would not necessarily mean that the 
metabolites are accumulating in those organs. Hence the conclusions are not confirmatory 
in certain cases. On the other hand if the molecule is tagged covalently with alkyl PEG, the 
presence of a metabolite can be conclusive, especially when used in conjunction with a 
sensitive and accurate technique like mass spectrometry. 
Although degradation of the pegylated analogue followed a largely similar pattern to that 
of insulin processing, some differences were observed in the cleavage sites in the presence 
of bacitracin. It is possible that additional cleavage occurs similarly to what has been 
reported for insulin, but were just not observed under our experimental conditions. Any 
actual differences in the degradation steps are unlikely to affect the safety or efficacy of 
pegylated insulin, since eventually the molecule, being a protein, will be completely 
digested. Therefore, in conclusion, modification of insulin using small molecular weight 
alkyl-PEG does not appear to affect protein processing significantly, while providing a 
useful tool for altering the pharmaceutical properties.  
Insulin degradation via Insulin degrading enzyme also seems to play an important role in 
reducing protein degradation. Duckworth et al. 1997 hypothesized that insulin interacts 
with insulin degrading enzyme in the cytosol. As a direct result of this interaction 
proteosomal catalytic activity is inhibited, hence they went on to propose that insulin 
degrading enzyme had a regulatory role as well.  
Further, the lack of metabolism of free PEG suggests that there is no induction of alcohol 
dehydrogenase or the cytochrome system. It can be hypothesized that a free terminal 
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alcohol group on PEG molecule is likely to induce liver enzymes to a greater extent 
compared to the methoxy ether terminal. 
In addition, an understanding of cellular processing may be useful for designing new 
analogues that are resistance to proteolytic enzymes, leading to desired pharmacological 
profiles. It would also be important to understand if a proteolytic resistant insulin 
derivative would similar cellular actions of the human insulin molecule, like inhibition of 
protein degradation, improved protein synthesis and inhibition of β–oxidation of lipids. A 
molecule which is more resistant to cellular processing could have a longer half-life in 
circulation and could prove to be useful in developing Insulin. With longer duration of 
pharmacokinetic profile. 
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Chapter 4 
 
 
Fate of oligomer, a modifier used for 
pegylated insulin analogue, in Wistar rats 
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4.1 Introduction 
Pegylated insulin analogues are modified human insulin compounds currently being tested in 
non-clinical studies to support eventual clinical development. The pegylated insulin used in 
this study is derived from human Insulin and contains an oligomer (methoxy triethylene glycol 
propionate) attached to the B29-Lys amino group of human Insulin. The outcome of in-vitro 
experiments conducted in hepatic carcinoma cell lines revealed that B29Lysine-ε-Oligomer 
was the distinct major metabolite of pegylated insulin.  In addition, free oligomer was also 
found along with other cellular metabolites (Dave et al.. 2008).  
Pegylated insulin is reported to be available systemically upon oral administration in patients 
with type 2 diabetes (Khedkar et al. 2010). From a safety perspective, it is important to 
understand the metabolites and fate of the metabolites.  
4.1.1 Absorption, Distribution, Metabolism, Elimination (ADME) studies: 
ADME studies are conducted primarily for synthetic molecules in an effort to establish tissue 
distribution, metabolic pathways, identification of metabolites and routes of elimination and 
elimination kinetics. Typically, metabolic profiling involves studying the molecules in in-vitro 
experiments followed by in-vivo models. Liver is a central organ where most drugs undergo 
metabolism due to the presence of several metabolizing enzymes. If the metabolites turn out to 
be reactive then they can irreversibly bind to cellular molecules and may cause hepatotoxicity 
or adverse reactions. The metabolism occurs in two phases. The first phase refers to 
hydrolysis, oxidation/reduction and dehydrogenation reactions (Meyer 1996) and the second 
phase typically involves glucoronidation or sulfation. The first phase is designed to break 
down the molecule or transform it in an attempt to detoxify, while the second phase increases 
molecular polarity to enhance the elimination process (Zimmerman et al. 1999). The reactive 
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metabolites are hard to detect as their half-life is short (Antoine et al. 2008). To determine the 
presence of reactive metabolites in early stages of development, metabolism is studied in in 
vitro systems like microsomal extracts, hepatocytes, cytosol, transgenic cell lines, liver 
sections or perfused liver (Brandon et al. 2003). The effort is to mimic the conditions as close 
to in vivo conditions as possible.  
Intact liver cells provide relevant information about the metabolism of drugs. However, 
isolation of liver cells is tedious and any damage to the cells would affect the quality of 
information. In an artificial environment, some enzymes may be over expressed or under 
expressed and hence the information may not exactly match the real situation (Pelkonen et al. 
2005). Liver slices may give a good representation of actual metabolism but preparation of 
liver slices is tedious and the preparations do not last long. An isolated liver closely mimics 
the in vivo condition, but has to be harvested from a live animal, which means that for every 
assay one animal needs to be sacrificed.  Liver cells do not express all the metabolic enzymes, 
on the other hand transgenic cell lines overexpress only one of the isoforms of enzyme. The 
cytosolic fraction of the liver homogenate contains soluble phase II enzymes, whereas S9 
fractions have all the enzymes, albeit at very low levels. Hence to generate near complete 
information regarding metabolism combining more techniques might be prudent (Antoine et 
al. 2008). 
4.1.2 Analytical techniques in ADME: 
Traditionally, radiolabelled compounds are used in ADME studies, which makes detection of 
the compounds in various tissues and body fluid easier by a scintillation counter. With the 
previous generation scintillation counters, the dose requirement was high. With the 
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development of high sensitivity liquid scintillation beta counter, the dose requirement has been 
greatly reduced (Deroubaix et al. 2004). Recently, another technique has been developed that 
uses stable isotope labelling and measurement by flow isotope ratio mass spectrometry. This 
technique is not yet widely used as it required further validation (Browne et al. 1998).  
Mass spectrometry is becoming widely used as a technique of choice for ADME. Accelerated 
mass spectrometry is a high sensitivity detection method for 14C. It may be possible to reduce 
the dose of radioactivity by 1000 fold to 50 nCi from 50 μCi that is required in standard 
ADME studies. The mass spectrometric methods have some disadvantages, such as the 
requirement to transformation (graphitization) of the sample in to solid graphite (Chung and 
Kim 2013). In addition it requires a high energy Van der Graaf accelerator as a special 
requirement, which makes the technique expensive to use. Also, the required sophisticated 
equipment is not widely accessible (Gamer 2000).  
Besides accelerated mass spectrometry, a new mass spectrometer called the Orbitrap, which is 
a high resolution instrument and with a good sensitivity, is becoming popular for qualitative 
and quantitative work.  
 
Figure 4.1: Spindle shaped ion trap of orbitrap instrument 
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Figure 4.2: Diagram representing the oscillation of Ions inside the orbitrap. 
The orbitrap mass analyser consists of a spindle shaped electrode surrounded by a coaxial 
electrode. The ions which enter the orbitrap oscillate around this spindle at a frequency 
proportional to their m/z. The frequency of these ions is detected and Fourier transformed to 
convert into mass spectrum by the following equation: 
Ȱ ൌ ට ௞௠ ௭Τ                       (Hu et al. 2005) 
where ω is the z-axis frequency, k is the force constant, m is mass of the ion and z is charge of 
the ion. The frequency based mass measurement results in high resolving power to the tune of 
100,000. Ion trap has one limitation, which is, it cannot hold large numbers of ions at the same 
time. Large ion injection in the trap leads to broad distribution of kinetic energy that reduces 
the resolving power and accuracy of the mass spectrometer. This problem has been solved by 
injecting the ions into the trap radially via an Rf only quadrupole called a C-trap (Makarov 
2000). The accuracy of mass measurement can be high with an error of up to 3 ppm. 
Peterman et al. showed that the orbitrap can be a very useful tool for examination of metabolic 
pathways of the anti-depressant compound nefazodone. In this study, high accuracy of the 
mass data helped them assign the structures of known and new metabolites of nefazodone. A 
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mass accuracy below 3 ppm was reported for all the metabolites detected (Peterman et al. 
2006). 
Prior to orbitrap mass spectrometer, triple quadrupole mass spectrometer (QqQ), and linear 
trap quadrupole-time of flight (Q-ToF) mass spectrometers were available of which QqQ mass 
spectrometer and linear trap instruments have been reportedly used for metabolite 
identification work (Bateman et al. 2009). Multiple reaction monitoring using the QqQ 
instrument is very useful in identifying multiple metabolites of the given drug (Baillie 1992). 
QqQ also has the capability to generate neutral loss and precursor ion scans, which help 
identify the larger group of metabolites. The full scan mode of QqQ however is not sensitive 
enough, hence ion trap instruments and Time of flight instruments have become popular as 
well. The advent of higher sensitivity and high accuracy machines has made mass 
spectrometry a technique of choice especially in the field of metabolite identification 
(Kostiaenen et al. 2003).  
ADME studies are conducted using a single dose in rodent or non-rodent small animals, 
usually rats, rabbits, dogs or monkeys. At times human studies may also be performed but 
there are ethical challenges in performing human ADME studies, especially when 
radiolabelled drug needs to be administered. Besides understanding how the pharmacological 
agent is cleared by the body and identify, the metabolites ADME studies help evaluate 
potential toxicological issues. Radiolabelling helps in identifying major metabolites in 
circulation, understand clearance pathways better and help understand tissue accumulation. 
While ADME studies performed in animals may not be directly applicable to humans due to 
differences in physiological aspect due to species differences, they provide enough indication 
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on the safety aspects of the pharmacological agent. ADME conducted in normal animals may 
not always reflect the actual picture and might require ADME to be studied in disease models. 
If the disease condition for which the drug is being developed affect kidney or liver, there is 
imminent possibility that the metabolism of the drug would be different from a normal subject. 
To precisely rule out these differences, disease models are usually preferred for ADME 
studies. 
In designing the ADME studies, the choice of labelling, specific activity and position of 
labelling are critical to the success of the trial. The choice of labelling is from tritium, 14C, 32P, 
35S and 131I (Heggie et al. 1987, Chando et al. 1998, Boado et al. 1995, Lu et al. 1982, 
Wafelman et al. 1997), of which 14C and 3H are the most popular ones. In the case of 
proteins/peptides 131I can be preferable over 14C or 3H. If 3H is used, then higher doses are 
required as 3H emits weak β-radiation (Beumer et al. 2006). 14C has a long half-life and gives 
a good amount of radio-activity. If full body autoradiography is to be used during the study, 
the amount of radioactivity becomes critical for getting enough signal to enable a clear 
understanding of tissue distribution. 
The animal strains used for the ADME studies should be well characterized and the source 
should be reliable. Normally, ADME studies are conducted only in male animals but if 
differences between genders are expected or known then studies should involve both male and 
female animals. Choice of gender is also governed by the country of registration and the 
regulations followed by different countries.  
In the past few years several molecules have been modified using Pegylation technology in an 
effort to slow down the elimination, thereby increasing the circulating half-life. Walsh et al. 
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(2003) reported increased half-life and reduction of antibody reactivity of lysostaphin 
conjugated to polyethylene glycol. GCSF, interferon and organophosporus hydrolase have 
been pegylated to increase their circulating half-life (Zhai et al. 2009, Bansal et al. 2011, 
Novikov et al. 2010, Soares et al. 2002). Abuchowski et al. 1977 reported alteration of 
immunological properties of bovine serum albumin by conjugating with PEG. The same group 
later reported changes in circulating half-life as well as changes in immunological properties 
of bovine adenosine deaminase in mice (Davis et al. 1981). 
A considerable amount of literature has been generated over the years in an attempt to 
understand the ADME of polyethylene glycols of different molecular weight ranges. Small 
molecular weight PEGs are used as solvents or co-solvents in formulations and have been 
tested for toxicity in animal models. Lockard et al. studied the efficacy and toxicity of PEG 
400 in rhesus monkeys, for its use in the formulation of sodium phenobarbital. They reported 
that animals receiving PEG400 at 60% concentration, as well as animals receiving PEG400 
and drug both, exhibited greasy lower extremities and oedema of genitals and legs along with 
loss of appetite (Lockhard 1979). Furuichi et al. (1984) examined absorbability of 
radiolabelled PEG4000 from gastrointestinal tract and compared with Intravenous 
administration. They observed that i.v PEG400 was almost completely recovered in urine and 
no hepatic or renal uptake was observed. Similarly, PEG administered in the gastric region 
directly was eliminated in urine as well with only 43% of the dose over 24 hrs. 
PEGs are largely unchanged in the body and are reported to get eliminated primarily in urine. 
Yamaoka et al. have studied the rate of elimination as a function of molecular weights and 
demonstrated that the rate of elimination slows down with the increase in molecular weight of 
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PEG. Hepatic elimination has also been reported for large molecular weight PEG (Yamaoka et 
al. 1994).  
In this chapter we have summarized our findings of a follow on study conducted with 
pegylated insulin to identify and confirm the possible metabolites of the compound in vivo in 
a rat model. The primary objective of this study was to identify and confirm the presence of 
Lys-Oligomer or free oligomer, the possible metabolites of pegylated insulin; as determined 
by in-vitro experiments, in rat urine and faeces. The study was an attempt to understand 
ADME of the oligomer in a qualitative manner.  
4.2 Regulatory Compliance: 
This study was conducted in an investigative manner to study the metabolic profile of 
Pegylated insulin. The in-life phase of this study was conducted at Syngene International Ltd, 
Bangalore, India. The study was approved by the animal ethics committee of Syngene 
International Ltd. 
4.3 Materials and methods: 
A total 8 male Wistar Rats of 8 - 12 weeks age and weighing approx 250 g were included in 
the study and were assigned to two groups with 4 rats each.  The test item administration and 
blood collection was staggered for 3 - 5 days. The study design is provided in Table 4.1. 
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Table 4.1: Study design 
 
 
Pegylated Insulin, batch# B-0860021A, was provided by Biocon Limited. The average 
molecular mass of Pegylated insulin was 6025 and protein content was 93.5%. Lysine-H-
Oligomer standard used as a control was prepared and supplied by Biocon Limited, and was a 
viscous yellow liquid having 98.2% purity. A 3 % solution of Sodium caprate in 150mM 
sodium phosphate buffer was used as vehicle for administration of test and control substances.  
4.3.1 Metabolic cages:  
Rats were accommodated in metabolic cages from Lab products Inc. The design of these cages 
allows up to 99% separation efficiency of urine and faeces, which assures minimum 
contamination. Components below the cage floor are removable without disturbing animals 
allowing tests to be conducted over a prolonged period of time without interruptions. These 
Test 
Compound 
Group 
& 
Group 
Size 
Dose Vehicle 
Pegylated 
insulin 
Group -1 
(4 
Males) 
200 mg/kg  3% w/v Sodium Caprate in 50 mM 
Sodium Phosphate buffer (pH ~7.8) 
Lysine-H-
Oligomer 
(Positive 
Control) 
Group -2 
(4 
Males) 
20 mg/kg 3% w/v Sodium  Caprate in 50 mM 
Sodium Phosphate buffer (pH ~7.8) 
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cages are easy to assemble, maintain, disassemble and clean and are made up of autoclavable 
polycarbonate and stainless steel components.  
Animal waste is directed through a collection funnel and onto a linear diffuser. The diffuser 
allows solid matter to travel down the top ridges of a 50% incline, passing over a urine port, 
and into a faecal collection vessel. Liquid waste flows along grooves down the inclined 
diffuser, passing through the urine port, and into a urine collection vessel. A urine deflector 
prevents excess urine from splashing and contaminating faecal specimens. Separate urine and 
faeces samples are collected in two standard 50 ml centrifuge vessels. 
 
Figure 4.3: Photo of a metabolic cage. 
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4.3.2 Dose Administration 
The animals were fasted at least 10 h prior to administration. The overnight fasting condition 
was selected as it is known that the presence of food will interfere with the absorption of 
pegylated insulin and also probably impact absorption of oligomer and would have impacted 
the study outcomes. A single dosage of 200 mg/kg and 20 mg/kg of the pegylated insulin and 
Lysine-H-Oligomer were administered to Groups 1 and 2, respectively by oral route, on day 1, 
day 2 and day 3, at a dose volume of 5 mL/kg. The dose of pegylated insulin was chosen from 
prior unpublished toxicology studies. The dose of Lysine-H-Oligomer was chosen arbitrarily. 
Food was provided to all the animals at approximately 0.5 hours post-dosing and was 
available ad-libitum. Animal weight was recorded prior to dosing on each day and the dose 
was calculated as mentioned. 
Table 4.2: Dose Summary 
Group Rat_No. 
Dose (mg/Animal) 
Dose 1 Dose 2 Dose 3 
G1 
1 54.0 57.2 56.6 
2 53.5 57.5 57.7 
3 56.3 60.0 59.2 
4 57.7 60.2 60.0 
Average Dose 55.38 58.73 58.38 
G2 
1 5.5 5.8 5.8 
2 5.6 5.7 5.7 
3 5.9 6.0 6.3 
4 6.0 6.0 6.0 
Average Dose 5.75 5.88 5.95 
 
4.3.3 Sample Collection & Handling 
Individual urine and faeces samples were collected from all animals at the intervals listed in 
the Table 3 below.   
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Table 4.3: Sample time and interval plan 
Dose no./ Day  Time intervals (h) 
Dose 1/ Day 1 Pre-dose, 0 - 6, 6 - 12 & 12 - 18, 18 - 24 hours post dose 
Dose 2/ Day 2 0 - 6, 6 - 12 & 12 - 18, 18 - 24 hours post dose 
Dose 3/ Day 3 to 5 0 - 6, 6 - 12, 12 - 18, 18 - 24, 24- 30, 48 & 72 hours post 
dose 
 
All the urine and faeces samples were stored frozen at -80 °C before taking up for analysis. 
4.3.4 Analytical Procedures 
The rat urine and faeces samples were processed and analysed for Lysine-ε-oligomer and free 
oligomer in rat urine and faeces using a suitable in-house analytical LC/MS/MS method. The 
term ‘metabolite recovery’ indicates the cumulative amount of a metabolite eliminated into 
urine and faeces which was calculated using the formula “∑(Concentration*Volume)”. Percent 
recovery was calculated using the formula “100xAmount Recovered/Dose”.  
All animals were observed before and after dosing for clinically relevant abnormalities. Blood 
glucose concentrations were measured from all the animals using calibrated glucometer at pre-
dose and 15 minutes post-dose.  
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4.3.5 Equipment 
HPLC System – SHIMADZU Prominence (Tokyo, Japan), Mass Spectrometer – TSQ 
QUANTUM ULTRA AM, Thermo Electron corportaion (San Jose, CA, US), Waters Solid 
Phase Extraction Vaccum Manifold (Waters corporation, Milford, MA, US), Ultra Low 
Temperature Freezer (Thermo Fisher scientific, Ashville, NC, US), Weighing Balance – 
Sartorius AG (Gottingen, Germany), Water purification system – Milli-Q Synthesis, 
(Millipore, Billerica, MA) 
 
4.3.6 Preparation of reagents 
Mobile phase A: 
Solution A was prepared by adding 10mL of Acetic acid into 990mL of Milli-Q water, and 
sonicated for 10min and degassed. 
Mobile phase B: 
Solution B was HPLC grade Acetonitrile.  
Diluent: 
Diluent was prepared by mixing 90 parts of water and 10 parts of acetonitrile to make 100 mL 
of diluent. 
Elution solvent: 
Elution solvent was prepared by mixing 90 parts of 1mM NaCl and 10 parts of acetonitrile to 
make 100mL of elution solvent. 
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4.3.7 Preparation of Stock Solutions 
4.3.7.1 Oligomer Stock solution: 
10 mg of Oligomer standard was accurately weighed and transferred into a 10 mL volumetric 
flask, dissolved and made up to 10 mL with 90:10 water and acetonitrile. Then the Stock 
solution was stored in the cold room (4˚C). 
4.3.7.1.1 Preparation of Stock dilutions for Oligomer in Urine: 
The stock dilutions were prepared as per Table given below from the Oligomer stock solution, 
using 90:10 water and acetonitrile, in the concentration range from 500.0 ng/mL to 5000.0 
ng/mL. 
4.3.7.1.2 Lysine-Oligomer stock solution: 
About 1.0 mg of L-Oligomer standard was accurately weighed into a 1mL volumetric flask, 
dissolved and made up to 1mL with 90:10 water and acetonitrile. The Stock solution was 
stored in a cold room (4˚C). 
4.3.7.1.3 Oligomer Stock solution: 
About 10 mg of Oligomer standard was accurately weighted and transferred into a 10 mL 
volumetric flask, dissolved and made up to 10 mL with 90:10 water and acetonitrile. The 
Stock solution was stored in a cold room (4˚C) 
Table 4.4: Illustration of the dilution scheme followed for calibration standards 
Stock.ID 
(ng/mL) 
Stock Conc. 
(ng/mL) 
Stock.vol. 
(mL) 
Make upto 
(mL) 
Final Conc. 
(ng/mL) 
1000000.0 1000000.0 0.1 10.0 10000.0 
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10000.0 10000.0 5 10.0 5000.0 
10000.0 10000.0 2 10.0 2000.0 
10000.0 10000.0 1 10.0 1000.0 
5000.0 5000.0 1.0 10.0 500.0 
2000.0 2000.0 1.0 10.0 200.0 
1000.0 1000.0 1.0 10.0 100.0 
500.0 500.0 1.0 10.0 50.0 
 
4.3.8 Prepartion of standards 
4.3.8.1 Preparation of Calibration Curve Standards 
4.3.8.1.1 Preparation of Spiked Urine Standards: 
The blank rat urine was spiked with the above-prepared stock dilutions (spiking solutions) to 
prepare the urine standards ranging from 0.1μg/mL to 75μg/mL as per the Table given below: 
Table 4.5: Illustration of the dilution scheme followed for calibration standards 
Stock.ID 
(ng/mL) 
Stock Conc. 
(ng/mL) 
Stock.vol. 
(mL) 
Making up the 
volume with 
Urine(mL) 
Final Conc. in 
urine (ng/mL) 
50000.0 50000.0 0.1 1.0 5000.0 
20000.0 20000.0 0.1 1.0 2000.0 
10000.0 10000.0 0.1 1.0 1000.0 
5000.0 5000.0 0.1 1.0 500.0 
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2000.0 2000.0 0.1 1.0 200.0 
1000.0 1000.0 0.1 1.0 100.0 
500.0 500.0 0.1 1.0 50.0 
 
4.3.8.1.2 Preparation of L-Oligomer spiked fecal standards 
To nine separate 10 mg faecal aliquot, 10μL of L-Oligomer from each of the stock solution 
with concentrations of 1, 2, 4, 10.0, 20.0, 40.0, 100.0, 200 and 400 μg/mL was added to get 
final standards of 1, 2, 4, 10, 20, 40.0, 100., 200 and 400 ng/mg standards. 
4.3.8.1 3 Preparation of Oligomer spiked fecal standards 
To nine separate 10 mg faecal aliquot, 10μL of Oligomer from each of the stock solution with 
concentrations of 1, 2, 4, 10, 20, 40, 100, 200, 300 μg/mL was added to get final standards of 
1, 2, 4, 10, 20, 40, 100, 200 and 300 ng/mg standards. 
4.3.9 Sample Preparation 
4.3.9.1 Preparation of samples 
4.3.9.1.1 Extraction of urine samples 
200μL of milli-Q water was added to 200μL of urine sample and vortexed for 1 min. Samples 
were treated with solid phase extraction technique for the removal of the matrix. Oasis HLB 
cartridges with 30mg, 1CC were used for the extraction. Cartridges were equilibrated with 
methanol followed by water and loaded with the sample. Washing was done with 1mL of 
water and analytes were eluted with 300μL of 90:10 1mM NaCl and acetonitrile. Samples 
were transferred to HPLC vials and 1μL was injected for the analysis. 
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4.3.9.1.2 Extraction of Fecal samples 
Dried faecal sample, 10 mg was added to an eppendorf tube to which 300μL of 1mM NaCl 
solution was added. This was vortexed for 15 minutes and centrifuged at 10,000rpm for 10 
min. The aqueous layer was transferred into HPLC vials and 1μL of this sample was injected 
into the HPLC for analysis. 
4.3.9.1.3 Solid phase extraction procedure: 
Cartridge conditioning was done using 1 mL methanol. 
Equilibration was done using 1 mL water. 
A 400 μl sample was loaded on each of the cartridge and washed with 1 ml of water.  
Elution was performed with 300 μL of 90:10, 1mM NaCl: Acetonitrile. 
4.3.9.1.4 Chromatographic conditions used during sample analysis 
Column: TSKgel amide column, 4.6 x 150mm  
Flow rate: 0.700mL/min. 
Volume of injection: 1μL 
Run Time: 11.00 min 
Column oven temperature: 40˚C 
Autosampler temperature:  4 ± 2˚C 
Gradient: 
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Time % B 
0.0 90.0 
6.0 10.0 
6.1 90.0 
11.0 90.0 
MS Conditions: 
L-Oligomer                           : Transitions that were monitored in MRM  
387.110 → 258.900 m/z 
387.110 → 342.360 m/z 
Oligomer                              : 258.960 → 187.100 m/z 
Spray Voltage                      : 400 V 
Vaporizer Temperature        : 300 ̊C 
Sheath Gas Pressure             : 45 psi 
Ion sweep Gas Pressure       : 2.0 psi 
Aux Gas Pressure                 : 60 psi 
Capillary Temperature         : 275 ̊C 
Tube Lens offset                  :150 V 
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Skimmer Offset                    : 0 V 
Collision Pressure                : 1.5 psi 
Collision Energy                   : 27/22 V(L-Oligomer/Oligomer) 
Probe Position                       : C 
Lateral Position of needle     : 0 
Micro meter                           : 1.5 μm 
4.3.10 Data Processing: 
Calibration curves were tested for linear fit. Where ever linear fit was not possible, data was 
linearized using a log transformation and then fitted. A standard linear equation was used for 
calculating the concentrations of unknowns. The equation is given below: 
Y = mx + C, where 
x = Analyte conc.  
Y = Analyte Area / ISTD Area 
m = Slope of the calibration curve 
C = y-axis intercept value. 
Mass spectrometer used was a TSQ Quantum ultra AM, triple quadrupole mass spectrometer 
manufactured by Thermo Electron corp (San Jose, CA, US) 
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Internal standards were not used in the analytical method. The concentrations were expected to 
be on the higher side hence lack of internal standard was not expected to affect the recovery of 
the metabolites. Typically an internal standard is used to help tighten the variability of the 
assay. In this case, the variability was not expected to affect the outcome of the experiment. In 
addition, no appropriate internal standard, which would show similar behaviour to the 
metabolites, could be identified at the time of planning the experiment.  
For HPLC, a generic small molecular weight compound method was chosen. The MS 
conditions were optimized for maximum signal intensity in multiple reaction monitoring 
mode. The transition followed for quantitation are provided above. 
The recovery of oligomer and lysine-oligomer was calculated by calculating expected molar 
equivalents of metabolites to pegylated insulin. Each mole of pegylated insulin (6025 gm) was 
expected to give rise to either 365 gm (1 mole) of lysine oligomer or 233 gm (1 mole) of free 
oligomer.  
If dose given was 50 mg per animal then  
݋݈݅݃݋݉݁ݎ݀݋ݏ݁ ൌ ݉݋݈݁ܿݑ݈ܽݎݓݐ݋݂݋݈݅݃݋݉݁ݎ ൈ ܦ݋ݏ݁݋݂݌݁݃ݕ݈ܽݐ݁݀݅݊ݏݑ݈݅݊ܯ݋݈݁ܿݑ݈ܽݎݓ݄݁݅݃ݐ݋݂݌݁݃ݕ݈ܽݐ݁݀݅݊ݏݑ݈݅݊  
Similarly, dose of oligomer was calculated using equation given below: 
ܮݕݏ െ ݋݈݅݃݋݉݁ݎ݀݋ݏ݁
ൌ ݉݋݈݁ܿݑ݈ܽݎݓ݄݁݅݃ݐ݋݂݈ݕݏ െ ݋݈݅݃݋݉݁ݎ ൈ ܦ݋ݏ݁݋݂݌݁݃ݕ݈ܽݐ݁݀݅݊ݏݑ݈݅݊ܯ݋݈݁ܿݑ݈ܽݎݓ݄݁݅݃ݐ݋݂݌݁݃ݕ݈ܽݐ݁݀݅݊ݏݑ݈݅݊  
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4.4 Results and discussions 
The response of oligomer in urine and feces was found to be non-linear when all the 
concentrations were included as part of calibration curve. The linearization of the response 
was done by log-log plot (Figure 4.4 and Figure 4.5), which was found to fit well and gave an 
R squared value of 0.9988. The back calculated recovery was found to be erroneous at the 
lower concentrations using this calibration curve. The calibration curve of lysine-ε-oligomer 
showed a linear response but yet again the back calculated recovery at the lower concentration 
showed over estimation by a significant margin, implying that the quantification below 1 
μg/mL would not be reliable in the case of urine standard and in the case of oligomer 
measurement in feces the limit would be 1 ng/mL. The recovery was found to be acceptable 
between 80-120% over the rest of the range. In the real samples while calculating absolute 
recovery, it was thought the lower concentrations would not a make significant difference to 
the total recovery as lower concentrations would contribute only a small fraction of total 
recovery and the overall error percentage would not affect the outcome of the study and 
conclusion. Hence it was decided to complete analysis of all samples with the said method. 
The following graphs are the calibration curves obtained for oligomer and lysine -oligomer 
after spiking in blank urine and faeces.  
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Figure 4.4: Calibration curve for free oligomer standard in blank urine. 
 
 
 
 
Table 4.6: Calibration curve for oligomer spiked in Blank Urine. 
Conc. 
(ng/mL) 
Peak 
Area log (conc) log (PA) 
Back calculated 
conc 
% 
recovery 
500 136741 -0.3010 5.1359 -0.4023 134% 
1000 271690 0.0000 5.4341 -0.0142 - 
2000 476072 0.3010 5.6777 0.3028 101% 
5000 1145459 0.6990 6.0590 0.7991 114% 
10000 2061755 1.0000 6.3142 1.1314 113% 
20000 2992292 1.3010 6.4760 1.3419 103% 
y = 0.7683x + 5.445
R² = 0.9882
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50000 4999284 1.6990 6.6989 1.6321 96% 
75000 6534568 1.8751 6.8152 1.7834 95% 
 
 
Figure 4.5: Calibration curve for lysine-oligomer standard in blank urine. 
 
 
 
Table 4.7: Calibration curve for lysine-oligomer standard in blank urine 
Conc. 
(ng/mL) 
Peak 
area 
Back calculated 
conc 
% 
recovery 
1 233180 -2.8756 -288% 
2 277679 1.0430 52% 
5 320396 4.8046 96% 
10 357325 8.0565 81% 
20 489629 19.7071 99% 
y = 11356x + 265835
R² = 0.999
0
1000000
2000000
3000000
4000000
5000000
6000000
0 50 100 150 200 250 300 350 400 450
Lo
g 
(p
ea
k 
ar
ea
)
Log conc (μg/mL)
143 
 
50 822821 49.0477 98% 
100 1461046 105.2493 105% 
200 2629799 208.1687 104% 
400 4749299 394.8101 99% 
 
 
Figure 4.6: Calibration curve for lysine-oligomer standard in blank feces 
Table 4.8: Calibration curve for lysine-oligomer standard in blank feces 
Conc. 
(ng/mg) Peak area 
Back calculated 
conc 
% 
recovery 
1 1080668 0.9474 95% 
2 2111863 1.9932 100% 
4 4494484 4.4095 110% 
10 10547300 10.5480 105% 
y = 986039x - 146533
R² = 0.9992
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20 20785918 20.9316 105% 
40 41559901 41.9997 105% 
100 97561747 98.7945 99% 
200 187969915 190.4827 95% 
400 398721798 404.2186 101% 
 
 
Figure 4.7: Calibration curve for oligomer standard in blank feces. 
 
Table 4.9: Calibration curve for oligomer standard in blank feces. 
Conc. 
(ng/mg) 
Peak 
Area 
Log 
(conc) 
Log 
(PA) 
Back 
calculated 
conc 
% recovery 
1 31515 0.0000 4.4985 0.1197 NA 
2 44894 0.3010 4.6522 0.3087 103% 
y = 0.8133x + 4.4011
R² = 0.9937
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4 64743 0.6021 4.8112 0.5042 84% 
10 135566 1.0000 5.1322 0.8988 90% 
20 270949 1.3010 5.4329 1.2686 98% 
40 564041 1.6021 5.7513 1.6601 104% 
100 1075626 2.0000 6.0317 2.0048 100% 
200 1971429 2.3010 6.2948 2.3283 101% 
300 2674432 2.4771 6.4272 2.4911 101% 
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Table 4.10: Individual Animal Data of Metabolite Recovery in Urine Following Oral Administration of IN-105 to Wistar Rats 
Rat_No. Time Intervals (hr) 
Dose 1 Dose 2 Dose 3 
Free Oligomer 
(ng/mL) 
Lys-Oligomer 
(ng/mL) 
 Volume 
(mL) 
Free Oligomer 
(ng/mL) 
Lys-Oligomer 
(ng/mL) 
 Volume 
(mL) 
Free Oligomer 
(ng/mL) 
Lys-Oligomer 
(ng/mL) 
 Volume 
(mL) 
1 Pre-dose 0.00 0.00 - - - - - - - 
  0 - 6 9670.60 34.27 3.5 9731.23 45.06 2.0 27941.63 59.62 4.0 
  6 - 12 24053.89 26.10 2.1 26450.06 38.47 2.5 28596.85 67.50 4.0 
  12 - 18 10516.16 19.91 5.8 37859.78 47.41 4.0 27512.95 45.18 2.0 
  18 - 24 6515.22 17.82 1.8 46127.81 41.29 1.0 19005.94 38.43 4.0 
  24 - 48 - - - - - - 3718.81 17.04 15.0 
  48 - 72 - - - - - - 694.66 7.70 20.0 
2 Pre-dose 0.00 0.00 - - - - - - - 
  0 - 6 6256.15 27.40 0.5 6408.56 91.05 2.5 23803.01 86.42 4.1 
  6 - 12 41448.21 28.62 3.8 17182.33 70.95 3.6 35664.26 36.35 5.0 
  12 - 18 16349.33 19.16 7.1 21860.44 46.24 5.6 37848.50 332.93 1.7 
  18 - 24 7507.98 13.27 1.2 29479.26 27.50 1.6 40876.25 22.99 2.0 
  24 - 48 - - - - - - 19460.18 15.94 18.0 
  48 - 72 - - - - - - 2216.81 8.42 23.0 
3 Pre-dose 0.00 0.00 - - - - - - - 
  0 - 6 10750.73 51.77 1.9 6051.48 47.18 4.9 15586.27 75.70 5.5 
  6 - 12 56050.75 27.98 3.1 19853.99 46.55 3.5 29686.54 54.22 3.0 
  12 - 18 24335.44 27.89 5.0 33167.91 14.04 4.5 41405.67 39.14 2.0 
  18 - 24 5730.84 27.15 3.2 21006.34 18.40 2.0 17582.37 16.25 4.0 
  24 - 48 - - - - - - 12197.08 16.34 13.0 
  48 - 72 - - - - - - 1177.05 2.84 21.0 
4 Pre-dose Missing Missing - - - - - - - 
  0 - 6 Missing Missing - 8048.92 27.21 3.5 9698.37 38.04 3.0 
  6 - 12 Missing Missing - 24591.35 36.92 4.2 14462.79 86.81 4.0 
  12 - 18 Missing Missing - 17931.08 15.41 7.5 9686.90 29.36 2.0 
  18 - 24 Missing Missing - 14177.88 13.01 3.0 11464.56 37.54 2.0 
  24 - 48 - - - - - - 5143.63 5.11 0.8 
  48 - 72 - - - - - - 250.77 1.33 43.0 
Missing: Sample Missing; ‘-’:  Sample Not Collected 
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Table 4.11: Individual Animal Data of Metabolite Recovery in Urine Following Oral Administration of Lys-H-Oligomer to Wistar Rats 
Rat_No. Time Intervals (h) 
Dose 1  Dose 2 Dose 3 
Free Oligomer 
(ng/mL) 
Lys-Oligomer 
(ng/mL) 
 Volume 
(mL) 
Free Oligomer 
(ng/mL) 
Lys-Oligomer 
(ng/mL) 
 Volume 
(mL) 
Free Oligomer 
(ng/mL) 
Lys-Oligomer 
(ng/mL) 
 Volume 
(mL) 
1 Pre-dose 0.00 0.00 - - - - - - - 
  0 - 6 3227.63 172.23 0.5 14468.54 84.46 3.5 38047.30 136.34 4.0 
  6 - 12 11437.95 82.37 4.0 22637.36 97.29 3.5 27693.13 84.41 4.0 
  12 - 18 20039.94 55.50 6.1 27219.96 66.17 4.5 35857.38 59.43 2.0 
  18 - 24 17301.85 50.01 3.4 28610.00 52.13 0.2 31806.59 50.04 4.0 
  24 - 48 - - - - - - 9473.11 37.29 16.0 
  48 - 72 - - - - - - 1460.04 25.03 20.0 
2 Pre-dose 0.00 0.00 - - - - - - - 
  0 - 6 4216.32 131.01 2.1 6437.33 119.56 5.1 17390.96 84.83 5.0 
  6 - 12 9812.86 82.11 3.8 14973.14 116.54 6.8 23928.84 106.33 2.2 
  12 - 18 8933.93 61.47 9.0 17631.73 52.71 7.2 20459.67 43.76 2.0 
  18 - 24 4854.38 17.06 3.0 16663.04 36.88 1.5 15517.64 27.14 4.0 
  24 – 48 - - - - - - 3451.75 18.84 22.0 
  48 – 72 - - - - - - 539.47 10.31 32.0 
3 Pre-dose 0.00 0.00 - - - - - - - 
  0 - 6 6343.61 72.16 3.00 11510.43 89.18 2.0 22149.12 140.94 4.0 
  6 - 12 22475.64 42.06 3.20 20029.30 51.68 3.9 33538.55 180.01 3.8 
  12 - 18 22528.48 26.84 7.80 27540.93 34.69 4.2 23103.29 33.96 2.0 
  18 - 24 10594.93 16.03 3.00 30874.03 14.31 4.0 21459.51 51.11 4.0 
  24 - 48 - - - - - - 11079.83 13.46 20.0 
  48 - 72 - - - - - - 804.62 4.26 40.0 
4 Pre-dose 0.00 0.00 - - - - - - - 
  0 - 6 10111.48 360.77 0.9 NA NA NA NA NA NA 
  6 - 12 37715.25 73.84 3.9 55686.29 357.52 2.0 18335.40 159.66 3.8 
  12 - 18 56056.43 30.82 2.4 16396.92 96.03 6.8 23956.69 61.76 2.0 
  18 - 24 NA NA NA 17187.95 48.77 1.5 15737.65 51.03 4.0 
  24 - 48 - - - - - - 4938.37 25.79 12.0 
  48 - 72 - - - - - - 745.76 39.90 19.0 
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Table 4.12: Individual Animal Data of Metabolite Recovery in Faeces Following Oral Administration of pegylated insulin to Wistar Rats 
Rat 
No. 
Time 
Intervals 
(h) 
Dose 1 Dose 2 Dose 3 
Free Oligomer 
(ng/mg) 
Lys-Oligomer 
(ng/mg) 
 Weight   
(g) 
Free Oligomer 
(ng/mg) 
Lys-Oligomer 
(ng/mg) 
 Weight 
(g) 
Free Oligomer 
(mg) 
Lys-Oligomer 
(ng/mg) 
 Weight    
(g) 
1 Pre-dose 0.00 0.00 0.00 - - - - - - 
0 - 6 0.12 0.11 1.21 NA NA NA 362.46 146.65 0.72 
  6-12 451.72 169.90 0.72 0.25 35.83 0.21 141.92 264.57 0.29 
 12-18 25.34 210.17 1.03 NA NA NA 18.79 193.22 0.27 
18 - 24 1.24 130.28 1.23 202.02 221.79 0.56 13.09 177.08 0.46 
24 - 48 - - - - - - 0.88 49.39 1.92 
  48 - 72 - - - - - - 0.07 4.37 3.51 
2 Pre-dose 0.00 0.00 0.00 - - - - - - 
0 - 6 NA NA NA NA NA NA 1.82 162.87 0.24 
  6-12 NA NA NA NA NA NA NA NA NA 
 12-18 775.91 226.10 0.72 NA NA NA 64.35 208.03 0.25 
18 - 24 75.98 176.54 1.12 105.18 190.24 0.75 17.79 199.78 0.55 
24 - 48 - - - - - - 0.98 92.71 3.61 
  48 - 72 - - - - - - 0.06 5.24 3.02 
3 Pre-dose 0.00 0.00 0.00 - - - - - - 
0 - 6 85.32 31.72 0.81 0.47 82.94 0.30 0.37 97.93 1.05 
  6-12 514.24 315.02 0.52 NA NA NA 79.54 338.39 0.42 
 12-18 12.99 281.39 0.59 3.35 281.72 1.31 6.96 270.27 0.41 
18 - 24 0.80 121.13 0.25 0.85 146.58 0.07 5.64 220.92 0.21 
24 - 48 - - - - - - 0.63 91.10 1.89 
  48 - 72 - - - - - - 0.04 4.73 3.43 
4 Pre-dose 0.00 0.00 0.00 - - - - - - 
0 - 6 NA NA NA NA NA NA 0.58 106.91 0.49 
  6-12 29.55 316.09 0.60 0.53 138.91 1.07 16.27 32.23 0.55 
 12-18 2.19 58.20 1.15 132.74 275.91 0.90 NA NA NA 
18 - 24 5.75 222.11 0.57 1.43 203.05 1.21 10.72 213.39 0.31 
24 - 48 - - - - - - 0.31 30.51 2.56 
  48 - 72 - - - - - - 0.04 3.40 3.40 
NA: Sample Missing; ‘-’:  Sample Not Collected  
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Table 4.13: Individual Animal Data of Metabolite Recovery in Faeces Following Oral Administration of Lys-H-Oligomer to Wistar Rats 
Rat 
No. 
Time 
Intervals 
(h) 
Dose 1 Dose 2 Dose 3 
Free Oligomer 
(ng/mg) 
Lys-Oligomer 
(ng/mg) 
 Weight      
(g) 
Free Oligomer 
(ng/mg) 
Lys-Oligomer 
(ng/mg) 
 Weight 
(g) 
Free Oligomer 
(ng/mg) 
Lys-Oligomer 
(ng/mg) 
 Weight       
(g) 
1 Pre-dose 0.00 0.00 0.00 - - - - - - 
0 - 6 NA NA NA 7.23 293.77 0.17 2.21 220.72 0.26 
  6-12 NA NA NA 3.56 207.58 0.74 1.07 142.23 0.88 
 12-18 0.81 1.16 0.23 NA NA NA 13.87 270.18 0.14 
18 - 24 2.08 11.79 0.24 6.31 299.85 0.30 5.10 249.81 0.31 
24 - 48 - - - - - - 0.25 81.13 2.23 
  48 - 72 - - - - - - 0.07 8.36 3.37 
2 Pre-dose 0.00 0.00 0.00 - - - - - - 
0 - 6 NA NA NA 0.45 99.82 0.21 1.40 111.18 0.44 
  6-12 NA NA NA 6.86 245.09 0.59 165.65 240.19 0.48 
 12-18 1.29 178.48 0.83 7.44 275.73 0.65 35.91 230.33 0.29 
18 - 24 1.39 188.08 0.24 3.26 175.79 0.29 5.52 122.40 0.65 
24 - 48 - - - - - - 0.87 63.56 1.91 
  48 - 72 - - - - - - 0.16 7.31 2.25 
3 Pre-dose 0.00 0.00 0.00 - - - - - - 
0 - 6 0.20 0.36 0.15 NA NA NA 1.45 134.40 0.05 
  6-12 6.85 236.08 1.03 NA NA NA 11.42 119.88 0.16 
 12-18 50.44 222.31 1.06 9.48 222.23 0.69 28.30 220.29 0.30 
18 - 24 3.66 210.60 0.28 13.77 224.96 0.55 22.56 186.81 0.73 
24 - 48 - - - - - - 0.88 65.89 1.88 
  48 - 72 - - - - - - 0.04 4.71 3.62 
4 Pre-dose 0.00 0.00 0.00 - - - - - - 
0 - 6 NA NA NA NA NA NA 33.21 180.76 0.21 
  6-12 1.48 3.13 0.38 NA NA NA 10.67 162.22 0.06 
 12-18 NA NA NA NA NA NA 399.72 333.74 0.31 
18 - 24 NA NA 0.21 597.53 304.74 0.56 141.60 280.69 0.95 
24 - 48 - - - - - - 0.60 48.37 2.45 
  48 - 72 - - - - - - 0.18 12.72 2.44 
NA: Sample Missing; ‘-’:  Sample Not Collected 
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Tables 4.10 to 4.13 also exhibited the few time points no urine or feces samples were 
obtained. In one case a few of the samples, which were kept separately, were accidently 
mixed up with samples from another study and hence were labeled as missing. 
All the animals showed a drop in blood glucose to the extent of 30 to 70% from baseline, 
indicating Insulin was being absorbed after the oral gavage (Table 4.14). Since the trial 
was over a period of 3 days, and volume requirement for pharmacokinetic analysis was 
high, it was decided not to draw blood for PK measurements. For antidiabetic drugs a 
reduction in blood glucose can be used as a surrogate marker. No drop in blood glucose 
levels was seen in control animal’s treated with Lys-H-Oligomer, which ruled out any 
impact of overnight fasting on the blood glucose levels and the reduction in glucose in test 
group was clearly attributed to the absorption of pegylated insulin. There was no adverse 
impact of low blood glucose noted in the study. There was a small increase in blood 
glucose level seen in group 2, which may be due to the stress animals experienced during 
handling. 
Table 4.14: Mean blood glucose reduction (N=4) in positive control and pegylated insulin 
treated animals 
Study Day  Group Test Compound ^Change in Mean % 
Blood Glucose (N=4) 
Day 1 1 Pegylated insulin p 71.39 
Day 2 1 Pegylated insulin p 63.72 
Day 3 1 Pegylated insulin p 29.15/60.99* 
Day 1 2 Lys-H-Oligomer n 20.50 
Day 2 2 Lys-H-Oligomer n 10.61 
Day 3 2 Lys-H-Oligomer n 10.05 
^: % Change as compared to pre-dose blood glucose values; p Decrease 
from baseline; n Increase from baseline 
*: 2 Non-responders (data presented with & without outliers) 
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4.4.1 Metabolite Recovery: 
Both free oligomer and Lysine-H-oligomer were quantified in rat urine and faeces samples 
collected over the 5 day observation period. The quantity of metabolite recovered in 
urine/faeces is more after dose 3 (Study days 3 to 5) as compared to dose 1 and 2. This 
could be due to very high doses being used in the study leading to incomplete clearance of 
metabolites within 24 hours. The accumulation is perhaps an artefact of very large doses 
and is not likely to be the case in practice at the pharmacologically effective doses in 
patients.  
Table 4.15: Mean concentration of metabolites recovered in rat urine following oral 
administration of 200 mg/kg of pegylated insulin. 
Trt 
Group, 
Test item  
Dose No. /  
Study Day  
Dose* 
(μg) 
Volume 
(mL) 
Amount 
Recovered 
(μg) 
Percent 
Recovered 
(%) 
G1               
(Pegylated 
insulin         
200 
mg/kg) 
            Free Oligomer 
Dose 1 / Day 1 1976 13.00 259.00 13.11 
Dose 2 / Day 2 2125 13.98 282.37 13.29 
Dose 3 / Day 3–5 2112 51.53 476.38 22.56 
               Lysine Oligomer 
Dose 1 / Day 1 3308 13.00 0.34 0.010 
Dose 2 / Day 2 3558 13.98 0.53 0.015 
Dose 3 / Day 3–5 3536 51.53 1.11 0.031 
*: Dose is a theoretical maximum recovery possible for each of the metabolite after 
administration of 200 mg/kg dose of pegylated insulin. 
Following administration of pegylated insulin to Wistar Rats, the major metabolite 
quantified in urine was free oligomer. The free oligomer formed 99% of the fraction of the 
total amount recovered in urine. The percent recovery of free oligomer in urine was 
approximately 13 –23% with highest amount recovered after the day 3 dosing as the 
samples were collected up to day 5. 
. 
152 
 
Table 4.16: Mean concentration of metabolites recovered in rat urine following oral 
administration of 20 mg/kg of Lysine-H-oligomer. 
Trt 
Group, 
Test item  
Dose No. /  
Study Day 
Dose* 
(μg) 
Volume 
(mL) 
Amount 
Recovered 
(μg) 
Percent 
Recovered 
(%) 
G2               
Lysine-H-
Oligomer    
(20 
mg/kg) 
            Free Oligomer 
Dose 1 / Day 1 3434 14.03 239.68 6.98 
Dose 2 / Day 2 3507 14.18 283.41 8.08 
Dose 3 / Day 3 
– 5 
3557 
57.95 458.58 12.89 
               Lysine Oligomer 
Dose 1 / Day 1 5750 14.03 0.85 0.015 
Dose 2 / Day 2 5873 14.18 1.20 0.020 
Dose 3 / Day 3 
– 5 
5955 57.95 1.96 0.033 
*: Molar equivalent to free oligomer & Lysine oligomer 
Following administration of Lysine-H-oligomer to Wistar Rats, the major metabolite 
quantified in urine was again free oligomer. The amount of free oligomer recovered was 
higher than that of lysine oligomer. The percent recovery of free oligomer in urine was 
about 7 to 13%. The highest recovery was found in the day 3 samples. Interestingly, very 
little lysine-ε-oligomer was recovered in Urine. 
Table 4.17: Mean concentration of metabolites recovered in rat faeces following oral 
administration of 200 mg/kg of pegylated insulin. 
Trt Group, 
Test item  
Dose No. /  
Study Day 
Dose* 
(μg) 
Weight 
(g) 
Amount 
Recovered 
(μg) 
Percent 
Recovered 
(%) 
G1                 
(Pegylated 
insulin           
200 mg/kg) 
            Free Oligomer 
Dose 1 / Day 1 2004 2.63 407.17 20.32 
Dose 2 / Day 2 2125 1.60 330.31 15.55 
Dose 3 / Day 3 
– 5 
2112 7.39 448.37 21.23 
               Lysine Oligomer 
Dose 1 / Day 1 3355 2.63 341.16 10.17 
Dose 2 / Day 2 3558 1.60 79.60 2.24 
Dose 3 / Day 3 
– 5 
3536 7.39 99.09 2.80 
153 
 
*: Molar equivalent to free oligomer & Lysine olilgomer 
Following administration of pegylated insulin to Wistar Rats, the major metabolite 
quantified in faeces was free oligomer. The concentration of free oligomer recovered was 
about 3 folds higher than that of lysine oligomer (Table 8). The percent recovery of free 
oligomer in faeces was about 15 to 21% and recovery of unchanged lysine oligomer was 
between 2 and 10% of the expected theoretical recovery. In terms of absolute quantity, 
lysine-oligomer was present in significantly higher quantity in faeces compared to that 
which was recovered in Urine. It is difficult to say if this was due to the presence of amino 
acid, due to lower solubility of lysine-oligomer, or some other as yet undetermined reason. 
Table 4.18: Mean concentration of metabolites recovered in rat urine following oral 
administration of 20 mg/kg of Lysine-H-oligomer. 
Trt 
Group, 
Test item  
Dose No. /  
Study Day 
Dose* 
(μg) 
Weight 
(g) 
Amount 
Recovered 
(μg) 
Percent 
Recovered 
(%) 
G2               
Lysine-H-
Oligomer    
(20 
mg/kg) 
            Free Oligomer 
Dose 1 / Day 1 3434 1.11 183.85 5.35 
Dose 2 / Day 2 3507 1.19 284.25 8.10 
Dose 3 / Day 3 – 
5 3557 6.59 472.99 13.30 
               Lysine Oligomer 
Dose 1 / Day 1 5750 1.11 16.06 0.28 
Dose 2 / Day 2 5873 1.19 91.10 1.55 
Dose 3 / Day 3 – 
5 5955 6.59 99.65 1.67 
*: Molar equivalent to free oligomer & Lysine oligomer 
A similar result was obtained following administration of Lysine-H-oligomer to Wistar 
Rats. The major metabolite quantified in faeces was free oligomer. The concentration of 
free oligomer recovered was about 6 to 12 fold higher than that of lysine oligomer (Table 
9). The percent recovery of free oligomer in faeces was about 5 to 13% and unchanged 
lysine oligomer was 0.2 to 1.7%. 
Table 4.19: Total recovery of free oligomer and lysine oligomer metabolites in rat urine 
and faeces following oral administration of pegylated insulin 
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Trt 
Group, 
Test item 
Dose No. /  
Study 
Day 
Dose* 
(μg) 
Recovery 
in Urine 
(μg) 
Recovery 
in Faeces 
(μg) 
Total 
Metabolite 
Recovered 
(μg) 
Percent 
Recovered 
(%) 
G1                
(Pegylate
d insulin  
200 
mg/kg) 
Free Oligomer 
Dose 1 / 
Day 1 2004 259.00 407.17 666.17 33.25 
Dose 2 / 
Day 2 2125 282.37 330.31 612.68 28.83 
Dose 3 / 
Day 3 – 5 2112 476.38 448.37 924.75 43.79 
Lysine Oligomer 
Dose 1 / 
Day 1 3355 0.34 341.16 341.50 10.18 
Dose 2 / 
Day 2 3558 0.53 79.60 80.13 2.25 
Dose 3 / 
Day 3 – 5 3536 1.11 99.09 100.20 2.83 
* Molar equivalent of free oligomer and Lysine oligomer 
The additive results of total recovery of the metabolites from both urine and faeces are 
summarized in Table 4.19. The total amount of metabolite recovered showed a mass 
balance between 30 to 45% of the total expected after administration of pegylated insulin. 
After each of the dosing, amount of free oligomer was larger as compared to lysine 
oligomer.  
Table 4.20: Total recovery of free oligomer and lysine oligomer metabolites in rat urine 
and faeces following oral administration of Lysine-H-oligomer 
Trt 
Group, 
Test item 
Dose No. 
/  
Study 
Day 
Dose* 
(μg) 
Recovery 
in Urine 
(μg) 
Recovery 
in Faeces 
(μg) 
Total 
Metabolites 
Recovered 
(μg) 
Percent 
Recovered 
(%) 
G2              
Lysine-H-
Oligomer   
(20 
mg/kg) 
Free Oligomer 
Dose 1 / 
Day 1 
3434 239.68 183.85 423.53 12.33 
Dose 2 / 
Day 2 
3507 283.41 284.25 567.66 16.18 
Dose 3 / 
Day 3 - 5 
3557 458.58 472.99 931.56 26.19 
Lysine Oligomer 
Dose 1 / 5750 0.85 16.06 16.91 0.29 
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Day 1 
Dose 2 / 
Day 2 
5873 1.20 91.10 92.30 1.57 
Dose 3 / 
Day 3 – 5 
5955 1.96 99.65 101.61 1.71 
* Molar equivalent to free oligomer & Lysine oligomer 
Similarly, upon oral gavage of lysine–oligomer, significantly higher amounts of 
metabolites were recovered in urine than in faeces, indicating lysine–oligomer gets 
absorbed systemically and is cleared by the kidneys. Total percentage of free oligomer and 
lysine -oligomer recovered following lysine-oligomer gavage was 12 to 26% and 0.3 to 
1.7%, respectively. The low recovery of the metabolites in both groups could be due to the 
fact that at the time of developing it was not possible to predict the expected concentrations 
of the metabolites. Hence the linear range was later found to be inadequate to cover the 
actual concentrations found in the sample, especially for the urine samples. Typically, 
since the response of the calibration curve saturates beyond a certain concentration, the 
estimation of actual samples falling in the non-linear range of the calibration curve is 
expected to be low. It was not possible to identify the extent of dilution that would have 
been required for some of the samples containing high amounts of metabolites. The lower 
recovery was not attributed to the absence of an internal standard for mass spectrometric 
analysis. In addition, the missing or unavailable samples may have resulted in lack of mass 
balance. 
When these results were obtained, it was decided to repeat the analysis for the urine 
samples only, as close to 99% metabolites was in the form of oligomer and present in 
urine. The samples were stored at -80°C until the time of the repeat analysis. The gap 
between the two analyses was close to 1 year. When the samples were reanalysed, the 
overall mass balance was found to be greater than 100% which obviously is incorrect. The 
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reason for this high recovery was not determined and has been attributed to long term 
storage problems. Hence only the results from first analysis are presented here and the 
repeat analyses have been ignored. Triethyleneglycol, which is structurally similar to the 
oligomer, was used as internal standard and a calibration curve was prepared along with 
quality control (QC) samples. There was no difference found in terms of the recovery of 
the QC samples, indicating that the recovery of the samples was not affected by the 
presence or absence of internal standard. 
4.5 Conclusions  
Based on the reduction in blood glucose levels (table 4.14) it can be concluded that 
pegylated insulin was systemically available following oral administration. A large 
proportion of administered pegylated insulin was broken down in gut and is excreted via 
faeces. The metabolite seen in the faeces was primarily lysine-oligomer while a 
significantly smaller fraction was seen as intact oligomer. Apart from lysine-oligomer and 
free oligomer no other metabolites could be detected in any of the samples. This could be 
due to the fact that the polypeptide of insulin is likely digested completely into dipeptides 
and amino acids and then recycled by the body for protein synthesis. PEGs are known to 
induce liver enzymes, but as described in previous chapter, the published data suggests that 
the liver enzyme induction happens with PEG alcohol. It is not clear if the PEG ether 
would induce the enzymes in a similar fashion. It is highly likely that the presence of 
methoxy ether groups either prevents the metabolism of PEG altogether or slows it down 
sufficiently that the excretion via kidney results in excretion of the metabolite unchanged. 
The total recovery of free oligomer was found to be between 30 to 46% of the theoretically 
possible recovery post pegylated insulin dosing. Similarly, lower recoveries of free 
oligomer were observed in the control arm post lysine–oligomer dosing. It appears that 
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pegylated insulin is broken down in the gut and during circulation to lysine-oligomer, 
followed by further hydrolysis of lysine-oligomer to free oligomer. Lysine-oligomer, upon 
oral administration, appears to get absorbed rapidly resulting in > 90% recovery in urine, 
when administered either in its intact form or as a free acid. Lysine-oligomer was also 
metabolized to the free oligomer form. The linkage between lysine and oligomer is an 
amide linkage. It is possible that a peptidase or an amidase is involved in the conversion of 
lysine-oligomer to free oligomer and it would be interesting to identify the specific enzyme 
responsible. However, this is beyond the scope of the present research. 
The reason for incomplete mass balance could not be determined. However, it can 
probably be attributed to the metabolite concentrations exceeding the linear range resulting 
in gross underestimation of metabolites. This study was not designed along the lines of 
classical ADME studies, which determine the rate of elimination or metabolites as well as 
tissue accumulation if any. There is a possibility that the incomplete mass balance could be 
due to the limitation of the study scope and/or an artefact of the study design. It could also 
be possible that given the use of very high doses, the complete elimination would have 
taken longer than anticipated, and had sampling been done over longer period of time, 
better mass balance could have been achieved. 
The results confirmed the findings of the earlier in-vitro metabolite identification study that 
pegylated insulin is broken down to lysine-oligomer and free oligomer. However, in the in 
vivo experiment, the ratio of free oligomer to lysine-oligomer was reversed, which may be 
due to more rapid metabolism in a living organism as opposed to laboratory grown cells. A 
more controlled study would help establish the mass balance. Also radiolabelling of 
oligomer would help determine the exact fate of oligomer and give an idea on tissue 
accumulation status. If the complete mass balance of oligomer is not achieved, then it 
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raises questions on the fate of remaining oligomer. A classical ADME study with more 
extensive tissue samples would give better clarity on oligomer fate. However, it is a good 
sign that most of the oligomer is recovered in its free acid form in urine, which alleviates 
the concern of accumulation to some extent. 
In a small study in human subjects with varying degree of renal impairment, it was 
determined that for Liraglutide, a novel GLP-1 analogue, there was no change in 
pharmacokinetics or renal clearance (Linnebjerg et al. 2007). On the other hand, for 
Exenatide, a natural analogue of GLP-1 with 57% homology to GLP-1, the half-life 
increased with increasing severity of renal impairment. Also, exposure to Exenatide 
appeared to be higher with increasing severity of the disease. Because of this higher 
exposure, there were more incidences of nausea and vomiting in subjects with renal 
impairment and Exenatide was poorly tolerated in such subjects (Jacobsen et al. 2009). 
Another ADME study was reported by a group of scientists from Japan. They studied the 
ADME of ε-polylysine, which is used as a preservative in food. While the end use of the 
product is non-therapeutic, ADME is important as food is consumed in large quantities 
making safety of preservative a major concern. In this study, ε-polylysine was 
radiolabelled using 14C and ADME was studied in a rat model. The group reported that 
there was no toxicity observed and close to 100% mass balance was achieved with greater 
than 90% radio activity being recovered in faeces. Metabolite profiling by HPLC showed 
that the primary metabolite was L-lysine and the group could conclude safe usage of ε-
polylysine as a preservative (Hiraki et al. 2003). 
The use of mass spectrometry facilitated by the presence of an oligomer tag worked well as 
a non-radioactivity method in identifying at least some of the metabolites. Lim et al. 2015 
recently published a non-radioactivity method for investigating metabolism of 
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adrenocorticotropic hormone (ACTH). In this method, the researchers tagged the ACTH 
fragment with 127I. The measurement of 127 m/z was done using Ion coupled plasma mass 
spectrometry (ICP-MS). 127I is a non-radioactive isotope of iodine and does not affect the 
metabolic profile of the peptide. The group was successful in measuring the ACTH 
fragment in various different human tissue preparation in an in-vitro setting.  
In the case of proteins, modification with a small oligomer is not likely to affect the 
ADME profile of the drug. However, more studies are required to validate and fully 
determine the utility of the use of oligomer tagging and mass spectrometry for ADME 
profiling. This method appears to be a useful method for ADME profiling, particularly for 
proteins and peptides drugs. 
Traditionally ADME studies are not carried out for peptide drugs as it is believed that the 
peptides are broken down into amino acids are recirculated in the body. The studies that 
are performed are mostly to understand qualitative aspects of ADME. With more and more 
peptide and modified peptide drugs coming to market there is a need for improved 
analytics to enable the study of metabolism and elimination of these drugs.  
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Chapter 5 
 
Summary and Future Directions 
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5.1 Summary 
Based on the work described in the thesis following conclusions were made:  
A novel pegylated insulin analogue is currently under clinical development. The 
therapeutically active compound is available in tablet dosage form. Sodium caprate as a 
novel permeation enhancer was used as an excipient. Upon granulation, we showed that 
sodium caprate particle properties are completely changed. Before granulation sodium 
caprate was present as fibrous material which led to high variation in the bulk density and 
flow properties. After granulation, the fibres fused, forming denser particles with a 
significant improvement in flow properties.  
The structural differences between recombinant human insulin and pegylated recombinant 
human insulin were studied using circular dichroism. These studies revealed that 
pegylation does not affect overall global structure of the molecule. Melting experiments 
using CD showed that the extent of unfolding of both the molecules were similar, however, 
pegylated insulin showed higher elevated Tm values, as compared to those for human 
insulin, indicating a more stable structure for the pegylated protein. The stabilization effect 
was more apparent at pH 7.4 and pH 9.6 where the extent of unfolding was significantly 
lower for pegylated insulin. At basic pH, the unfolding due to temperature was greater for 
human insulin than for pegylated insulin. The excipients appeared to stabilize the insulin in 
a higher order association state, which was observed in the higher Tm value. The higher 
association state could not be observed using size exclusion chromatography, which 
indicates that the higher association state was reversible in nature. 
Tableting affected the structure of pegylated insulin, resulting in an intact structure with 
higher levels of beta sheet. Unfolding of the molecular structure was greater at higher 
temperatures for pegylated insulin after tableting, than for pure pegylated insulin or its 
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blend with the excipients. The higher oligomeric state could not be observed using size 
exclusion chromatography. The overall globular structure was shown to be intact, based on 
hydrogen-deuterium exchange and ESI-MS data, suggesting that the changes during 
tableting are reversible.  
This shows that modification of protein with a short chain alkyl PEG was not detrimental 
to insulin and the formulation excipients offered some protection against unfolding due to 
pressure and temperature during tableting. This indicates that there is a considerable scope 
for using protein modification for making designer molecules for oral delivery, and also 
that a tablet dosage form is a feasible option for protein drug delivery. To our knowledge, 
this is first ever study exploring the impact of compression on protein structure in solid 
state. 
As part of this dissertation, the fate of the oligomer was studied in vitro using a hep G2 cell 
line. Several pegylated metabolite fragments of the polypeptides were identified using 
mass spectrometry combined with liquid chromatography. A potential sequence of 
chronological events for degradation of pegylated insulin was identified, wherein the 
separation of two chains was identified as a potential first step breakdown of pegylated 
insulin possibly involving glutathione transhydrogenase or a similar enzyme. 
This was further confirmed by using bacitracin, a known inhibitor of glutathione 
transhydrogenase. In presence of bacitracin, a new potential metabolite was identified 
where the individual chains were partially cleaved, yet the disulphides were found to be 
intact. It was also shown that the amide linkage between the epsilon amine and alkyl-PEG 
was hydrolysed to a small extent. Although the A-chain of the two molecules are identical, 
we identified two new sites of hydrolysis in the A-chain that have not been previously 
reported for insulin. 
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During the in vivo study of metabolism in a rat model, free oligomer was identified as a 
primary metabolite. A large portion of this metabolite was found in urine, suggesting that 
the small alkyl PEG, being highly water soluble, is excreted via kidney into urine. This is a 
significant finding as it re-enforces the safety of using small alkyl PEG for modification of 
proteins.  
5.2 Future Direction: 
Based on the work done in this thesis several areas have been identified where future work 
would be valuable. 
ADME studies for proteins and peptides are not very commonly performed. However, as 
more and more therapeutic proteins and their modified versions come to the market, 
understanding the ADME will become critical. ADME studies need to be tailored for 
specific structures and their functions. In the case of pegylated or modified molecules, an 
important issue is determining the fate of the pegylation unit or the modification. 
For any oral insulin it is important to show that the insulin when given orally gets absorbed 
and goes straight to the liver via the portal vein. In addition, it is important to understand 
the distribution in terms of what percentage of absorbed dose goes to the liver and what 
percentage of absorbed dose spills over into the periphery. This would help establish that 
oral insulin indeed restores the portal-peripheral axes of insulin secretion, which is the 
primary benefit expected of oral insulin. It is also important to study different dosage 
forms and the impact of the unit processes involved on protein structure and function, as 
the forces involved in making dosage forms could play a significant role in developing 
therapeutically active and commercially viable alternate delivery systems for proteins. 
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Future of oral insulin 
There is a need to develop a more physiological form of insulin delivery, and pegylated 
insulin is just a beginning. The pegylated insulin studied as part of this work, is a prandial 
insulin which provides glucose control for up to 2 to 3 hours after a meal. There may be 
scope for developing a better product with a longer duration of action. A basal oral insulin 
may have a larger impact on control of diabetes, hence there is scope for developing a 
basal oral insulin. In addition to improving the duration of action, there is scope to improve 
bioavailability of insulin. 
To achieve longer duration of action, without compromising onset of action, the molecule 
may have to be modified for slower clearance. Following are the options that can be 
explored: 
a) Increasing the molecular size by modifying insulin by conjugation with a large 
molecule like a high molecular weight polyethylene glycol or a large protein that will 
reduce renal clearance. 
b) Increase the protein binding which will prolong the circulating half-life of insulin. 
c) Modifying the insulin sequence to make the molecule more resistant to degrading 
enzymes 
To ensure adequate bioavailability, it will be important to make the molecule resistant to 
different proteases, so that a sufficient amount of pharmaceutically active form survives 
long enough to be available for absorption. In this study, we focused on comparing the 
degradation of pegylated insulin versus human insulin by pepsin. If any protein is delivered 
in the intestinal region, then the onset of action would be governed by the drainage of the 
dosage form from stomach to intestinal region hence gastric motility would play a critical 
role. The time to passage to intestine varies greatly from day to day and person to person 
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which would make the availability of insulin less predictable. For insulin, having a tight 
control over onset and peak of action is important, as it can result in serious consequences 
if the timing does not match with presence of food or high glucose levels. Considering this, 
for a successful oral delivery, the best place for insulin delivery is the upper 
Gastrointestinal tract (stomach or upper duodenum), which would provide a reasonable 
control over insulin action. Thus, ensuring resistance to pepsin degradation is of the key 
property to ensuring good bioavailability. 
As an initial proof of concept we did some basic in-silico work to show that by replacing 
amino acids, it is possible to make the molecule resistant to digestive enzymes. The work 
is presented in the following section. 
5.3 Protein modeling toward future insulin analog design 
The following modelling work was done using freely available proteomics resources from 
the website www.expasy.org. 
It is valuable to evolve or model the insulin molecule so as to devise strategies to make it 
more resistant to proteases, increase the solubility, increase permeability and perhaps 
increase circulating half-life to be able to mimic different desirable profiles.  
Identification of Proteolytic degradation sites in Insulin: 
A-chain primary sequence: GIVEQ CCTSI CSLYQ LENYC N  
pI 3.79, Calculated Molecular weight: 2383.7 
Pepsin at pH 1.3  
Total cleavage sites 8  cleavage positions 12, 13, 14, 15, 16, 18, 19 
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Pepsin at pH > 2  
Total cleavage sites 4  cleavage positions 12, 13, 15, 16 
B-chain primary sequence: FVNQH LCGSH LVEAL YLVCG ERGFF YTPKT  
pI 6.9, Calculated Molecular weight: 3429 
Pepsin at pH 1.3 Total cleavage sites 11  cleavage positions 1, 5, 6, 10, 
11, 14, 15, 16, 17. 24, 25 
Pepsin at pH > 2 Total cleavage sites 11  cleavage positions 1, 5, 6, 10, 
11, 14, 15, 16, 17. 23, 25 
Amino acids at these cleavage sites were replaced in order to test for pepsin resistance 
without affecting the secondary and tertiary structure of insulin, insulin receptor binding, 
and IGF receptor binding, so that the structure function relationship remains intact. In the 
A-chain cleavage occured between Ser-Leu, Leu-Tyr, Tyr-Asp, Asp-Leu, Asn-Tyr and 
Tyr-Cys. In an in-silico peptide cutter, when Leu was replaced with iso-leucine or valine at 
13 and 16 position of the peptide, and tyrosine at 14th position were replaced with histidine 
or tryptophan, the peptide cutter did not show any possible cleavages at those positions.  
A-chain primary sequence: GIVEQ CCTSI CSIHQ IENYC N  
Pepsin at pH 1.3 , Total cleavage sites 2  cleavage positions 18, 19 
Pepsin at pH > 2 Total cleavage sites 0   
Name of the sequence is A-chain. 
Sequence consists of 21 amino acids. 
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Target Sequence: 
GIVEQCCTSI CSLYQLENYC N    
Secondary Structure was predicted using http://www.biogem.org/tool/chou-fasman/ 
serer. (Chou and Fasman 1974) 
• * Query 1 GIVEQCCTSICSLYQLENYCN 21  
• Helix 1 <-------------> 21  
• Sheet 1 EEEEEEEEEEEEEEEEE 21  
• Turns 1 T 21  
• Total Residues: H: 15 E: 17 T: 1 Percent: H: 71.4 E: 81.0 T: 4.8  
 
 
Name of the sequence is A-chain. 
Sequence consists of 21 amino acids. 
Target Sequence: 
GIVEQCCTSI CSIYQLENYC N    
Secondary Structure: 
• * Query 1 GIVEQCCTSICSIYQLENYCN 21  
• Helix 1 <-------------> 21  
• Sheet 1 EEEEEEEEEEEEEEEEE 21  
• Turns 1 T 21  
• Total Residues: H: 15 E: 17 T: 1 Percent: H: 71.4 E: 81.0 T: 4.8  
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Name of the sequence is A-chain. 
Sequence consists of 21 amino acids. 
Target Sequence: 
GIVEQCCTSI CSIHQIENYC N    
Secondary Structure: 
• * Query 1 GIVEQCCTSICSIHQIENYCN 21  
• Helix 1        <------------------> 21  
• Sheet 1      EEEEEEEEEEEEEEEE 21  
• Turns 1    T 21  
• Total Residues: H: 15 E: 17 T: 1 Percent: H: 71.4 E: 81.0 T: 4.8  
 
 
The exercise shown here is only an illustration of what is possible and how replacing 
amino acids may or may not change the secondary structure dramatically. The secondary 
prediction software showed that there may not be any change in structure with these 
replacements of amino acids, yet these changes are predicted to make the chain more 
resistant to pepsin. Since the prediction is only for standalone A-chain, once it is associated 
with B-chain, depending on the accessibility of these sites, the number of changes required 
might be different for improving resistance. 
A similar exercise was performed for B-chain. 
B-chain primary sequence: FVNQH LCGSH YLVCG ERGFF YTPKT  
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Pepsin at pH 1.3 Total cleavage sites 14 cleavage positions 1, 5, 6, 10, 11, 14, 
15, 16, 17, 24, 25 
Pepsin at pH > 2 Total cleavage sites 11 cleavage positions 1, 5, 6, 10, 11, 14, 
15, 16, 17, 24, 25 
Name of the sequence is B-chain. 
Sequence consists of 30 amino acids. 
Target Sequence: 
FVNQHLCGSH LVEALYLVCG ERGFFYTPKT    
Secondary Structure: 
• * * Query 1 FVNQHLCGSHLVEALYLVCGERGFFYTPKT 30  
• Helix 1       <>                 <------------->                             30  
• Sheet 1      EEEEE             EEEEEEEE             EEE            30  
• Turns 1              T          T                         TT             T      30  
• Total Residues: H: 10 E: 16 T: 5 Percent: H: 33.3 E: 53.3 T: 16.7  
 
 
Name of the sequence is B-chain mutant. 
Sequence consists of 30 amino acids. 
Target Sequence: 
FVNQHTCGSH IVEATYIVCG ERGFWYTPKT    
Secondary Structure: 
• * * Query 1 FVNQHTCGSHIVEATYIVCGERGFWYTPKT 30  
• Helix 1                              <----------->                                 30  
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• Sheet 1     EEEEE              EEEEEEEE           EEE          30  
• Turns 1                           T                        TT             T    30  
• Total Residues: H: 8 E: 16 T: 4 Percent: H: 26.7 E: 53.3 T: 13.3  
 
 
B-chain primary sequence: FVNQH TCGSH IVEAT YIVCG ERGFW YTPKT  
Pepsin at pH 1.3 Total cleavage sites 6  cleavage positions 1, 15, 16, 23, 25, 25 
Pepsin at pH > 2 Total cleavage sites 2  cleavage positions 1, 23 
Similar to the A-chain, in the B-chain when Leu at the 6th position was replaced with 
threonine, leu at the 11th position was replaced with isoleucine, Val at the 12th position was 
replaced with iso-leucine, Leu at the 15th position was replaced with threo, Leu at the 17th 
position with Iso-leu and phenyl alanine at the 25th position with tryptophan. Despite so 
many changes the resultant peptide was predicted to have only 2 possible cleavage sites, 
hence is likely to be more resistant to pepsin compared to the natural analogue. 
The secondary structure prediction of these individual modified chains showed that there 
was minimal or no change in the secondary structure. These pepsin resistant sequences of 
A-chain and B-chain were used in combination for predicting a 3D structure of protein. 
The structure prediction was done using Phyre server (Kelly and Sternberg 2009). For the 
purpose of modelling, a hypothetical 6 amino acid long connecting sequence was used to 
create a single chain molecule. 
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Figure 5.1 Image on the right panel shows 3D model of insulin structure, the image on the 
left depicts predicted 3D model for mutant insulin structure with 8 amino acid changes.  
The predicted structures (Figure 5.1) showed a high degree of similarity for the mutated 
sequence despite a change in 8 amino acids. A similar exercise needs to be performed to 
test more combinations of amino acids to select a mutant sequence with least structural 
difference. The confidence in the presented modelling work is low, as the accuracy of 
prediction has not been tested. In addition, the freely available resources are capable of 
predicting the structures of single chain proteins and also are based on the structures of 
known proteins. Insulin consists of two chains which makes the prediction unreliable to 
some extent. For more accurate predictions, more exhaustive work needs to be done using 
energy minimisation models. 
Once a more proteolytic resistant active molecule is designed, any further modification 
may be done to achieve the desired pharmacological profile. Modification may be done 
using appropriate pegylation. It is necessary to check for immunogenicity, since proteolytic 
resistant proteins are more likely to be immunogenic (Delamarre et al. 2006). Besides 
immunogenicity, the molecule might need evaluation for protease resistance (in vitro), 
protein binding, glucose uptake, lipogenesis activity, insulin receptor binding, IGF receptor 
binding, aggregation behavior etc. There is a considerable work that would be needed to be 
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done to take the development of oral delivery toward clinical use. A good target product 
profile can help focus the development of such molecules with tailored properties. 
 
Figure 5.2 Illustration of the development steps for next generation oral insulin. 
Figure 5.2 shows a potential development path that can be followed for developing a next 
generation of insulin. There is a significant scope for further development of a next 
generation of molecules, which would provide the desired glycemic control at lower doses 
of insulin. The above modeling work was done toward proof of concept for future insulin 
analog design. 
In addition to tinkering with insulin itself at the molecular level, finding more efficient 
permeation enhancers is another area of interest. There is a need to improve the 
bioavailability of proteins when given orally without compromising the safety of the 
patients. Thus designing insulin analogs, finding safer and efficient permeation enhancers, 
and the development of better formulation technologies, are key to developing successful 
oral insulin products. 
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